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ABSTRACT OF DISSERTATION

PNEUMOVIRUS INFECTIONS: UNDERSTANDING RSV AND HMPV ENTRY,
REPLICATION, AND SPREAD
Pneumoviruses including human metapneumovirus (HMPV) and respiratory
syncytial virus (RSV) are significant causes of respiratory tract infections globally.
Children, elderly, and immunocompromised patients are at the greatest risk for
developing severe infections, which can have devastating outcomes. Although
these viruses are ubiquitous with significant impacts on human health, there are
no antivirals or vaccines available. The only FDA approved therapy is a
monoclonal antibody for RSV, given prophylactically during the infectious season,
and this treatment is only available for high risk infants. The work presented in this
thesis aims to increase our understanding of how these viruses enter, replicate,
and spread to better characterize the basic molecular mechanisms used, opening
avenues for potential antiviral therapies. We first analyzed the fusion protein of
HMPV and how low pH is important for entry of some viral strains. We analyzed
previously uncharacterized strains and found that residues initially hypothesized
to be critical for low pH fusion are not always required, suggesting a more complex
regulation of fusion. We then explored the role of the proteolytic cleavage event
which is required for HMPV F as well as many other important respiratory
pathogens, including influenza. We found that many proteases involved in
activating influenza HA are also important for activating HMPV F, which has not
previously been reported. We then used our understanding of cleavage to employ
a treatment strategy targeting host proteases involved in this activation to prevent
entry and spread. We next conducted a side-by-side comparison of infection,
spread, and inhibition using a physiologically relevant 3-D human airway epithelial
model system. We found that RSV and HMPV demonstrate significantly different
infection and spread kinetics as well as phenotypes during infection, highlighting
an interesting dichotomy between two closely related viruses. We further analyzed
therapeutic potential for several monoclonal antibodies, finding that prophylactic

interventions prevent entry and spread, but treatment after entry suggests that both
HMPV and RSV can be inhibited during entry. However, RSV likely spreads
through cellular release and re-entry whereas HMPV utilizes a mechanism that is
antibody independent after establishing the initial infection. Lastly, we examined
the concept of viral co-infections, as co-infections with RSV and HMPV have been
reported to cause more severe disease in patients. We provide evidence that RSV
and HMPV co-infected cells can occupy the same inclusion bodies, but further
investigation suggests that HMPV and RSV replication synergy may be limited.
Collectively, the data presented in this dissertation provide new understanding of
pneumovirus infections and reveals important information about the molecular
mechanisms of pneumovirus entry and spread.

KEYWORDS: Human metapneumovirus, Respiratory syncytial virus, human
airway epithelium, inclusion bodies, co-infection, fusion protein.
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Chapter 1: Introduction
Paramyxo- and pneumovirus classification, epidemiology, and human
health impact
Mononegavirales is an order of viruses containing a negative sense, singlestranded RNA genome. This Order is made of up eight different families:
Bornaviridae,

Filoviridae,

Mymonaviridae,

Namiviridae,

Paramyxoviridae,

Pneumoviridae, Rhabdoviridae and Sunviridae (1). Paramyxoviruses, in particular,
have well known members responsible for significant health and economic burden
worldwide. Members of paramyxoviridae cause disease in animals and humans,
with potential for zoonotic transmission (2). One of the most highly pathogenic and
well-known members is measles virus (MeV), which has become an increasing
health concern in recent years due to decreased compliance with current
vaccination regimens (3, 4). MeV is typically contracted during childhood and
causes respiratory illness that can progress and cause complications such as
pneumonia and encephalitis. MeV was responsible for severe morbidity and
mortality until a vaccine developed in the 1960’s led to significant reduction in the
incidence, associated deaths, and hospitalizations (5). Another paramyxovirus,
mumps virus (MuV), also causes disease during adolescence but vaccination led
to fewer deaths and hospitalizations. Recently, particularly in developed nations,
the vaccine that targets MeV and MuV (MMR vaccine) has been scrutinized and
therefore, large populations have become non-compliant with the current
vaccination regimen. This opposition to vaccination has led to a significant
increase in MeV and MuV outbreaks, particularly in the United States and has once
again become a major global health concern (3-5).
Other important members include Hendra (HeV) and Nipah (NiV) which
cause respiratory disease and encephalitis in horses (HeV) and pigs (NiV). HeV
and NiV have had reports of zoonotic transmission to humans with mortality rates
ranging between 40-100%, but the amount of cases has been low (6-13). For these
viruses, there is no current therapeutic treatment or vaccination in humans.
1

However, there has been a prophylactic treatments and vaccinations developed
for horses against HeV that has demonstrated strong potential in high risk
situations (14, 15). Parainfluenza viruses (PIV) cause significant morbidity and
mortality in humans and PIV1-3 are responsible for respiratory illness in
immunocompromised patients, infants, and children (16, 17).
Two other significant viruses are respiratory syncytial virus (RSV) and
human metapneumovirus (HMPV, further described below), both of which cause
widespread and severe respiratory tract infections. Both viruses were previously a
sub-family of paramyxoviridae, but were recently reclassified to a new family,
pneumoviridae (18). Although this places them in their own family, many aspects
of viral infection and protein function remain highly conserved between them,
allowing us to compare and contrast with information currently known about
paramyxoviruses.
RSV was first isolated in 1956 from a chimpanzee presenting with a
respiratory tract infection, and eventually determined to be of human origin (19,
20). RSV is now known as one of the leading causes of respiratory tract infections
in infants and children, and it is estimated that there are 34 million infections and
3.4 million hospitalizations per year in children under 5 years of age (21, 22). In
addition to infecting children, RSV causes severe infections in premature infants,
elderly and immunocompromised patients (21-27). Even though this virus was
identified more than 60 years ago, there are currently no vaccines or antivirals
available other than a prophylactic treatment given during the infectious season to
high risk infants that blocks a protein on the surface required for entry (28, 29).
Therefore, RSV remains one of the most detrimental pediatric viruses.
Human metapneumovirus
Another significant but less well-known respiratory virus, HMPV, was
isolated in 2001 from children exhibiting symptoms similar to those infected with
RSV (30). Even though it was only recently identified, it is thought to have been
circulating in humans as early as 1958 (30-32). When examining the origin of
2

HMPV, it is hypothesized that it recently evolved from zoonotic transmission of
another member of the pneumoviridae family, avian metapneumovirus C (AMPV),
based on high sequence homology (30). In addition, the genetic mapping of HMPV
is also closely related to that of RSV, which encodes for the same proteins as well
as two additional non-structural proteins (33).
Since its discovery, HMPV has been characterized as a major human
pathogen, causing significant respiratory illness worldwide. Nearly everyone has
been infected by the age of 5, is seropositive by the age of 10, and reinfection is
common throughout life (30, 34-36). It is second to RSV as the cause of lower
respiratory tract infections in children (36, 37). Similar to RSV, children, elderly,
and immunocompromised patients are more likely to harbor serious infections.
Importantly, some infants hospitalized with RSV for severe bronchiolitis showed
co-infection with HMPV, which suggests co-infection with both viruses may lead to
more severe disease. (38-40).

Within the normal, healthy population, HMPV

infection appears symptomatically similar to etiologic agents of upper respiratory
infections, including cough, sneezing, rhinitis and other symptoms categorized as
the “common cold” (41). However, in patients with limited capacity to fight infection,
it causes more severe symptoms including wheezing, croup, bronchiolitis, and
respiratory distress which can often lead to hospitalization or death (30, 31, 36, 37,
42-49). In long- term care patients over the age of 65, some studies suggest that
HMPV can cause illness in up to 72% of patients during outbreaks (50-54).
Furthermore, HMPV has been associated with myocarditis and those with
congenital heart defects are at significant risk for developing severe infections (36,
48, 55-57). Patients with chronic respiratory illness are also at high risk, including
those with cystic fibrosis, asthma, or chronic obstructive pulmonary disease.
Severe infection with HMPV during childhood has also been associated with
complications in adulthood such as increased incidences of asthma or
hyperresponsiveness in the respiratory tract (58-64).
Immunocompromised individuals, including those infected with HIV,
transplant recipients, or cancer patients have a significantly diminished immune
3

system, allowing for opportunistic infections to develop. HMPV infected patients
with HIV were 5.4 times as likely to be hospitalized compared with HIV negative
children (65). Additionally, pediatric patients with cancer were hospitalized nearly
50% of the time due to weakened immunity (66). While HMPV infection is
transmitted through the respiratory tract, there has been HMPV RNA detected in
the central nervous system and brain tissues of patients with fatal encephalitis (6769). HMPV has also demonstrated mechanisms for establishing viral persistence.
HMPV infections without respiratory symptoms have been reported in stem cell
transplant patients, resulting in serious and sometimes fatal illness (70, 71). In
animal models, replicating HMPV could be recovered at 60 days post infection
(dpi) and detected more than 180 dpi by PCR (63, 72, 73). HMPV was shown to
be present in neuronal processes in the lung suggesting immune privileged sites
can keep the virus hidden from the immune system. This eventually leads to the
viral reactivation following decreased immune function such as glucocorticoid
administration (74). HMPV also demonstrates the ability to prevent apoptosis in
cell culture which could offer a potential mechanism used to establish persistence
(75).
HMPV infections follow behind annual influenza and respiratory syncytial
virus seasons, with yearly epidemics peaking between November and April (76,
77) . There are two subgroups of HMPV (A and B) which are further divided into
A1, A2, B1 and B2 based on viral glycoprotein sequences (78, 79) (Fig. 1A). Both
A and B can co-circulate and lineage dominance varies from year to year (80-84).
Most research studies found that between 5 and 15% of respiratory tract infections
are due to HMPV, trailing behind RSV and influenza (32, 43, 45, 46, 48, 84-86).
While HMPV is ubiquitous and responsible for severe upper and lower respiratory
tract infections, there are still no current FDA approved antiviral or vaccinations
available. Therefore, a more thorough understanding of the viral lifecycle and
molecular mechanisms required for infection is needed to discover novel antiviral
targets against this significant human pathogen.

4

Paramyxo- and pneumovirus structure and the role of glycoproteins in
infection
All paramyxo- and pneumoviruses have a negative sense, single-stranded
RNA genome between 13-19kb in length which encodes for 6-10 proteins. These
proteins perform all the requirements to enter target cells, recruit host factors,
replicate, and assemble viral components, and mediate transmission to a naïve
host (87). These viruses encapsidate the negative sense RNA genome (vRNA) in
the viral nucleoprotein (N). This encapsidated RNA then associates with the large
RNA-dependent RNA polymerase (L) and the phosphoprotein (P), a polymerase
co-factor. vRNA, N, P and L coalesce to make up the ribonucleoprotein (RNP)
complex which associates with the matrix protein (M) just below the lipid bilayer.
Within the lipid bilayer are at least two surface glycoproteins: the fusion protein (F)
and the attachment protein (HN, H or G). The attachment protein nomenclature is
based on the ability to bind (H) or bind and cleave (HN) sialic acid. Attachment
proteins that cannot bind or cleave sialic acid are referred to as G (88, 89). These
proteins are the minimal components required for infection and family members
encode additional proteins that serve various functions specific for that virus (89).
HMPV contains a viral genome between 12 and 13kb in length. Within this
genome, it encodes for 8 viral proteins that make up the infectious particle and
replication machinery. On the outside of the particle, there is a lipid bilayer derived
from the infected host cell. Within this membrane are 3 surface glycoproteins: F,
G and the small hydrophobic protein (SH). Just below the lipid bilayer lies a layer
of M that is associated with the lipid membrane, membrane glycoproteins, and the
RNP complex. Two other proteins, M2-1 and M2-2, act as processivity and
transcription factors for generating genome and messenger RNA for viral protein
production (Fig. 1B). The genomic layout for HMPV is: 3’-N-P-M-F-M2-SH-G-L-5’
(Fig. 1C) (30, 90-93).
In order for enveloped viruses to enter cells, it must fuse the viral and
cellular membranes. The initial viral interactions are mediated by viral surface
glycoproteins. This interaction subsequently promotes the fusion protein to fuse
5

the two membranes and mediate viral entry. F is essential for paramyxo- and
pneumovirus entry due to the requirement of enveloped viruses for membrane
fusion to initiate infection (covered in more detail below). Inhibiting F through
various methods including mutagenesis, small molecule inhibitors and neutralizing
antibodies prevents its function and subsequently, mitigates infection. This
mechanism of targeting F is utilized by the immune system in order to neutralize
the virus. This approach is also one of the leading targets for antiviral therapeutics
of viruses that require fusion for entry (94-104). Simplistically, the attachment
protein is thought to bring the virus into close proximity with a target cell, allowing
F to then mediate entry. However, some fusion proteins in the absence of their
cognate attachment protein are unable to mediate fusion, suggesting that the
attachment protein of some viruses is specifically involved in activating F (105113). Both HMPV and RSV G proteins have also been implicated in mitigating the
immune system as well, suggesting other roles in addition to their proposed
attachment function (114-120).
Some family members also encode the SH protein, but these demonstrate
less conservation compared with the fusion or attachment proteins. In addition,
little is known is known about the specific functions during infection. Some studies
have shown recombinant viruses lacking SH have minimal growth defects in cell
culture (121-125). In pneumoviruses, including HMPV, RSV and AMPV,
recombinant viruses lacking SH showed a decrease in viral fitness and replication
in animal models, suggesting the role of SH is important in a more physiologically
relevant system (124, 126, 127) . Further studies focusing on the role of SH have
suggested a role in modulating the immune system or preventing host cell death
through inhibition of apoptosis (128-130). Interestingly, both RSV and HMPV SH
proteins demonstrate viroporin like activity (131, 132) which allows the movement
of small molecules across the membrane, similar to the ion channel, M2, from
influenza A virus (IAV) (133). Recombinant RSV and HMPV viruses containing F
but lacking G and/or SH, still promote infection and spread, albeit less efficiently
than WT viruses (91, 120, 121, 123, 124, 134-136). These findings support that F
is the main mediator of entry for pneumoviruses while G and SH are not essential.
6

In some clinical isolates, there has been a duplication in G for both RSV and HMPV
which suggests a boost in pathogenicity or viral fitness (137-142). More recently
for RSV, it was suggested that virus grown in cell culture was unaffected by G
neutralizing antibodies whereas use in 3-D tissue model systems demonstrated
significantly reduced infectivity (143, 144). Furthermore, all current analyses of
both RSV and HMPV isolates show G and SH are present, suggesting that keeping
these genes increases viral fitness (31).
Fusion protein mediated entry
All paramyxo- and pneumoviruses contain a type I fusion protein (89, 145,
146). Other well studied class I fusion proteins include IAV HA (147), human
immunodeficiency

virus

type 1 (HIV)

envelope protein (gp160)

(148),

coronaviruses (CoV) including severe acute respiratory syndrome (SARS) (149,
150) and middle eastern respiratory syndrome (MERS) (150, 151) spike protein
(S), and EboV glycoprotein (GP) (152, 153). Studies examining these viruses has
allowed for a significant understanding of how they function and what factors are
important for mediating entry. Type I fusion proteins are a single pass
transmembrane protein with a predominantly alpha-helical conformation (154). For
paramyxo- and pneumoviruses, these proteins contain a similar domain
organization and protein structure. The N-terminus of the protein contains a protein
cleavage site, followed by a hydrophobic fusion peptide (FP). Just beyond the FP
is the heptad repeat A (HRA) region, the HRB region, transmembrane domain (TM)
and C-terminal tail (CT) (Fig 1.2A) (87, 89, 155-164). After synthesis, these
monomers subsequently trimerize to form a homo-trimeric protein complex. This
form of the protein contains of a globular head, composed of the HRA and Nterminus of the protein, and a helical stalk domain, which contains the HRB, TM
and CT (Fig 1.2B). These proteins are subsequently trafficked through secretory
pathways to viral assembly sites through the endoplasmic reticulum and golgi
apparatus where they are post translationally modified by glycosylation (155, 156).
Addition of post translational modifications are important for many processes
including protein folding, trafficking, molecular association, target cell entry,
7

immune evasion, and viral tropism for many viruses that utilize type I fusion
proteins (165-168).
Type I fusion proteins of paramyxo- and pneumoviruses require proteolytic
activation in order to function properly. These cleavage events occur just before a
stretch of hydrophobic amino acids, termed the fusion peptide (FP). This cleavage
process cuts the full length F0 precursor to yield a disulfide linked heterodimer
composed of F1 and F2 subunits (Fig 1.1A). This cleavage activates the protein
and generates the meta-stable, pre-fusion form presents on the outside of the virus
(154, 155). The proteases required for cleavage differ greatly depending on the
virus. For IAV, the pancreatic derived serine protease, trypsin, has been historically
used to activate the HA protein, but trypsin is not present in the airway (147). More
recent studies have identified several type-II transmembrane and secreted serine
proteases which are present in the airway cleave a single basic amino acid residue
within HA (169-178). Furthermore, these airway proteases demonstrate further
specificity to specific strains of the virus (173, 175, 176). For highly pathogenic
pandemic forms of IAV, this cleavage motif has been mutated, allowing
intercellular cleavage by proteases recognizing multibasic cleavage sites such as
furin and other furin-like pro-protein convertases (179, 180). These mutations
completely alter HA cleavage efficiency and subsequently, its pathogenicity.
Another example is the closely related pneumovirus, RSV, which utilizes this same
family of pro-protein convertases. Unlike other type I fusion proteins, RSV F is
cleaved at two separate cleavage motifs, removing a small 27 amino acid peptide
and creating a fusogenically active fusion protein (155, 181, 182).
Coronaviruses, including SARS and MERS, have emerged as significant
human pathogens in recent history, causing severe morbidity and mortality.
Studies have identified key aspects of viral infection to better understand how
these viruses emerged, transmitted to humans, and caused severe disease. More
recently, a novel coronavirus, SARS-CoV2, emerged in late 2019, leading to a
global pandemic (183-185). The SARS fusion protein, S, has been shown to be
proteolytically processed at a single basic residue, similar to the IAV HA protein as
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well as at an additional aliphatic residue. The novel SARS-CoV2 shares high
homology to SARS S, where a single basic amino acid arginine (R) cleavage site
is present at the canonical basic residue cleavage motif (186, 187). Sequencing of
SARS-CoV2 S revealed an insertion of amino acids n-terminal to the original basic
cleavage site, which increases recognition by furin-like proteases, similar to
mutations observed for that of highly pathogenic influenza (188). It has been
suggested that this small modification to one cleavage site within SARS-CoV2 S
has increased its cleavage efficiency which likely lead to increased infectivity.
In HMPV, the fusion protein cleavage has not been extensively
characterized. HMPV F is proteolytically processed at a motif, RQSR, with
cleavage occurring just after the c-terminal arginine, allowing the FP to be released
for fusion (30, 121, 189, 190). This RXXR motif has been previously characterized
for furin as a minimal recognition sequence (191). However, furin and other proprotein convertase family members that recognize this basic motif have not been
reported to cleave this site in HMPV F. To date, only two proteases have been
identified: trypsin and TMPRSS2 (192), a type II trans-membrane protease that is
also involved with processing IAV HA and SARS S (170, 173, 176, 187). The
majority of HMPV strains require the addition of exogenous trypsin in order to
propagate efficiently. However, there are some identified strains that possess a
cleavage site mutation, where RQSR has mutated to RQPR. This single amino
acid change generates a trypsin independent cleavage site, allowing viruses to
propagate efficiently in the absence of exogenous trypsin (193, 194) although it
doesn’t appear to affect cleavage (189). In addition, this motif has been suggested
as a potential furin cleavage site, similar to that found in pseudomonas endotoxin
(195). However, what endogenous proteases can cleave HMPV F has not been
previously examined.
After cleavage, these meta-stable fusion proteins must be activated in
order to initiate fusion. This activated form is important and must be regulated both
temporally and spatially to ensure that fusion results in entry. However, the prefusion form is dynamic, where intermolecular and intramolecular interactions
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generate a protein “breathing”, allowing for tolerance of the changing environment
without prematurely triggering the protein (196, 197). This protein flexibility allows
the virus to withstand a variety of conditions while keeping the protein active and
stable until fusion can be initiated. For many paramyxoviruses, this initiation is
accomplished through the interaction of the attachment protein. When the
attachment protein interacts with the appropriate cellular factor, it then transduces
a signal to F which begins a dramatic refolding process from the pre-fusion form
(87, 89, 94, 95, 106, 145, 155, 156, 163, 164, 198). Crystal structure determination
of F proteins has been a key factor in our ability to understand how these proteins
function and recent advances in biochemistry and molecular biology has allowed
for isolation and modifications of a significant number of proteins. These studies
have generated pre-fusion [NiV (199), HeV (200), PIV3 , MeV (201), PIV5 (202,
203), RSV (204), and HMPV (205)] and post-fusion structures [NDV (206), RSV
(207), and HMPV (208)] for a variety of paramyxo- and pneumovirus fusion
proteins. Understanding the structural characteristics of these proteins has
generated tools to better understand the dynamic refolding process and fusion
intermediates through biochemical analysis in other type I fusion proteins (161,
209-211).
Upon triggering, the F protein inserts the helical hydrophobic FP into the
membrane of the target cell. Once the FP is inserted, F continues to refold, forming
a fusion intermediate hairpin structure. This refolding continues, pulling the target
and viral membranes together. Full fusion is mediated by the interaction of the
helical HRA and FP with the HRB and TM domains of the protein, which come
together, forming an energetically stable six-helical bundle (6-HB), indicative of the
post-fusion form of the protein (Fig 1.2C) (87, 89, 94, 106, 145, 155-164, 198, 211).
Merging two lipid bilayers requires overcoming a significant energy barrier.
Membrane fusion mediated by the F protein is an ATP independent process.
Therefore, it is hypothesized that the energy required to fulfill complete fusion is
stored as potential energy between the pre- and post-fusion forms and appropriate
stimulus generates activation energy needed to initiate refolding. This fusion event
is comparable to SNARE mediated vesicle fusion, where a target and receptor
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SNARE protein pair interact and “zipper” to merge two membranes (212-214). The
energetically favorable interaction provides energy to merge two membranes
together and release the vesicle cargo. This highly stable SNARE protein complex
must then be separated in an ATP dependent manner to be recycled and used
again. However, our current knowledge suggests F proteins are unable to revert
from the post-fusion to pre-fusion state. In addition to this intermolecular
association, viruses also utilize other mechanisms to overcome energy barriers
during entry. Enveloped viruses utilize the interface between lipid microdomains
and the adjacent plasma membrane, which modify the lipid membrane. More
specifically, cholesterol present in these domains bends the lipid membrane similar
to that of early hemi-fusion intermediates. This change in membrane architecture
is favored by viral fusion due to by lowering the energy threshold required for entry
(215-219). In combination with this, viruses likely utilize multiple copies of the
fusion protein. For studies looking at HIV gp160, it was suggested that only one
fusion protein contains enough energy to mediate viral entry whereas other viruses
require more (220-223).
Fusion for most paramxoviruses occurs at neutral pH, which suggests that
viral membrane fusion occurs at the plasma membrane (89, 106, 145, 155). For
some type I fusion glycoproteins, there is no attachment protein, and entry is
mediated by a single surface glycoprotein. Alternatively, some viruses contain an
attachment protein that does not mediate the activation of F and therefore, some
other stimuli must activate the fusion protein (145). For IAV HA, the virus is taken
up through endocytosis after binding sialic acid on the surface of target cells. The
virus traffics through the endosomal pathway where a steady decrease in pH
occurs. This increase in acidity is used as a timing mechanism, as sufficiently low
pH will eventually trigger the HA protein to mediate fusion (147, 224-227). Another
example is GP from EboV. EboV enters through cellular micropinocytosis by
expressing phosphatidyl-serine on the outside of its viral membrane which is
recognized by host proteins on the cell surface, such as TIM-1. Once taken up by
the cells, GP protein is processed by host proteases in the endosomal pathway.
This cleavage process allows the GP protein to interact with its internal cellular
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receptor, Neiman-Pick C1 (NPC1), and this interaction initiates fusion (152, 228237). In addition to cleavage and receptor interaction, some studies have
suggested the use of cations such as calcium and potassium as well as low pH as
a potential trigger to enhance fusion, although there is inconclusive evidence (152,
235-238).
Our lab and others have demonstrated some strains of HMPV (subtype A2)
utilize a similar mechanism to IAV for fusion activation (239-242). Previous studies
found that HMPV interacts with its surface attachment and entry factors, heparan
sulfate and αVβ1 integrin. These interactions allow HMPV to bind and enter
through clathrin-mediated endocytosis (123, 243). As HMPV moves through the
endosomal pathway, a steady decrease in pH occurs. This subset of HMPV F
proteins use an increase in acidity to activate fusion and initiate viral entry (Fig
1.3). However, low pH induced fusion is only predicted to be in strains harboring
specific amino acids uniquely found within the A2 subtype (239-242). There are a
limited number of strains available for analysis and more information is needed to
further our understanding of these residues involved in fusion. Furthermore, other
factors that activate F proteins, such as a cellular receptors or cofactors that are
unaffected by low pH have yet to be elucidated.
Transcription and Replication
Once fusion has occurred and the RNP is released into the cytoplasm, the
L protein of HMPV begins viral replication to generate the positive sense
antigenomic RNA which acts as a template for replicating the negative sense viral
genome (vRNA) (89). In addition, L also functions to generate the viral mRNA from
the genomic template. L follows a start-stop model of transcription, resulting in a
gradient of mRNA where the 3’ genes are more highly transcribed than 5’ (244246). However, the factors that contribute to whether the polymerase chooses to
generate vRNA, antigenomic RNA, or mRNA has largely remained unknown but
recent studies have generated interesting hypotheses for how this process may
occur. For RSV, studies have reconstituted the L and P proteins to study their
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ability to replicate RNA de novo. In order for transcription or replication to occur, L
must be loaded with a nucleotide triphosphate, which allows binding to the
template strand to initiate elongation. The beginning of the genome contains the
sequence 3’ UGC 5’ and which nucleotide is loaded in the polymerase determines
whether it will initiate transcription or replication (247). Genome replication occurs
when an ATP nucleotide is present and binds to the first position and replicates
the entire genome. Polymerases loaded with GTP will mediate binding to position
3 and therefore, unable to replicate the entire genome, shifting to transcription of
viral genes. This finding suggests RSV utilizes the cellular nucleotide pool
concentrations as a timing mechanism to switch between these two functions (248250). While this process has not been published for HMPV yet, these same
principles likely apply and may help explain the function of all polymerases within
mononegavirales (250).
As viral protein synthesis occurs, both RSV and HMPV form punctate
cytosolic structures which reside close to the nucleus (251, 252). These structures,
termed inclusion bodies (IBs), are minimally composed of N, P, L, M2-1 and vRNA
(Fig 1.3) (251-255). It is suggested that IBs function to keep the required viral and
host factors in close proximity to each other for efficient viral transcription and
replication. Another hypothesis is that IBs keep the viral RNA sequestered from
the cellular response factors that recognize double stranded RNA, such as RIG-I
and MDA5 (253). These structures have been reported for a wide variety of other
viruses in mononegavirales including plant and animal RabV (256-260), EboV
(261), Marburg virus (262), vesicular stomatitis virus (263), PIV3 (264, 265), and
PIV5 (266), suggesting that this type of structure is likely a conserved and
important function during the viral lifecycle. The origin of these structures is varied
depending on the virus. For example, PIV3 is able to restructure the endoplasmic
reticulum membranes, generating viral replication compartments in the cytoplasm
(265). This same tactic is utilized by many positive sense single stranded RNA
viruses to meet the needs for viral replication (267, 268).

13

Pneumovirus IBs have been examined more closely and interestingly, they
do not demonstrate molecular kinetics similar to those structures surrounded by a
membrane. Instead, these organelles demonstrate dynamics of a phenomenon
called liquid-liquid phase separation, something that has been also reported for
RaV, VSV and MeV(269-271). In this process, pH, salt concentration, molecular
density, and electrostatic interactions are thought to mediate association. These
molecular aggregates eventually separate out from the surrounding solution
primarily based on intramolecular interactions that drive an energetically favorable
process to form a liquid-liquid interface (272-275). This process for RSV and
HMPV selects for viral specific components, keeping them in close proximity for
efficient replication. Viral proteins may also recruit other cellular factors that are
required for these processes and exclude host antiviral factors. Due to the lack of
lipid membrane, some molecules may diffuse in or out of the organelle much
quicker, allowing for import of nutrients and export of viral factors. Further
investigation

of

IBs

in

RSV

infection

demonstrated

an

internal

compartmentalization of IBs, termed IB associated granules (IBAGs), serving
unique functions for RNA synthesis and viral transcription (255).
While many viral factors have been identified, cellular factors utilized by the
virus and sequestered in IBs have not yet been elucidated. Understanding the
components of IBs could reveal important information about viral and cellular
requirements for efficient transcription and replication. These factors could then be
targeted for a wide range of viruses that utilize these during infection, offering
potential for broad-spectrum antiviral therapy.
Viral Assembly and spread
Once viral proteins have reached adequate concentrations, they are
trafficked to sites of assembly at the plasma membrane (88, 89, 156). The RNP
complex is then shuttled from IBs where they interact with proteins present at
assembly sites. Once this association has occurred, there are two methods of viral
particle formation (Figure 1.3). The first is the classical pathway for enveloped
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viruses (276, 277). The viral proteins and RNP complex associate and begin
pinching the plasma membrane, releasing an infectious virus. This virus is then
able to release from the infected cell and move to a naïve host, bind, and enter to
start the infectious process. However, recent studies of many viruses have
demonstrated that this is not always the case (278-280). Other mechanisms for
these viruses show that while some viral particles are spherical, many tend to be
pleomorphic in nature. Some viruses are filamentous, generating tubular
extensions from the cellular membrane composed of viral proteins and RNA (84,
279, 281-286) and these often lead to varying particle sizes and morphologies.
Some other viruses remain largely cell associated, with minimal released virus
detected (279, 287, 288). The current understanding of viral assembly and spread
for many enveloped viruses is rapidly changing with increases in the technology
we have to study them.
One interesting example is MeV which enters the respiratory tract through
aerosol droplets, similar to other respiratory viruses. Once inside a naïve host,
MeV particles bind host dendritic cells and aveolar marcrophages through the
interaction between the measles fusion protein, H, and cellular receptors CD150
(also called signaling lymphocytic activation molecule, SLAM), the complement
system protein, CD46 (also called membrane cofactor protein, MCP) and the
attachment factor DC-SIGN. CD46 is the receptor for the vaccine strain while
circulating MeV utilized SLAM for entry. Interestingly, MeV has been shown to
infect some cell lines independently of either MCP or SLAM, suggesting another
potential mediator of viral entry (289-291). More thorough analysis determined this
receptor was Nectin-4, a protein that is expressed primarily in the adherens
junctions during cellular polarization in the airway epithelial. This basolateral
restriction prevents MeV from interacting with this factor during entry (292). Upon
infection, MeV activates the immune system, causing respiratory tract
inflammation, resulting in damage to the epithelial layer. This disruption allows
MeV to access the Nectin-4 protein in cell-cell junctions to begin infecting the lung
epithelial layer. Nectin-4 is then utilized in a mechanism of direct cell-to-cell spread
of MeV from one cell to a neighboring cell, independent of apical release of the
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virus (292, 293). However, at later stages of infection, Nectin-4 also plays a role in
viral release where mediates direct transfer of virus to lymphocytes and
subsequent exit from the host via aerosols.
Studies using 3-D human airway epithelial model systems which more
accurately recapitulate the lung environment (covered in more detail below) have
further demonstrated the interesting entry and spread dynamics of MeV (292, 294297). These have confirmed the importance of Nectin-4 in direct cell-to-cell transfer
but have also revealed another interesting mechanism of spread. In these
environments, MeV utilizes F-actin to transfer the RNP complex directly from one
cell to another. This allows the virus to theoretically bypass the first several hours
of infection by skipping the need to assemble and release a new viral particle which
then re-enters a cell to initiate infection. Additionally, multiple replication competent
complexes are also introduced which increases infectivity and replication efficiency
before the immune response can inhibit these processes.
The changing paradigms are seen for both RSV and HMPV as well, as
recent studies suggest cell-to-cell spread is an important aspect for the
pneumovirus lifecycle (251, 280, 288, 298, 299). These methods of spread include
the formation of syncytia, intercellular extensions, and polyploid virions (Figure
1.4). It has been widely demonstrated that enveloped viruses ultimately use fusion
as a means of viral entry (146, 154). This same mechanism also generates
multinucleated bodies when two or more cells fuse together. Fusion of the
cytoplasm of a non-infected cell with an infected one subsequently increases
nutrients and resources. This process also mediates infection of a naïve cell during
the process. Using this mechanism of spread avoids viral release and reentry
which greatly benefits infectivity and replication (279, 280, 300). For RSV, syncytia
formation has been examined in viruses that possess a hyperfusogenic fusion
protein, forming large syncytia in cell culture. Infection of mice with this
recombinant virus demonstrated increased pathogenic effects suggesting that this
increased fusogenicity and syncytia formation is beneficial for virus replication
(301).
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Both RSV and HMPV form filamentous structures that extend toward
neighboring cells. RSV induced the formation of actin based, actin-related protein
(Arp2) dependent filopodia in A549 lung epithelial cells that is important for viral
spread (298). HMPV also forms long actin-based extensions that extend from
infected cells. These structures are important for direct cell-to-cell spread of the
virus in the presence of neutralizing antibody, where spread was only modestly
decreased (288). We hypothesize these extensions are likely aiding in direct
transfer of RNP complexes, similar to that of MeV or aiding in the surfing of viral
particles from one cell to another along the extensions, which has been seen for
viruses such as HIV (Fig 1.4) (279, 280, 300).
These same filamentous structures play another role in the transfer of virus
released from cells. Viral protein and RNP complexes that coalesce at the plasma
membrane are associated with the formation of the filamentous form of viruses.
Filamentous forms of the virus generate virions that contain multiple copies of the
viral genome within the same particle (Fig 1.4). This creates an infectious particle
with an increased chance of initiating successful infection by delivering more viral
templates and replication machinery (302-304). While not demonstrated for RSV
or HMPV, other paramyxoviruses have shown that polyploid viruses are common,
suggesting a viral fitness advantage (279, 280, 300).
Current mechanisms and 3-D model systems for studying respiratory virus
infections
The respiratory tract is a complex organ system that promotes movement
of air from the nasal passages through the sinuses, down the pharynx, and into
the lungs. This canal is primarily lined with pseudostratified columnar epithelial
cells. There are other specific cell types that perform unique functions, such as
goblet cells that produce mucus, basal cells that differentiate and restore the
epithelial layer, and ciliated cells that move mucus up and out of the respiratory
tract. This organ system is critical for gas exchange that not only supplies oxygen
but also removes carbon dioxide, regulating blood pH, and controlling water
17

balance. In addition to its physiological role, it is also an important immune barrier
against invading pathogens (305, 306). Cells in the respiratory tract secrete a
range of proteases that cleave the extracellular matrix and secrete antimicrobial
proteins. The innate and adaptive immune systems also play a critical role in
protecting the tissues from infection by recognizing and breaking down invading
bacteria, viruses or fungi (307-311). Taken together, the complexity of the
respiratory tract makes it difficult to study infection and more physiologically
relevant models are needed to further our understanding of infection.
The current methodology to study viruses uses immortalized cell lines
grown in 2-D monolayers. These cell lines are often selected for specific features
that enhance growth, replication and recovery of virus. Infection in cell
monolayers allows us to better understand viral-host interactions, how the cell
responds to infection, and how the virus subverts cellular mechanisms to evade
detection and use cellular components to benefit viral replication. While these
studies are invaluable and ground-breaking research has been conducted using
these, ultimately, they lack some key characteristics from tissues that must be
considered. This pitfall is partially mitigated with the use of animal model systems
to study infection. While these model systems consider the complexity of entire
organ systems, humans only share partial conservation of key cellular factors
that can complicate translation to humans. These limitations make it important to
explore and develop other model systems that consider both tissue type and
organism specificity.
Human airway epithelial tissues (HAE) have been developed as a model
system to overcome the gap in current methods of research. Primary airway cells
isolated from the nasal passage or lung, which maintain proliferative ability and
pluripotency, are seeded on a trans-well (312, 313). After reaching confluency, the
media from the apical surface is removed, generating an air-liquid interface
mimicking the environment present in the lung. This then stimulates the
differentiation of cells into a multi-layer pseudostratified cellular layer composed of
bronchial or nasal epithelial cells and goblet cells. These cultures can recapitulate
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the 3-D environment and contain functional cilia as well as mucus production (Fig
1.5). These tissues are a model system to study respiratory pathogen-host
interaction and develop anti-viral therapeutics. HAE tissues have been widely
utilized to study important pathogens such as IAV, RSV, PIV3 and MeV (107, 144,
291, 294, 296, 297, 314-332). HMPV infection in these tissues has been examined,
although few studies have been reported (121, 135, 318, 333). This model system
offers significant advantage to understand HMPV infection in vivo while
maintaining a simplistic in vitro approach allowing for validation of important
aspects of viral infection as well as discovering other important host-viral
interactions.
Dissertation overview
Human metapneumovirus is a recently discovered and important
respiratory virus that infects nearly everyone during their life. It’s severity ranges
from mild “cold-like” symptoms to severe respiratory illness or even death. There
are currently no antiviral or vaccine available and understanding more about the
viral lifecycle will help to develop novel targets to treat and prevent infection. RSV,
another important respiratory pathogen similar to HMPV, also lacks a critical
molecular understanding of viral lifecycle needed to develop novel therapeutics to
fight infection. The data presented in this dissertation aims to further our
understanding of the molecular mechanisms of HMPV and RSV infection through
4-main questions.
First, we examine the function of the HMPV F fusion protein by analyzing
molecular interactions at the protein level. It is currently unknown which factors
contribute to triggering the F conformational changes required for membrane
fusion. However, a subset of HMPV F proteins were shown to use low pH as a
biological sensor to initiate this process. Analysis of F proteins currently available
in our lab and others suggests there are specific residues that contribute to this
phenotype. However, there are few strains examined and more are needed to
better understand which amino acids are critical for this function. We analyzed the
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F protein from strains of HMPV not previously characterized that contain key
residues previously implicated in low pH mediated fusion. We find that there are
key electrostatic interactions involved in this phenomenon and identify novel
interactions that modulate fusogenic activity and protein dynamics.
Next, we then investigated the proteolytic processing of the HMPV F protein
which is required for activation and the proteases that are able to cleave HMPV F
have not been previously determined. Exogenous trypsin is able to cleave a basic
amino acid residue just n-terminal to the fusion peptide. Addition of trypsin has
traditionally been used to propagate HMPV in cell culture. Another group
demonstrated that overexpressing a transmembrane serine protease, TMPRSS2,
also led to efficiently replication in vitro. Here, we demonstrate that HMPV can
utilize a variety of serine proteases that are also important for other respiratory
viruses including SARS and influenza A virus. We then explore this conserved
phenomenon as a means for broad spectrum anti-viral development against
several viruses that require serine proteases for activation by using a naturally
occurring protease inhibitor.
In addition to understanding the molecular mechanisms of HMPV F, we
then focused on comparing the two pneumoviruses, HMPV and RSV, in a 3-D
human airway epithelial (HAE) model system. Using HAE tissues, we find that RSV
and HMPV infection and spread kinetics are significantly different. To determine
why these closely related viruses demonstrate drastically different phenotypes, we
probed several different aspects of viral entry, replication and spread. We then
explored the use of neutralizing antibodies to examine the therapeutic potential for
inhibiting entry and spread for both viruses.
Co-infections for both RSV and HMPV have been reported, resulting in
increased disease severity. To better understand this phenomenon, we analyzed
co-infected cells to identify how both viruses interact during replication and spread
in vitro. We find that these RSV and HMPV can occupy the same replication
organelles, where vRNA and protein from both viruses coalesce. We examined
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several protein interactions involved in replication to understand how coalescence
in IBs affects viral replication and spread during infection and how this may lead to
increased disease severity.
Altogether, the results presented in this dissertation generate novel
information on the molecular mechanisms and processing of the HMPV F protein
not previously known. These findings identify key molecular aspects of low pH
fusing strains as well as which host factors are involved in proteolytic processing
for activation. We then examined two closely related pneumoviruses and
conducted a side-by-side comparison of infection, replication, and spread in HAE
tissues, which has not been previously examined. We find an interesting dichotomy
between two closely related pneumoviruses and generate a better understanding
for how these viruses can mediate infection and spread using an in vitro 3-D airway
epithelial model system. We then test the therapeutic potential of neutralizing
antibodies for both RSV and HMPV. Lastly, we examined the synergistic capability
of cells co-infected with RSV and HMPV and determined how this affects viral
replication and spread. Overall, we identify novel information at the protein level
as well as viral infection in a physiologically relevant model system. These findings
further our understanding of infection and highlight potential for therapeutic
intervention against RSV and HMPV as well as other respiratory viruses that utilize
similar molecular mechanisms during infection.
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Figure 1.1: Schematic representation of the HMPV particle structure and genomic layout. (A)
Phylogenetic classification of HMPV. (B) HMPV particle depicting the basic structure and protein
localization of an infectious particle. (C) Genomic layout of the negative sense genome and protein
open reading frame position.
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Figure 1.2 HMPV Fusion protein cleavage, structure, and fusion mechanism. (A) HMPV F is
synthesized as a monomeric 539 aa polypeptide which is then cleaved at single basic amino acid
residue N-terminal to the fusion peptide (FP). The basic layout is shown for protein domains
including the heptad repeat A (HRA) and B (HRB) domains, followed by the transmembrane (TM)
and C-terminal tail (CT). (B) The 3-D protein crystal structure of the pre and post fusion F protein
demonstrating the globular head and helical stalk domains. Colors correspond to the protein
schematic in A. (C) Upon appropriate stimulation, HMPV mediates membrane fusion by inserting
the fusion peptide into a target membrane, undergoing a large conformational change from the preto post-fusion state (shown in B), mediating fusion of the viral and target membranes.
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Figure 1.3: Viral lifecycle of HMPV. HMPV attaches to a target cells and enters through clathrin
mediated endocytosis where fusion with the endosomal membrane releases the viral
ribonucleoprotein complex. Transcription of viral proteins mediates the formation of inclusion
bodies for genomic replication and transcription. Newly synthesized viral genome and proteins then
accumulate at the plasma membrane at assembly sites where newly synthesized particles will
undergo budding or mediate the formation of filamentous extensions for cell-to-cell spread.
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Figure 1.4: HMPV mechanisms of entry and spread. After viral entry and replication, HMPV
spreads to uninfected cells. Formation of extensions between infected cells mediates direct cell-tocell spread. These extensions allow viral particles to (1) move alone the surface (2) directly transfer
nucleic acid materials or (3) move replication organelles from one cell to another. Alternatively,
virus fusion may mediate the formation of syncytia (4), which can also infect cells and mediate
genome or replication body transfer. Infected cells then mediate spread of HMPV through (5)
formation of intercellular extensions (6) polyploid viruses containing multiple genome copies or (7)
particle budding which will spread from infected to non-infected cells.
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Figure 1.5: Human airway epithelial tissue (HAE) culture model system. 3-D HAE tissues
contain both epithelial and goblet cells present in a pseudostratified tissue layer. These tissues are
then grown on a trans-well with an air-liquid interface containing an exposed apical surface and a
nutrient rich media at the basolateral surface. These tissues also contain functional cilia as well as
mucus production, creating an authentic primary cell culture model system.
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Chapter 2: Material and Methods
Cell Lines. VERO (ATCC), BSR (provided b Karl-Klaus Conzelmann, Max
Pettenkofer Institus) and LLC-MK2 (ATCC) cells were grown in Dulbecco’s
Modified Eagles Media (DMEM;Hyclone) supplemented with 10% fetal bovine
serum (FBS; Sigma). For BSRs, 0.5 mg/mL G418 was added every third passage
to keep selection for cells constitutively expressing the T7 polymerase. BEAS-2B
(ATCC) and HEp-2 (Medimmune) cells were maintained in Opti-MEM (Invitrogen)
supplemented with 2% FBS or BEBM supplemented with BEGM Single Quoat Kit
and growth factors (Lonza). 293 Freestyle cells (Invitrogen) were maintained in
293 Freestyle expression media on an orbital shaker. All cells were maintained at
37°C and 5% CO2.
Plasmids, Antibodies and Proteases. HMPV Fusion protein (F) within pGEM3Zf (+) was kindly provided by Ursula J. Buchholz (NIAID, Bethesda, Maryland).
All HMPV F proteins mutants were completed using Quick-Change site-directed
mutagenesis and confirmed by sequencing (Stratagene). F genes were then
subcloned to pCAGGS by digesting with EcoR1 and Sph1 (New England Biolabs).
Plasmids for pcDNA3.1-TMPRSS2-Myc, pcDNA3.1-HAT-Myc and pcDNA3.1Matriptase were provided by Dr. Marco Strauss and Dr. Gary Whittaker (Cornell
University). TMPRSS2 and HAT plasmids were subcloned into pCAGGS by EcoRI
and NdeI. Colonies were picked and sequenced the determine proper insertion.
54G10 anti-HMPV F monoclonal antibody plasmid was kindly provided by John
Williams (University of Pittsburgh, Children’s Hospital; please see recombinant
antibody production). pTM1 L, M2-1, N, P and CAT-Luciferase minigenome
reporter assay plasmids for HMPV were a kind gift from Dr. Rachel Fearns (Boston
University). pCNDA3.1 L, P, M2-1, N and luciferase minigenome were kindly
provided by Dr. Richard Plemper (Georgia State University). Both reporter gene
systems utilize the T7 promotor.
Viruses.

Recombinant
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fluorescent

protein
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metapneumovirus stain CAN 97-83 (rgHMPV) with a codon stabilized SH gene
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was kindly provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda,
Maryland). HMPV (MOI 0.01) was propagated in VERO cells and incubated at
37°C in Opti-MEM supplemented with 2 mM L-glutamine and 0.3 µg/mL TPCKtrypsin every other day. After 10 days, 1x SPG (218mM Sucrose, 4.9 mM Lglutamic acid, 3.8 mM KH2PO4, 7.2 mM K2HPO4) from the 10x stock was added to
the media and cells were scraped and kept cold. Cell pellets were spun down at
2500 rpm for 10 min on a Sorvall ST-8R centrifuge (Thermo). Supernatants were
added to 20% sucrose in TNE buffer (50 mM Tris-HCL, pH 7.4, 100mM NaCl, 0.1
mM EDTA) cushion. Virus was pelleted at 27,000 rpm in a SW-28 rotor on an
Optima XPN-90 ultracentrifuge (Beckman). Supernatant was aspirated and 100 µL
of Opti-MEM was added to each tube and incubated rocking overnight. The next
day, pellets were fully resuspended and aliquoted and snap frozen. Recombinant
green fluorescent protein expressing human respiratory syncytial virus A2 (rgRSV)
long was a kind gift from Medimmune/Astrazeneca. rgRSV MOI 0.1 was added to
HEp-2 cells in Opti-MEM and after 3 h incubation, Opti-MEM with 2 mM glutamine
was added and cells were incubated for 4 to 5 days until CPE developed. Cells
were then scraped and freeze-thawed 1 time. Cell debris was spun at 2500rpm
and supernatant was mixed with sucrose phosphate from a 10x stock to make 1x
(Hyclone, special order from Astrazeneca/Medimmune). Virus was then flash
frozen. Viral titers determined by infected Vero cells and counting fluorescent
particle formation.
Transfection. All HMPV F and protease constructs were transiently expressed
using the mammalian expression vector pCAGGS allowing for high levels of
protein expression in mammalian cell culture. Cell lines were transiently
transfected with plasmid DNA using either Lipofectamine reagent/ Plus reagent
(Invitrogen) according to manufacturer’s protocol. Mini-replicon plasmids were
transiently expressed by transfection using Lipofectamine 3000 reagent
(Invitrogen). Manufacturer’s protocols were followed accordingly unless stated
otherwise. 293 Freestyle cells were transfected using 293-fectin according to the
manufacturers protocol.
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Syncytia Assay. Vero cells (80-90%) were split into 6-well plates and transiently
transfected with 2 µg pCAGGS-HMPV F or empty pCAGGS using Lipofectamine
and Plus Reagent. The next day, cells were washed with PBS and incubated for
1hr in Opti-MEM with 0.3 µg/mL TPCK-trypsin. Cells were then rinsed once with
PBS pH 7.2 (GIBCO) before adding PBS buffered with 10 mM HEPES and 5 mM
MES at low (pH 5) or normal (pH 7) for 4 min. Cells were then placed back in OptiMEM with TPCK-trypsin for 2 h. These steps were repeated a total of 4 times. After
the final treatment, normal culture media was placed on the cells and syncytia
formation was observed at 24 to 48h post transfection. Images were taken using
a Nikon Ti2 with a 4x or 10x objective. The fusion index (f) was calculated as f=[1(C/N)], where C is the number of cells in a field after fusion and N is the number of
nuclei.
Luciferase Reporter Gene Fusion Assay. Vero cells in 60 mm dishes were
transfected with 1.5 µg of HMPV F wild type or variant and 1.5 µg of T7 control
plasmid containing luciferase cDNA (Promega) under the T7 promoter using
lipofectamine reagent and plus reagent according to the manufacturers protocol.
The next day, Vero cells were lifted with trypsin-EDTA, resuspended in DMEM
supplemented with 10% FBS and overlaid onto two 35 mm dishes or two wells in
a 6-well plate of confluent BSR cells, which constitutively express the T7
polymerase. Combined cells were incubated at 37°C for 60 min. Cells were then
rinsed once with PBS pH 7.2 before adding PBS buffered with 10 mM HEPES and
5 mM MES low or normal pH. Cells were treated for 4 min and then Opti-MEM
supplemented with 0.3 µg/mL TPCK trypsin was added and incubated for 1 h at
37°C. Cells were once again treated as described. After treatment, DMEM
supplemented with 10% FBS was added and cells were incubated for 4 h at 37°C.
Cells were analyzed for luciferase activity according to the luciferase activity
system (Promega) and analyzed on the Spectramax iD3 (Molecular Devices).
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Gel Electrophoresis and Western Blotting. Protein samples were analyzed via
15% SDS-PAGE, unless otherwise noted. For recombinant protein expression,
protein samples were taken pre- and post-induction to assess expression using instain gels (Bio-Rad) or using Coomassie staining. For Western blot analysis,
immunoprecipitated protein was transferred to polyvinylidene difluoride (PVDF)
membrane (Fisher) at 50 V for 80 min at 4°C. After blocking with 5% milk in Trisbuffered saline with 0.05% Tween-20 (TBS-T), membranes were incubated with
corresponding antibody. Membranes were washed with TBS-T and incubated with
anti-mouse or anti-rabbit 700/800 infrared secondary antibody at 1:10,000
(Jackson). Membranes were washed again with TBS-T and visualized with the BioRad ChemiDoc system or LiCor imaging systems.
Expression, metabolic labelling and immunoprecipitation. Vero cells (approx.
80-90%

confluent)

in

6-well

plates

were

transiently

transfected

using

Lipofectamine and Plus reagent (4 µg of total pDNA). 18 to 24 h post-transfection,
cells were washed with PBS and starved for 45 min in DMEM deficient in cysteine
and methionine and subsequently labeled for 3h with cysteine/methionine deficient
DMEM containing Tran35S-label (50 µCi/mL; MP Biomedicals). After labelling,
wells were washed 2x with PBS and lysed in 500 µL RIPA lysis buffer [100 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholic acid,
1 mM phenylmethylsulfonyl fluoride, 25 mM iodoacetamide , and complete miniEDTA protease inhibitor (Roche)] and frozen. Plates were then thawed and
scraped. Lysates were centrifuged at 136,500xg for 15 min at 4°C. Supernatants
were moved to 1.5 mL Eppendorf tubes and mixed with 6 µg of 54G10 antibody
for HMPV F and incubated rocking for 3 h rocking. Proteins were then
immunoprecipitated by incubating with 30 µL of Protein A-Sepharose beads (GE
Healthcare) for 30 min. The beads were washed 2X with RIPA + 0.30 M NaCl, 2X
with RIPA + 0.15 M NaCl, and 2X with SDS Wash II (150 mM NaCl, 50 mM TrisHCl, pH 7.4, 2.5 mM EDTA).
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Surface biotinylation protein labeling. Vero cells (approx. 80-90% confluent) in
6-well plates were transiently transfected using Lipofectamine and Plus reagent (4
µg of total pDNA). 18 to 24h post-transfection, cells were washed with PBS and
starved for 45 min in DMEM deficient in cysteine and methionine and subsequently
labeled for 3 h with cysteine/methionine deficient DMEM containing Tran35S-label
(100 µCi/mL; MP Biomedicals). Cells were washed 3 times with 3 mL of ice-cold
PBS pH 8.0, and surface proteins were biotinylated using 1 mg/mL EZ-Link SulfoNSH-Biotin (Pierce) in PBS with rocking for 35 min at 4°C followed by incubation
at room temperature for 15 min. Cells were then washed 2 times with ice-cold PBS
and lysed with 500 µL of RIPA lysis buffer. Cellular lysates were centrifuged at
136,500xg for 15 min at 4°C. The supernatant was placed into a 1.5 mL
microcentrifuge tube, and 6 µg of 54G10 antibody was added and incubated
rocking for 3h at 4°C. Proteins were then immunoprecipitated by incubating with
30µL of Protein A-Sepharose beads for 30 min. The beads were washed 2X with
RIPA + 0.30 M NaCl, 2X with RIPA + 0.15 M NaCl, and 2X with SDS Wash II (150
mM NaCl, 50 mM Tris-HCl, pH 7.4, 2.5 mM EDTA). Then, 60 µL of 10% SDS was
added, and the boiled for 10min, removed to a new tube, and repeated with 40 µL
of 10% SDS for a total of 100µL. Ten microliters of the supernatant was removed
to analyze the total protein population. To the remaining supernatant, 30 µL of
Streptavidin beads (Pierce) and 400µL of biotinylation dilution buffer (20 mM Tris
(pH 8), 150 mM NaCl, 5 mM EDTA, 1% Triton X—100, 0.2% bovine serum
albumin) were then added for 1 h at 4°C with rocking. HMPV F was analyzed by
15% SDS-PAGE and imaged using the Typhoon imaging system (GE Healthcare).
Band densitometry was completed using ImageQuantTL to quantify protein
expression (% expression= Sum of F0 and F1, normalized to WT).
Rescue of mCherry HMPV. The plasmids for rescue of HMPV strain JPS07E2,
p(+)JPS07E2, pCITE-76N, pCITE-76P, pCITE-76M2-1 and pCITE-76L were a
kind gift of Dr. Makoto Takeda (National Institute of Infectious Diseases, Tokyo).
We replaced the GFP cassette in p(+)JPS07E2 with an mCherry cassette, using
restriction sites NheI and SacI. For virus rescue, BSR cells were transfected with
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2.5 µg of p(+)JPS07E2, 1 µg of pCITE-76N, 1 µg of pCITE-76P, 0.5 µg of pCITE76M2-1 and 0.5 µg of pCITE-76L using Lipofectamine3000. 48 h post transfection,
BSR cells were scrapped and overlaid on top of Vero cells growing in a 60 mm
plate. Co-cultured cells were kept in Optimem supplemented with glutamine 2 mM
and TPCK-Trypsin 0.3 µg/mL. Virus was harvested at day 6 post-infection and
tittered in Vero cells as previously described (288).

Inhibition of HMPV viral infection in cell culture by SPINT2. VERO (200,000)
cells were plated into 24-well plates. The following day, cells were infected with
MOI 1 rgHMPV for 3 h. Cells were washed with PBS and 500 µL OPTI-mem with
or without 500nM SPINT2 (Provided by Dr. Gary Whittaker) and 0.3 µg/mL of
TPCK-trypsin was added and incubated for up to 96 h. The SPINT2 and trypsin
was replenished in new OPTI-mem every 24 h. For each time point, media was
aspirated and 100 µL of OPTI-mem was added to cells followed by scraping and
flash freezing. These samples were then titered on confluent VERO cells up to a
dilution of 10-6 to calculate viral titer. Graph shows 4 independent replicates with
internal duplicates plotted as individual points. Some data points not shown are
due to sample loss during preparation, with a minimum of 6 points per group and
3 independent replicates.
Cleavage and inhibition of HMPV F by SPINT2. VERO cells were plated into 6well plates. The following day, 2µg HMPV F or 1:1 with a plasmid containing
TMPRSS2, HAT or Matriptase was transfected in using Lipofectamine and plus
reagent. The following day, cells were radiolabeled with 50 µC of S35 for 4 h and
exogenous proteases KLK5 (150 µM), KLK12 (150 µM) and Matriptase (200 µM)
were added during the label. 3 µg/mL of TPCK trypsin was used as a control for
both transfected and exogenous proteases. For cleavage inhibition, KLK5, KLK12
and Matriptase were pre-incubated with 0 nm, 10 nm or 500 nm of SPINT2 for 10
min and then added to cells for 4 h. Cells were washed and lysed in RIPA lysis
buffer and processed for gel electrophoresis and imaging.
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Fluorescence-activated cell sorting (FACS) analysis. 50,000 VERO cells were
plated into 24 well plates and subsequently infected with rgHMPV or rgRSV with
or without prior treatment in Opti-MEM for 3 h and then washed and placed in
normal culture media. Cells were then incubated overnight at 37°C. The following
day, cells were washed with PBS and lifted with 100 µL of Trypsin-EDTA. Lifted
wells were placed into 5 mL snap-cap tubes and mixed 1:1 with 2x fixation buffer
[4% paraformaldehyde (PFA), 100 mM EDTA pH 8] for a final concentration of 2%
PFA and 50 mM EDTA. Samples were mixed by vortexing and then analyzed by
FACS analysis.
Recombinant antibody production. 54G10 recombinant protein expression
system was kindly provided by Dr. John Williams (University of Pittsburg,
Children’s Hospital). Suspension 293F cells were split 1.5x107 cells per T-75 flask
in 28 mL of expression media. The next day, 60 µL of 293-fectin was mixed with
60 µg of heavy chain plasmid and 60µg of light chain plasmid in a total of 2mL
Opti-MEM (per flask). Cells were then incubated for an additional 4 days and then
spun down at 300xg for 5 min and the supernatant was collected and stored at 4°C
and the pellet was resuspended in fresh media by vortexing and placed back into
the flask to incubate for another 4 days. At day 8 post transfection, cells were spun
down, and the supernatant was taken and placed with the previous supernatant
and cells were discarded. The supernatant was filtered through a 0.45 µm filter
and ran over a gravity flow column containing sepharose beads with protein A to
bind antibody. After binding, the column was washed with wash/bind buffer (0.15
M NaCl, 20 mM Na2HPO4, pH 7.0). The beads were treated with elution buffer (0.1
M glycine, pH 3.0) and this was eluted into a tube containing neutralization buffer
(1 M Tris-HCl, pH 8.5) at roughly 1:10 the volume of elution. Eluted protein was
then concentrated using a centrifuge filter (Amicon) (3,000 MWCO) in a swing
bucket rotor according to manufacturer recommendation. Once the volume was
reduced to 1 mL, an aliquot was tested using the 280nm reading on a nanodrop
and protein purity was analyzed by blot analysis.
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Confocal Microscopy. HAE tissues were removed from trans-wells and frozen in
O.C.T compounding embedding media (EM Sciences). 10-20 µm tissue sections
were cut using a MICROM HM525cryostat and collected on Superfrost Plus slides
and heat fixed at 55°C for 30 min. Sections were permeablized in 0.5% Triton X100 for 15 min at 4°C followed by blocking in 1% normal goat serum. Sections
were incubated with primary antibodies for RSV F (1:600), N (1:200), P (1:600)
(Abcam) or Keratan Sulfate (1:1,200) (EMD Millipore) overnight at 4°C. The
following day, tissues were washed with 0.05% tween-PBS, secondary antibodies
(Jackson) and TRITC-Phalloidin (1:1,000) (Invitrogen) were added at room
temperature for 1 h, washed and mounted using SloFade plus DAPI (Invitrogen).
Pictures were taken using a Nikon A1 confocal microscope and analyzed with NISElements software (Nikon).
Stellaris Fluorescent in situ hybridization (FISH) for viral RNA detection.
Forty-eight DNA probes targeting the HMPV and RSV vRNA genome between nt
1-5,467 were obtained from BioSearch Technologies (Novato, CA) and designed
using the software provided by the company. Each probe is 20 nt long and linked
at the 3’ end to Quasar fluorophore. Cells were fixed for 10-30 min with 4% PFA
and then permeabilized overnight with 70% ethanol at 4°C. The next day cells were
washed once with 2x SSC-10% formamide buffer, and then incubated overnight at
25°C in hybridization buffer (4x SSC, 1x Denhardt’s solution, 150 µg/mL ssDNA, 2
mM EDTA, 50% formamide in DEPC treated water) containing the probes at a
concentration of 2.5 mM. After 24 h, cells were washed two times for 20 min with
2x SSC-10% formamide buffer and slides were then mounted using Vectashield
mounting media.
Fluorescence threshold analysis. GFP cells present within infected tissues,
were quantified with either NIS elements “object count” or ImageJ (FIJI) using the
“adaptive threshold” analysis plugin. Briefly for ImageJ quantification, fluorescent
microscopy images of HAE tissues were imported, background subtracted for each
image and converted B&W. Using several test images, the adaptive threshold was
34

set to ensure that all data points with minimal background were obtained, and this
macro was used for all images within that replicate. Finally, particle density was
quantified using “analyze particles” and total density was quantified as percent
area. GFP expression was also analyzed using NIS elements software using
threshold analysis based on area coverage using the “object count” plug-in and
selecting a fluorescence threshold. All counts were taken as percent area
coverage.
Infection of Human Airway Epithelial (HAE) tissues. Human tracheal bronchial
differentiated airway (Epiairway) tissues were purchased from Mattek and
maintained in 3 mL of Air-100 media at 37°C for one week prior to infection, with
the media changed and the apical surface washed with 0.9% NaCl every other day
to remove mucus. Prior to infection, the basal surface was washed with hepes
buffered saline (HBS) for 30 min and the apical surface was washed three times
with 0.9% NaCl every 10 min with incubation. For HMPV, the apical surface
washes were completed using alpha-lysophosphatidylcholine (Sigma) in HBS (75
µg/mL). Tissues were infected with either rgRSV or rgHMPV on the apical surface
and incubated for 3 h at 37°C. The apical side of tissues were then washed once
with HBS and incubated at 37°C. Media containing 0.3 µg/mL TPCK-trypsin was
added to rgHMPV infected tissues and replenished daily. Images were obtained
using a Zeiss Axiovert-100 or a Nikon Ti-2. After the final time point, both apical
and basal sides were washed with PBS and fixed in 4% paraformaldehyde for 20
min at room temperature.
Microneutralization and spread in HAE tissues. For microneutralization, rgRSV
(MOI 1) was preincubated with MEDI8897 or Palivizumab for 1 h at 37°C. rgHMPV
(MOI 3) was preincubated with 54G10 for one hour at room temperature. Both
rgRSV and rgHMPV incubations were completed in a total volume of 150 µL TEER
buffer (Mattek). For spread, HAE tissues were infected with rgRSV (MOI 0.3) or
rgHMPV (MOI 3.0). Antibody dilutions were completed in 50 µL of TEER buffer
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and added to the apical surface. The initial antibody was added at 6 hpi and
replenished every 24 h post inoculation until experiments were completed.
Statistical analysis. Statistical analysis was preformed using Prism7 for Windows
(Graphpad). A p-value of less than 0.05 was considered statistically significant.
Multiple comparisons tests were generated using a one-way ANOVA with a
Bonferroni multiple comparison correction. P values are indicated as defined: *
P<0.05, ** P<0.005. *** P<0.0005, **** P<0.0001.
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Chapter 3: Human metapneumovirus fusion protein triggering: Increasing
complexities by analysis of new strains
*This work was completed with the help of Andres Chang and Edita Klimyte, who
both contributed intellectually to this work. Andres generated the HMPV F clones
from the viral stocks used during all experiments. Edita Klimyte conducted syncytia
and luciferase assays used in this chapter (shown in Fig 3.1, I generate the figures
for this data). I performed protein expression and cleavage shown in figure 3.2, the
protein model for figure 3.3, and the co-expression syncytia and luciferase fusion
experiments in figure 3.4. This chapter is adapted from a manuscript (Kinder et al.
Virology. 2019 May;531: 248-254)
Introduction
Human metapneumovirus (HMPV) is a recently discovered enveloped,
negative-sense, single-stranded RNA virus. Although first identified in 2001,
HMPV has now been shown to be a cause for respiratory tract infections in humans
worldwide since at least 1958 (30-32). Nearly everyone is initially infected by five
years of age and reinfection is common throughout life (34). Infection leads to a
variety of symptoms ranging from coughing and wheezing to pneumonia and
bronchiolitis, potentially requiring hospitalization in severe cases. In addition,
infants, immunocompromised, and elderly patients are most likely to develop
severe infections (31, 36, 37, 42-46). While HMPV is ubiquitous and responsible
for severe upper and lower respiratory tract infections, there is still no FDA
approved antiviral treatment or vaccination available. Therefore, a more thorough
understanding of the viral lifecycle and molecular mechanisms required for
infection are needed to discover novel antiviral targets.
HMPV is phylogenetically classified into two genetic lineages (A and B) and
further characterized into sub-lineages (A1, A2, B1 and B2) based on the
sequences of two surface glycoproteins: the fusion protein (F) and the attachment
protein (G) (78). To infect cells, enveloped viruses fuse their membrane with host
cell membranes, a process mediated by one or more viral surface glycoproteins.
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In the instance of HMPV, this process is mediated by F alone in vitro and in vivo,
whereas closely related paramyxoviruses require both F and G (157, 189, 334). F
is a homo-trimeric class I fusion protein present within viral membranes as well as
membranes of infected host cells. To become activated, F is proteolytically cleaved
from the precursor form (F0), into the metastable, disulfide-linked heterodimer
(F1+F2) (158, 159). Cleavage can be accomplished by the addition of exogenous
trypsin in vitro (189), although in vivo it is thought that F is cleaved by secreted or
cell surface proteases present in the host. Once cleaved, HMPV F can be triggered
to undergo an essentially irreversible and energetically favorable conformational
change from the pre-fusion form to the post-fusion state with released potential
energy driving membrane fusion (189, 240-242).
HMPV particles have been shown to be internalized via clathrin mediated
endocytosis in human bronchial epithelial cells through a dynamin dependent
mechanism (242, 335). Further evidence demonstrated that for HMPV, viral and
host membrane fusion takes place within the endosomes (335). Some strains of
HMPV, mainly within clade A, utilize low pH generated through endosomal
acidification as a mechanism to trigger the fusion protein, similar to HA from
influenza. However, this is proposed to not be true for all strains of HMPV (189,
240-242, 335). For fusion proteins that are triggered by low pH, it is hypothesized
that repulsive electrostatic forces between critical residues lead to global protein
destabilization, initiating the conformational transition from the pre-fusion to postfusion state (336-338). It has been proposed that specific histidine (H) residues
become protonated at low pH and subsequently interact with neighboring basic
residues to destabilize the pre-fusion state and initiate membrane fusion. In HMPV
F, H435 within the globular head is thought to serve as a pH sensor (241, 242).
Recently, a high-resolution structure of a stabilized pre-fusion HMPV F
[NL/1/00(A1)] was solved [PDB: 5WB0] (205). This structure revealed that lysine
(K) 20 and glutamic acid (E) 433 interact to form a potential salt bridge. Under low
pH conditions, protonation of the neighboring H435 may lead to cation electrostatic
repulsion driving conformational changes and promotes membrane fusion. Studies
with recombinant HMPV containing mutations in this region have confirmed its
38

importance for viral infectivity (239, 241). Additional residues have been identified
as playing a role in low pH triggered fusion, including K296, W396, and N404.
Furthermore, studies using F proteins from prototype strains from each clade have
suggested that fusion induced by low pH is restricted to clade A virus fusion
proteins, and glycine (G) 294 is critical for low pH triggered fusion (240, 241).
However, few HMPV F proteins have been studied in each clade and therefore
additional analysis is needed to further understand this mechanism.
In this study, we examined three previously uncharacterized HMPV F
proteins for their fusion activity, protein expression, and cleavage activation levels.
The first F protein, cloned from TN83-1211, contained a unique H434 residue,
adjacent to a previously characterized histidine at 435 demonstrated to be critical
for low pH fusion. Protein mutagenesis in our reference strain supports its
contribution to increased fusion at low pH and more efficient cleavage by trypsin.
The second F protein, cloned from TN94-49, is able to promote low pH mediated
fusion without G294, although this residue was previously identified as critical for
this mechanism of membrane fusion. The third HMPV F protein, cloned from TN9612, contains E at position 294. Interestingly, TN96-12 was unable to mediate fusion
at either neutral or low pH conditions, or in the presence of the attachment protein,
G. This finding suggests additional factors are necessary to trigger the F protein.
Taken together, these results further demonstrate the complexity of HMPV F
mediated membrane fusion and the significant phenotypic differences observed
with only a few amino acid changes.

Results
To examine HMPV fusion, F protein genes were cloned from three available
HMPV strains: TN94-49, TN96-12 and TN83-1211, all isolated in the Williams
laboratory and propagated and stored at BEI resources. These F isolates were
sequenced and compared to a low pH prototype strain, CAN97-83, used as a
positive control in these studies. HMPV F is highly conserved, and therefore few
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amino acid changes were detected between strains. The TN94-49 F clone differed
from CAN97-83 F by only 6 amino acids (Fig 3.1D). One notable difference was
residue 294, which contained K294 instead of G294, a glycine residue previously
suggested as essential for low pH triggered fusion for clade A HMPV F proteins
(240). When comparing TN96-12 F clone to CAN97-83 F, 9 amino acid changes
were present, including E294 instead of G294. Lastly, the F isolate from TN831211 only differed from CAN97-83 by two amino acids, S175 and H434, and did
not match the published isolate sequence of TN83-1211. However, this mutation
was present in several clones analyzed, suggesting the viral stock may have had
a heterogeneous population of virus present. For clarity, we refer to this protein
as S175H434 F. The presence of a unique amino acid in S175H434, H434, instead
of the highly conserved Q434 in all other published strains, led us to further study
this F isolate. The neighboring residue H435 is hypothesized to play a critical role
in electrostatic repulsion with neighboring residues after protonation at low pH,
acting as a physiologic timing sensor to promote fusion. Based on these findings,
we hypothesized that the second histidine at position 434 could potentially be
involved in fusion of S175H434 after exposure to low pH, similar to the function
observed for H435. In addition, TN94-49 containing K294 and TN96-12 containing
E294 were of interest to assess the role of these amino acids in low pH mediated
fusion compared to G294.
To determine whether these F isolates were able to promote neutral or low
pH- mediated membrane fusion, we first conducted a syncytia assay. As previously
reported, CAN97-83 F promoted fusion when exposed to low pH and was therefore
used as a positive control for low pH triggered fusion (Fig. 3.1A). TN94-49 F
generated syncytia following low pH treatment, similar to CAN97-83 F, but no
syncytia formation was observed at neutral pH. Interestingly, TN96-12 F was
unable to generate cell-to-cell fusion at both neutral and low pH, whereas
S175H434 F generated minimal background syncytia at neutral pH and robust
syncytia formation after exposure to low pH that was significantly higher than the
syncytia observed with CAN97-83 F (Fig 3.1A, quantified in 3.1B). To confirm our
findings in the syncytia assay, we utilized a luciferase reporter assay as a second
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cell-to-cell fusion assay metric. Consistent with the syncytia assay, TN94-49 F
exhibited no fusion above background at neutral pH, and low pH induced activity
similar to that of CAN97-83 F, while S175H434 F exhibited significantly higher
(nearly 500%) low pH-induced fusion activity compared to CAN97-83 F. Again,
TN96-12 F-mediated fusion was undetectable above background levels (Fig 3.1C).
F S175H434 differs from CAN97-83 F by only two amino acids yet
demonstrates significantly increased low pH-induced membrane fusion (Fig 3.1 AC). H435 has been implicated in low pH-mediated triggering, so it appeared that
H434 might serve a similar role. To examine the contribution of H434 in fusion, we
generated a point mutation in CAN97-83 WT F using site-directed mutagenesis,
changing Q at position 434 to H (CAN97-83 Q434H). We then conducted both
syncytia and luciferase reporter assays to examine fusion activity of this mutant.
Interestingly, syncytia assays demonstrated that CAN97-83 Q434H was able to
recapitulate the high level of fusion observed for S175H434 (Fig 3.1A), and
quantification of the fusion activity demonstrated a similar fusion profile to that of
S175H434 (Fig 3.1B). The luciferase reporter assay again confirmed that CAN9783 Q434H demonstrated fusion activity similar to S175H434 and significantly
higher than WT CAN97-83 F (Fig 3.1C). Together, these results demonstrate that
the hyperfusogenic phenotype observed in S175H434 is primarily mediated by a
single amino acid change, Q434H.
Fusion mediated by F requires that the protein is synthesized, trafficked to
the surface and proteolytically processed. As fusion is correlated with cell surface
expression and cleavage activation, we utilized radioactive metabolic labelling
coupled with surface biotinylation to examine both total and surface protein
expression and cleavage activation profiles for each F isolate. Interestingly, we
identified significant differences in the total and surface protein expression levels
between the F proteins. Compared to CAN97-83 WT F, TN94-49 F had similar
levels of total (F0+F1) and surface expression, (Fig 3.2A and quantified in 3.2B),
which correlated with the similar fusion activities found for these proteins (Fig
3.1C). The two F proteins shown to promote high levels of fusion, S175H434 and
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CAN97-83 Q434H, both displayed higher average total protein expression
(approximately 6-fold and 3-fold, respectively, compared to CAN97-83 F; Fig 3.2A
and 3.2B), though this difference was only statistically significant for S175H434 F.
The two highly fusing F proteins also displayed higher average surface protein
expression (approximately 10-fold and 7-fold, compared to CAN97-83), though
again statistical significance was only reached for S175H434 F. These results
suggest that higher surface expression levels may be at least partially responsible
for the higher levels of fusion observed for S175H434. However, TN96-12 F failed
to promote fusion, despite similarly high surface expression, demonstrating that
surface expression is only one factor contributing to overall fusion (Fig 3.1B).
These findings demonstrate that a single amino acid change was able to increase
the fusion protein expression compared to WT, suggesting that this area of the
protein is involved in protein stability or turnover and offering a potential
explanation for the phenotypes observed.
HMPV F is synthesized as an inactive, monomeric protein that must be
proteolytically processed into the heterodimeric, disulfide linked F1 and F2, in order
to mediate fusion. In vitro, exogenous trypsin cleaves the protein within the
cleavage motif to generate the fusogenically active form. Due to the requirement
of cleavage for fusion, we examined the relative amount of trypsin cleavage for
each F variant. To identify a potential role for proteolytic activation by trypsin on
𝐹𝐹
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population of F (Fig 3.2C). Interestingly, F variants that were more highly

expressed, S175H434, TN96-12, and CAN97-83 Q434H were cleaved at
significantly higher levels than CAN97-83 or TN94-49, potentially contributing to
the observed hyperfusogenic phenotypes (Fig 3.2C). Though the higher levels of
CAN97-83 Q434H protein expression did not reach statistical significance, this
protein displayed significantly higher levels of protein cleavage compared to
CAN97-83 WT F.
These findings suggest the hyperfusogenic phenotypes observed for
S175H434 F were due in part to the presence of higher levels of F at the surface
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as well as increased cleavage activation. The finding that CAN97-83 Q434H
yielded significantly increased membrane fusion and cleavage suggests H434 is
important for this phenotype. Conversely, TN96-12, which failed to mediate cellto-cell fusion in both syncytia and luciferase reporter assays, was significantly
more abundant in total, and approaching significantly higher surface populations
(p=0.0685). In addition, it was cleaved significantly higher when compared to
CAN97-83 F. Although cleaved significantly higher when compared to CAN97-83
F, TN96-12 F was unable to mediate fusion in cell-to-cell fusion assays suggesting
there may be other factors necessary for triggering of this F isolate which are not
present on the cell surface.
Discussion
In this study we examined the fusion activity, expression, and cleavage of
three previously uncharacterized F proteins. Previously, we have reported low pHpromoted membrane fusion for CAN97-83, and others have reported this
phenomenon only within clade A strains of HMPV (189, 240-242), with a glycine
residue at position 294 (G294) described as a requirement for low pH-promoted
fusion (240). However, TN94-49 F contains a lysine (K) at this position and
promotes fusion after exposure to low pH, indicating that either of these residues
can be present at position 294 in an HMPV F protein which promotes low pHinduced fusion (Fig 3.3). Genetic variability analysis of HMPV F proteins
demonstrated that position 294 is one of two positively selected sites with relaxed
selective constraints for the amino acids G, K or E, indicating that when one of
these are present at this position, viral fitness is unaffected (339). Analyses from
the Melero group (240, 241) indicated that E294 was present with neutral pH fusing
F proteins, while previous results from several groups showed low pH fusion with
F proteins containing G294. Our findings demonstrate that K294 can also be
present in a low pH induced F protein. Additional amino acids at positions 296, 396
and 404 (Fig 3.3) have been described to modulate low pH fusion sensitivity (241).
However, these amino acids are completely conserved in the strains of HMPV
examined in this study.
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HMPV F S175H434 displayed a hyperfusogenic phenotype and significantly
increased protein expression of both total and surface populations compared to
CAN97-83 F, but only two amino acid changes were present between the two
proteins. One notable amino acid difference was H434, which is in close proximity
to a previously identified amino acid, H435, shown to be important for low pH
triggered fusion.
demonstrated

We generated a CAN97-83 mutant, containing Q434H, and

this

single

amino

acid

mutation

could

recapitulate

the

hyperfusogenic phenotype and expression patterns observed for S175H434 F.
Due to its close proximity, H434 may contribute to low pH mediated fusion through
a similar mechanism to H435, which has been hypothesized to interact with
surrounding residues and, upon protonation, destabilize the pre-fusion form to
initiate refolding to the post-fusion form. Recently, a high-resolution pre-fusion
structure of HMPV F was published. Examination of the structure suggests the
need for destabilization in the heptad repeat B region to trigger the refolding event
to the post-fusion conformation (205). This structure also suggests a model for the
role of H435 in fusion, as a potential electrostatic disruption between E433 and
K20 by protonated H435 upon acidification could provide this destabilization (Fig
3.3A and 3.3C). Additionally, K438 could play a role given the close proximity of
the residue to the H434 and H435 amino acid positions, potentially enhancing this
destabilization and increasing fusion activity (Fig 3.3A and 3.3D) (239). Lastly,
there are significant differences in the overall protein expression of F from the
examined strains, suggesting a potential role in protein folding, overall stability, or
turnover rates for H434. When examining known sequences of HMPV F proteins,
H434 was not present, which suggests that the hyperfusogenicity conferred by this
amino acid may not be beneficial to HMPV infectivity. For parainfluenza virus 3
(PIV3), a closely related paramyxovirus, enhancement of receptor binding and
fusion within the monolayer was detrimental for replication in human airway
epithelium and in vivo during infection in cotton rats (328). However, when
examining a hyperfusogenic F protein mutant from a more closely related
pneumovirus, respiratory syncytial virus, there were increased viral loads, severe
lung pathology and weight loss in mice compared to controls (301), so whether
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hyper-fusogenicity is preferentially selected by HMPV during infection is not well
understood. Interestingly, when HMPV was incubated with the neutralizing
monoclonal antibody 54G10, one of the detected escape mutations was Q434H.
No changes in binding affinity of 54G10 for the Q434H mutant were detected,
suggesting that this mutation may introduce structural changes into the F protein
which provide some potential benefit (340).
Our results show that TN96-12 was also highly expressed in both total and
surface populations but does not mediate fusion in cell-to-cell fusion assays. Coexpression of TN96-12 F with G at neutral or low pH was not sufficient to induce
syncytia formation in cell culture (Fig 3.4A and 3.4B), indicating that lack of the G
protein is not the reason for the absence of fusion. TN96-12 HMPV is a clinical
isolate, able to initiate infection in patients as well as propagate in cell culture, and
thus must have a functional fusion protein. Therefore, our findings point toward the
need for other host factors required for fusion of some HMPV strains in order to
escape the endosome and initiate infection, and the lack of fusion in our assays
suggests these factors may not be present on the cell surface. Currently, heparan
sulfate proteoglycans and RGD binding integrins are proposed cellular factors for
association and entry of HMPV through endocytosis (123, 243, 335, 341). It is
possible that there are other critical factor(s) within the endosome that interact with
HMPV F and trigger the fusion protein, similar to the use of the endosomal receptor
NPC-1 by Ebola virus GP (234).
Taken together, the results in this study highlight the diversity of HMPV F
activity and the complexity associated with fusion. Our results indicate that the
contribution of a single amino acid can be responsible for observed phenotypes,
demonstrating that minor evolutionary changes can lead to significant phenotypic
differences that alter HMPV infection and tropism. Further studies are necessary
to better understand and elucidate key contributing factors of fusion protein
stability, cleavage and host factor interaction required for HMPV infection, as well
as which key residues and regions of the F protein are vital for fusion and entry of
the virus.
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Figure 3.1. HMPV F proteins from different strains exhibit variable fusion activity
promoted by low pH. (A) Representative images of syncytia formation of cells expressing the
HMPV F proteins after pulses at pH 5 or pH 7 (n = 3). (B) The fusion index was calculated using
the equation f = [1 – (C/N)] where C is the number of cells in a field after fusion and N, the number
of nuclei. Six fields were scored per condition representative of 3 independent experiments. “*”s
indicate statistical significance compared to fusion for CAN97-83 (A2) F after pH 5 pulses (n=3) [*
p<0.05, ** p<0.005, *** p<0.0005 and **** p<0.0001]. Graph was broken into two experiments
(denoted by the graph break and colors: red/orange bars represent independent experiment from
green/blue). Statistical significance within these assays is compared to CAN97-83 within each
independent experiment. (C) Luciferase reporter gene assay of Vero cells transfected with HMPV
F upon which BSR cells were overlaid and subjected to two pH pulses. Data are presented and
normalized to CAN97-83 (A2) F luminescence (fusion) at pH 5 (n = 3) +/- standard deviation. *
Indicates statistical significance compared to CAN97-83 F after pH 5 pulses. Graphical
representation and statistics were conducted as described in B. (D) Partial protein sequence
analysis of F from 4 strains of HMPV surrounding key residues at positions 294 and 435. Sequence
alignment was generated using ClustalW. The asterisk “*” indicates identical residues and the colon
“:” indicates conserved substitutions.
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Figure 3.2. HMPV F protein expression and cleavage by exogenous trypsin. (A)
Representative gels of total and surface protein expression in metabolically labeled Vero cells
expressing empty vector pCAGGS-MCS (Mock), CAN97-83 F, S175H434 F, TN94-49 F, TN96-12
F, and mutant CAN97-83 Q434H F in the presence of 3.0 μg/ml of TPCK-trypsin. (B) Quantification
of the total and surface protein populations for F (F0 and F1 forms) in metabolically labeled Vero
cells. Data are presented as normalization to CAN97-83 (A2) F expression, which was set to 1 (n =
4). “*”s Indicate statistical significance compared to F for CAN97-83 F (n= 4) [# P<0.07, * p<0.05,
** p<0.005, *** p<0.0005 and **** p<0.0001]. (C) Quantification of the relative amount of fusion
protein cleavage within the surface population of F calculated using F1/(F1 + F0) and normalized to
CAN97-83, set as 1.
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Figure 3.3: HMPV residues identified thus far involved in low pH mediated fusion. A) The
pre-fusion homo-trimeric structure of HMPV F of NL/1/00 (pdb: 5WB0) with residue positions
identified for low pH fusion highlighted including (B) 396 (C) 20, 433, 434, 435(D) 294, 296, 396,
404 and 438. Images generated using Pymol protein structure software.
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Figure 3.4: Addition of HMPV G to TN96-12 F is unable to mediate fusion at low pH. A) HMPV
F (TN 96-12) was co-transfected with or without G at various ratios in VERO cells and fusion activity
was measured in a luciferase reporter assay. B) Co-transfected cells were subjected to H&E
staining and bright field microscopy to examine syncytia formation. White arrows indicate presence
of multinucleated syncytia present in the representative field. Error bars represent the standard
deviation of two independent replicates completed in duplicate.
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Chapter 4: SPINT2 inhibits proteases involved in activation of both
influenza viruses and metapneumoviruses
* This work was completed in collaboration with Dr. Marco Strauss and Dr. Gary
Whittaker (Cornell University) who provided constructs for TMPRSS2, HAT and
Matriptase enzymes as well as completing the peptide cleavage assay and kinetics
for HMPV F (Table 4.1). In addition, they conducted all of the influenza assays and
corresponding figures (Figures 4.1, 4.2, 4.4, 4.5, and 4.7). I performed all other
experiments and generated the associated figures (Figures 4.3 and 4.6). This
chapter was adapted from a co-written manuscript (Kinder and Straus et al 2020.
Virology. 543:43-53).
Introduction
Influenza-like illnesses (ILIs) represent a significant burden on public health
and can be caused by a range of respiratory viruses in addition to influenza virus
itself (342) . An ongoing goal of anti-viral drug discovery is to develop broadly
acting therapeutics that can be used in the absence of definitive diagnosis, such
as in the case of ILIs. For such strategies to succeed, drug targets that are shared
across virus families need to be identified.
One common cause of influenza, which shaped the term ILI, are influenza
A viruses (IAV), including H1N1 and H3N2, that cross species barriers from their
natural avian hosts and infect humans (343, 344). Novel emerging viruses such as
H7N9 that has caused hundreds of deaths since its appearance in China in 2013
pose an additional concern (345). The World Health Organization (WHO)
estimates that each year about 1 billion suffer from flu infections, 3 to 5 million
people worldwide are hospitalized with severe illness and approximately 290,000
to 650,000 people die from the disease (346). Mortality rates can dramatically rise
during influenza pandemics as observed with the Spanish flu of 1918, the Asian
pandemic of 1957 and the Hong Kong pandemic of 1968 (344, 347). Vaccinations
can provide an effective protection against seasonal and pandemic outbreaks but
provide limited or no protection when viruses evolve and/or acquire mutations
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resulting in antigenically distinct viruses. This antigenic drift or shift requires that
new vaccines be produced quickly and in vast amounts which can be problematic
especially during pandemics. In addition to vaccines, several antiviral therapies
have been applied to treat influenza A infections such as adamantanes acting as
M2 ion channel blockers (amantadine, rimantadine) and neuraminidase inhibitors
which block the cleavage of sialic acid in newly formed virions (oseltamivir,
zanamivir) (348). However, several influenza subtypes including the most common
H1N1 and H3N2 have emerged globally that are resistant against adamantanes
and similar observations were made with respect to oseltamivir (348). More
recently, baloxavir marboxil (BXM) which is an inhibitor of the influenza polymerase
acidic subunit (PA) was approved as an antiviral therapy (349). Although it is fully
effective against currently circulating influenza A and B viruses clinical trial studies
have already shown that treatment with BXM selects for influenza virus with
specific amino acid substitutions in PA resulting in reduced susceptibility to the
drug (350, 351).
Another common cause of ILI are pneumo- and paramyxoviruses, including
human metapneumovirus (HMPV), respiratory syncytial virus, and parainfluenza
viruses. Clinical presentation of these viruses resembles many of the symptoms of
influenza, where they cause significant morbidity and mortality as well as a large
economic burden (352, 353). HMPV is ubiquitous, with nearly everyone infected
by the age of 5 and reinfection is common throughout life, impacting children, the
elderly and immunocompromised individuals (30, 36, 354). While HMPV is a
common cause of ILI, there are currently no approved vaccines or antiviral
therapeutics. Further research is needed to establish targets for intervention, and
factors required for infection need to be examined in more detail.
Certain influenza viruses and HMPV appear to share common activating
proteases. The influenza fusion protein hemagglutinin (HA) is synthesized as a
precursor that needs to be cleaved by host cell proteases to exert its fusogenic
activity (355, 356). Cleavage separates the precursor HA0 into HA1 and HA2, which
remain associated via disulfide bonds and leads to exposure of the fusion peptide
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at the N-terminus of HA2 (355, 356). Low pathogenicity avian influenza (LPAI)
usually possess a monobasic cleavage site which consists of 1 – 2 nonconsecutive basic amino acids and which is generally cleaved by trypsin-like serine
proteases such trypsin, as well as members of the type II transmembrane serine
protease (TTSP) family including TMPRSS2, TMPRSS4, HAT (TMPRSS11D) and
matriptase (355-357). In addition, some other proteases such as KLK5 and KLK
12 have been implicated in influenza pathogenicity (177). In humans these
proteases are localized in the respiratory tract and therefore influenza infections
are usually confined to this tissue. In contrast, highly pathogenic avian influenza
(HPAI) viruses are defined by a polybasic cleavage site which consists of 6 – 7
basic residues allowing them to be activated by members of the proprotein
convertase (PC) family such as furin and PC6 (358). These proteases are not
confined to a specific tissue and dramatically increase the risk of a systemic
infection.
Similar to influenza HA, HMPV requires the fusion protein (F) to be
proteolytically processed at a single basic residue to generate the active,
metastable form. Without this cleavage process, the F protein is unable to mediate
viral entry into the target cell. However, to date, only trypsin and TMPRSS2 have
been shown to effectively cleave HMPV F and other proteases have yet to be
identified (189, 192).
In addition, other respiratory viruses have been reported to utilize similar
proteases for activation, including SARS-CoV and MERS-CoV, demonstrating that
targeting these proteases would inhibit multiple respiratory pathogens (359). The
fact that proteolytic activation is such a crucial step for several respiratory viruses
that predominately require a specific class of proteases makes these proteases a
viable target for the development of novel antiviral therapies (360). Earlier studies
described the administration of the serine protease inhibitor aprotinin to inhibit
influenza replication and demonstrated that aprotinin successfully inhibited IAV
activation and replication (361). However, when targeting host specific factors
there are potential off target effects, and therefore the potential side effects of
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targeting host proteases requires further investigation. Hamilton et al. reported that
the hepatocyte growth activator inhibitor 2 (HAI-2) effectively inhibited trypsinmediated cleavage of H1N1 and H3N2 in vitro and in vivo (362). HAI-2 is encoded
by the SPINT2 gene and hereafter we will also refer to the protein as SPINT2.
SPINT2 is 225 KDa plasma membrane-localized serine protease inhibitor found in
epithelial cells of various tissues including the respiratory tract and all major organs
(363). In most tissues, SPINT2 co-localizes with matriptase suggesting a
regulatory role of SPINT2 on matriptase-mediated cleavage events. However, the
finding that SPINT2 is also expressed in brain and lymph node cells indicates that
it might regulate other proteases than matriptase (363). Recent reports associated
the physiological role of SPINT2 with the inhibition of human serine-type proteases
such as matriptase, plasmin, kallikreins (KLK) and coagulation factor Xia (364-367)
. SPINT2 possesses one transmembrane domain and two kunitz-type inhibitor
domains that are exposed to the extracellular space and which are believed to
facilitate a potent inhibition of target proteases. Wu et al. recently described that
the kunitz-type domain 1 of SPINT2 is responsible for matriptase inhibition (367).
A major function of SPINT2 is its role as a tumor suppressor because downregulation diminishes the prospect of survival of several cancers such as
hepatocellular carcinoma, gastric cancer, prostate cancer or melanoma (368-371).
However, SPINT2 was also associated with placenta development and epithelial
homeostasis (372, 373).
A previous study from our lab described the effective inhibition of trypsin by
SPINT2 resulting in dramatically reduced cleavage of influenza A HA using a
model protease and subsequently reduced viral growth in cell culture and mouse
studies (362). Here, we report that purified SPINT2 protein inhibits several host
proteases found in the human respiratory tract, such as matriptase and TMPRSS2,
that are relevant for the activation of influenza viruses currently circulating and
causing significant disease outbreaks. To demonstrate broad applicability, we also
tested the potential of SPINT2 to inhibit the activation of the fusion protein (F) from
human metapneumovirus (HMPV), a member of the pneumovirus family. We
confirm the original findings that HMPV F is proteolytically processed by trypsin
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and TMPRSS2. In addition, we found that HAT, KLK5 and matriptase were able to
cleave F, but KLK12 could not. Our results show that SPINT2 can inhibit the
activation of proteases that are responsible for the activation of influenza H1N1,
H3N2 and H7N9 HA as well as HMPV F. In a cell culture model, we demonstrate
that viral loads are significantly reduced in the presence of SPINT2 when infections
were conducted with A/CA/04/09 and A/X31. Moreover, the application of SPINT2
24 h post infection inhibited the activation of influenza A viruses with the same
efficacy as when SPINT2 was added to cell culture medium at the time of infection.
Thus, SPINT2 exhibits the potential to serve as a novel and efficient antiviral
therapeutic to relieve patients from influenza A, human metapneumovirus, SARSCoV and potentially other respiratory viruses that require these host factors for
entry.
Results
SPINT2 inhibits recombinant human respiratory tract proteases that cleave
HMPV F and HA cleavage site peptide mimics
Using a fluorogenic peptide cleavage assay that utilizes fluorogenic
peptides mimicking the HA cleavage site we previously tested the ability of SPINT2
to inhibit proteases shown to cleave HAs from seasonal and pandemic influenza
A strains that infected humans (171, 374). We found that certain HA subtypes such
as H1, H2 and H3 are cleaved by a wide variety of human respiratory proteases
while others such H5, H7 and H9 displayed more variability in cleavage by
proteases and seemed less well adapted to proteases present in the human
respiratory tract (171). Here, we extended our previous study and tested a peptide
mimicking the cleavage site of the pneumovirus fusion protein of HMPV F using a
variety of proteases known for their ability to cleave the peptide mimic (Table 4.1A)
(189, 190). When we tested the cleavage of a peptide mimicking the HMPV F
cleavage site using trypsin, matriptase, KLK5, KLK12, HAT or plasmin we found
that all proteases except KLK12 were able to proteolytically cleave the peptide
(Table 4.1A). However, the Vmax values for matriptase (9.24 RFU/min), KLK5 (5.8
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RFU/min) and HAT (2.99 RFU/min) were very low compared to trypsin (135.2
RFU/min) suggesting that the three proteases have a low affinity interaction and
processivity for HMPV F.
Next, trypsin, matriptase and KLK5 were selected for the SPINT2 inhibition
assays as described below. For the SPINT2 inhibition assays, trypsin (which
typically resides in the intestinal tract and expresses a very broad activity towards
different HA subtypes and HMPV F) served as a control (375). In addition, furin
was used as a negative control that is not inhibited by SPINT2. As none of the
peptides used in combination with the aforementioned proteases has a furin
cleavage site we tested furin-mediated cleavage on a peptide with a H5N1 HPAI
cleavage motif in the presence of 500 nM SPINT2 We continued by measuring the
Vmax values for each protease/peptide combination in the presence of different
SPINT2 concentrations and plotted the obtained Vmax values against the SPINT2
concentrations on a logarithmic scale. Using Prism7 software, we then determined
the IC50 that reflects at which concentration the Vmax of the respective reaction is
inhibited by half. SPINT2 cleavage inhibition of a representative H1N1 cleavage
site by trypsin results in an IC50 value of 70.6 nM (Table 4.1B) while the inhibition
efficacy of SPINT2 towards matriptase, HAT, KLK5 and KLK12 ranged from 11 nM
to 25 nM (Table 4.1B). However, inhibition was much less efficient for plasmin
compared with trypsin (122 nM). We observed a similar trend when testing
peptides mimicking the H3N2 and H7N9 HA cleavage sites using trypsin, HAT,
KLK5, plasmin and trypsin, matriptase, plasmin, respectively (Table 4.1B). With
the exception of plasmin, we found that human respiratory tract proteases are
inhibited with a higher efficacy compared to trypsin. We expanded our analysis to
peptides mimicking HA cleavage sites of H2N2, H5N1 (LPAI and HPAI), H6N1 and
H9N2 that all reflected the results described above (Table 4.1B). Only cleavage
inhibition of H6N1 HA by KLK5 did not significantly differ from the observation
made with trypsin (Table 4.1B). When we tested the inhibition of HMPV cleavage
by trypsin, matriptase and KLK5, SPINT2 demonstrated high inhibition efficacy for
all three tested proteases with measured IC50 for trypsin, matriptase and KLK5 of
0.04 nM, 0.0003 nM and 0.95 nM, respectively (Table 4.1C). Compared to the IC50
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values observed with the peptides mimicking influenza HA cleavage site motifs the
IC50 values for the HMPV F peptide were very low.
Cleavage of distinct full-length HA subtypes and HMPV F is efficiently
inhibited by SPINT
Cleavage of peptides mimicking cleavage sites of viral fusion proteins do
not always reflect the in vivo situation and requires validation by expressing the
full-length fusion proteins in a cell culture model to test cleavage and cleavage
inhibition of the respective protease (171). However, before conducting these
experiments we wanted to ensure that SPINT2 does not have a cytotoxic effect on
cells. Therefore, 293T cells were incubated with various concentrations of SPINT2
over a time period of 24 hours. PBS and 500µM H2O2 served as cytotoxic negative
and positive controls respectively. We observed a slight reduction of about 10 -15
% in cell viability when SPINT2 was added to the cells (Fig 4.1).
To test SPINT2-mediated cleavage inhibition of full-length HA we
expressed the HAs of A/CA/04/09 (H1N1), A/x31 (H3N2) and A/Shanghai/2/2013
(H7N9) in 293T cells and added recombinant matriptase or KLK5 protease that
were pre-incubated with 10nM or 500nM SPINT2. Trypsin and the respective
protease without SPINT2 incubation were used as controls. Cleavage of HA0 was
analyzed via Western Blot and the signal intensities of the HA1 bands were
quantified using the control sample without SPINT2 incubation as a reference point
to illustrate the relative cleavage of HA with and without inhibitor (Fig 4.2A and
4.2D). Trypsin cleaved all tested HA proteins with very high efficiency that was not
observed with matriptase or KLK5 (Fig 4.2B- 4.2D). However, H1N1 HA was
cleaved by matriptase and KLK5 to a similar extent without and with 10nM SPINT2.
500nM SPINT2 led to a relative cleavage reduction of about 70% and 50% for
matriptase and KLK5, respectively (Fig 4.2A and 4.2B). KLK5-mediated cleavage
of H3N2 HA was reduced by about 10% when KLK5 was pre-incubated with 10nM
SPINT2 and by about 60% when 500nM SPINT2 was used (Fig 4.2A and 4.2C).
When we tested the cleavage inhibition of matriptase with H7N9 HA as a substrate
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we found that 10nM and 500nM SPINT reduced the cleavage to 40% and 10%
cleavage, respectively, compared to the control. (Fig 4.2A and 4.2D). In contrast,
10nM SPINT2 had no effect on KLK5-mediated cleavage of H7N9 HA while 500nM
reduced relative cleavage by approximately 70% (Fig 4.2A and 4.2D).
In order to determine whether SPINT2 also prevented cleavage of HMPV F
we first examined which proteases, in addition to trypsin and TMPRSS2, were able
to cleave HMPV F. First, we co-transfected the full length TMPRSS2, HAT and
matriptase with HMPV F in VERO cells. The F protein was then radioactively
labeled with 35S methionine and cleavage was examined by quantifying the F0 full
length protein and the F1 cleavage product. We found that TMPRSS2 and HAT
were able to efficiently cleave HMPV F while matriptase decreased the expression
of F, though it is not clear if this was due to general degradation of protein or lower
initial expression. However, matriptase demonstrated potential low-level cleavage
when co-transfected (Fig 4.3A and 4.3B). We then examined cleavage by the
exogenous proteases KLK5, KLK12 and matriptase. Compared with the trypsin
control, KLK5 and matriptase were able to cleave HMPV F, while KLK12 was not
(Fig 4.3C and 4.3D). In agreement with the peptide assay, cleavage of HMPV F by
KLK5 and matriptase was less efficient than for trypsin and both peptide, and fulllength protein assays demonstrate that KLK12 does not cleave HMPV F. This also
serves as confirmation that matriptase likely cleaves HMPV F, but co-expression
with matriptase may alter protein synthesis, stability or turnover if co-expressed
during synthesis and transport to the cell surface. Next, we tested SPINT2
inhibition of exogenous proteases trypsin, KLK5 and matriptase. We pre-incubated
SPINT2 with each protease, added it to VERO cells expressing HMPV F and
analyzed cleavage product formation. SPINT2 pre- incubation minimally affected
cleavage at a concentration of 10nM but addition of 500nM SPINT2 resulted in
inhibition of trypsin, KLK5 and matriptase-mediated cleavage of HMPV, similar to
our findings for HA (Fig 4.3E and 4.3F).
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SPINT2 inhibits HA mediated cell-cell fusion
The above presented biochemical experiments demonstrate that SPINT2 is
able to efficiently inhibit proteolytic cleavage of HMPV F and several influenza A
HA subtypes by a variety of proteases. For a functional analysis to determine
whether SPINT2 inhibition prevents cells to cell fusion and viral growth, we
examined influenza A infection in cell culture. While HMPV is an important human
pathogen, Influenza grows significantly better in cell culture compared with HMPV.
First, we tested whether cleavage inhibition by SPINT2 resulted in the inhibition of
cell-cell fusion. As described above, matriptase and KLK5 were pre-incubated with
10nM and 500nM SPINT2 and subsequently added to VERO cells expressing
A/CA/04/09 (H1N1) HA or A/Shanghai/2/2013 (H7N9) HA. Cells were then briefly
exposed to a low pH buffer to induce fusion and subsequently analyzed using an
immune fluorescence assay. When matriptase and KLK5 were tested with 10nM
SPINT2 and incubated with VERO cells expressing H1N1 HA, we still observed
syncytia formation (Fig 4.4A). However, 500 mM SPINT2 resulted in the abrogation
of syncytia formation triggered by cleavage of the respective HA by matriptase and
KLK5. We made the same observation when we tested KLK5 and H7N9 HA (Fig
4.4B). Matriptase-mediated H7N9 HA syncytia formation was inhibited by the
addition of 10nM SPINT2 (Fig 4.4B). To ensure that cell-cell fusion inhibition is a
result of HA cleavage inhibition through SPINT2 but not a side effect of SPINT2
treatment per se we expressed A/Vietnam/1204/2004 (H5N1) HA in VERO cells
and treated them with the inhibitor. H5N1 HA possesses a HPAI cleavage site and
is cleaved intracellularly by furin during its maturation process. SPINT2 does not
inhibit furin and is not able to cross cell membranes. Thus, SPINT2 can not
interfere with the proteolytic processing of H5N1 HA and therefore this control
allows to examine whether SPINT2 interferes with cell-cell fusion. Figure 4.4C
shows that H5N1 HA forms large syncytia in the absence of SPINT2 as well as in
the presence of 500 nM SPINT2. Hence, we conclude that SPINT2 does not have
a direct inhibitory effect on cell-cell fusion.
SPINT2 reduces viral growth in cell culture
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To understand whether SPINT2 was able to inhibit or reduce the growth of
virus in a cell culture model over the course of 48 hours we transfected cells with
human TMPRSS2 and human matriptase, two major proteases that have been
shown to be responsible for the activation of distinct influenza A subtype viruses.
TMPRSS2 is essential for H1N1 virus propagation in mice and plays a major role
in the activation of H7N9 and H9N2 viruses (176, 376, 377). Matriptase cleaves
H1N1 HA in a sub-type specific manner, is involved in the in vivo cleavage of H9N2
HA and our results described above suggest a role for matriptase in the activation
of H7N9 (177, 376). At 18 hours post transfection we infected MDCK cells with
A/CA/04/09 (H1N1) at a MOI of 0.1 and subsequently added SPINT2 protein at
different concentrations. Non-transfected cells served as a control and exogenous
trypsin was added to facilitate viral propagation. The supernatants were harvested
48 hours post infection and viral titers were subsequently analyzed using an
immuno-plaque assay.
SPINT2 initially mitigated trypsin-mediated growth of H1N1 at a
concentration of 50nM and the extent of inhibition slightly increased with higher
concentrations (Fig 4.5A). The highest tested SPINT2 concentration of 500nM
reduced viral growth by about 1 log (Fig 4.5A). We observed a similar pattern with
cells transfected with human matriptase (Fig 4.5B). Growth inhibition started at a
SPINT2 concentration of 50nM and with the application of 500nM growth was
reduced by approximately 1.5 logs (Fig 4.5B). When we infected cells expressing
TMPRSS2 with H1N1 and added SPINT2, viral growth was significantly reduced
at a concentration of 150nM. Addition of 500nM SPINT2 led to a reduction of viral
growth of about 1.5 logs (Fig 4.5C). We also tested whether SPINT2 could reduce
the growth of a H3N2 virus because it is major circulating seasonal influenza
subtype. However, TMPRSS2 and matriptase do not seem to activate H3N2
viruses (175, 177). Hence, trypsin and SPINT2 were added to the growth medium
of cells infected with A/X31 H3N2. Compared to control cells without added
inhibitor SPINT2 significantly inhibited trypsin mediated H3N2 growth at a
concentration of 50nM (Fig 4.5D). At the highest SPINT2 concentration of 500nM
viral growth was reduced by about 1 log (Fig 4.5D).
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We also examined the effect of SPINT2 inhibition of HMPV spread over
time. VERO cells were infected with rgHMPV at MOI 1 and subsequently treated
with 500nM of SPINT2 and 0.3µg/mL of TPCK-trypsin. Every 24 hours, cells were
scraped, and the amount of virus present was titered up to 96hpi with SPINT2 and
trypsin replenished daily. We find that un-treated cells are infected and
demonstrate significant spread through 96hpi. Conversely, cells infected and
treated with SPINT2 had no detectible virus up to 48hpi and very minimal virus
detected at 72 and 96hpi, demonstrating that SPINT2 significantly inhibition HMPV
viral replication and spread (Fig 4.6).
Antiviral therapies are often applied when patients already show signs of
disease. Therefore, we tested if SPINT2 was able to reduce viral growth when
added to cells 24 hours after the initial infection. Cells were infected with 0.1 MOI
of A/CA/04/09 (H1N1) and trypsin was added to promote viral growth. At the time
of infection, we also added 500nM SPINT2 to one sample. A second sample
received 500nM SPINT2 24 hours post infection. Growth supernatants were
harvested 24 hours later, and viral growth was analyzed. We found that viral
growth was significantly reduced by regardless whether SPINT2 was added at the
time of infection or 24 hours later (Fig 4.7).
Discussion
Influenza A virus has caused four pandemics since the early 20th century
and infects millions of people each year as seasonal ‘flu, resulting in up to 690,000
deaths annually (346) . Vaccination efforts have proven to be challenging due to
the antigenic drift of the virus and emerging resistance phenotypes (378).
Moreover, the efficacy of vaccines seems to be significantly reduced in certain
high-risk groups (379). Prevalent antiviral therapies to treat influenza A virusinfected patients such as adamantanes and neuraminidase inhibitors target viral
proteins but there is increasing number of reports about circulating influenza A
subtypes that are resistant to these treatments(348). HMPV causes infections in
the upper and lower respiratory tract expressing very similar symptoms as
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influenza infections and resulting in significant morbidity and mortality (352, 353).
The most susceptible groups are young children, older adults and people that are
immunocompromised (30, 36, 354). Currently, there are not treatment against
HMPV infections available. In this study we focused on a novel approach that uses
antiviral therapies targeting host factors rather than viral proteins offering a more
broad and potentially more effective therapeutic approach (360). We demonstrate
that SPINT2, a potent inhibitor of serine-type proteases, can significantly inhibit
cleavage of HMPV F and HA, impair HA-triggered fusion of cells and hence,
reduce the growth of various influenza A strains in cell culture.
We assessed cleavage of the HMPV fusion protein in vitro using a peptide
cleavage assay modified from previously work on other viral fusion proteins (171,
374). The HMPV F peptide was cleaved by trypsin, plasmin, matriptase and KLK5
but was unable to be cleaved by KLK12. To confirm these findings in a system in
which the entire HMPV F protein was subject to cleavage, we co-expressed the
fusion protein with TMPRSS2, HAT and matriptase proteases, or treated F with
exogenous proteases KLK5, KLK12 and matriptase. These findings are the first to
identify proteases besides trypsin and TMPRSS2 that are able to cleave HMPV F.
In addition, HMPV appears to utilize many of the serine proteases that influenza
uses for HA processing and therefore, offers strong potential for an antiviral target.
SPINT2 demonstrates greater advantage over other inhibitors of host
proteases such as e.g. aprotinin that was shown to be an effective antiviral but
also seemed to be specific only for a subset of proteases (361). It can be argued
that a more specific protease inhibitor which inhibits only one or very few proteases
might be more advantageous because it may result in less side effects. With
respect to influenza A infections, TMPRSS2 could represent such a specific target
as it was shown to a major activating proteases for H1N1 and H7N9 in mice and
human airway cells (176, 376, 377, 380, 381). However, there is no evidence that
that application of a broad-spectrum protease inhibitor results in more severe side
effects than a specific one as side effects may not be a consequence of the
protease inhibition but the compound itself may act against different targets in the
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body. The reports demonstrating that TMPRSS2 is crucial for H1N1 and H7N9
virus propagation in mice and cell culture suggest that it also plays a major role in
the human respiratory tract. So far, however, it is unclear whether the obtained
results translate to humans and other studies have shown that for example human
matriptase is able to process H1N1 and H7N9 (177, 382).
Our peptide assay suggests that SPINT2 has a wide variety of host
protease specificity. With the exception of plasmin, all the tested proteases in
combination with peptides mimicking the cleavage site of different HA subtypes
expressed IC50 values in the nanomolar range. Interestingly, the IC50 values
obtained for cleavage inhibition of HMPV F were substantially lower, in the
picomolar range. This suggests that the HMPV cleavage may be more selectively
inhibited by SPINT2. However, the western blot data showed that addition of the
lowest concentration (10 nM) of SPINT2 did not result in cleavage inhibition of
HMPV F by the tested proteases. Differences in sensitivity of SPINT2 between
influenza HA and HMPV require further investigation.
SPINT2 poses several potential advantages over other inhibitors that target
host proteases. Cell culture studies showed that, for example, matriptasemediated H7N9 HA cleavage was efficiently inhibited at a concentration of 10nM
SPINT2. In contrast, the substrate range for aprotinin, a serine protease inhibitor
shown to reduce influenza A infections by targeting host proteases, seemed to be
more limited (361). Other synthetic and peptide-like molecules designed to inhibit
very specific serine proteases such as TMPRSS2, TMPRSS4 and TMPRSS11D
(HAT) were only tested with those proteases and their potential to inhibit other
proteases relevant for influenza A activation remains unclear (383-385). Currently,
the most promising antiviral protein inhibitor is camostat which is already approved
in Japan for the treatment of chronic pancreatitis (386). Recently, it was
demonstrated that camostat inhibited influenza replication in cell culture and
prevented the viral spread and pathogenesis of SARS-CoV in mice by inhibition of
serine proteases (385, 387). However, camostat was applied prior to the virus
infection and it was administered into the mice via oral gavage (387).
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A previous study showed that SPINT2 significantly attenuated influenza A
infections in mice using a concentration that was 40x lower than the described
camostat concentration and intranasal administration was sufficient (362). Our
current study suggests that SPINT2 is able to significantly inhibit viral spread
during an ongoing infection and does not need to be applied prior or at the start of
an infection. The mouse study also showed that SPINT2 can be applied directly to
the respiratory tract while camostat that is currently distributed as a pill and
therefore less organ specific. In addition, camostat is synthetic whereas SPINT2 is
a naturally occurring molecule which may attenuate potential adverse effects due
to non-native compounds activating the immune system. Future research will be
conducted to test if SPINT2 can be applied more efficiently via an inhaler and to
explore potential side effects in mice studies. However, when we tested the
potential of SPINT2 to inhibit viral replication in a cell culture model we were only
able to achieve growth reductions of approximately 1 -1.5 logs after 48 hours with
a concentration of 500nM SPINT2. One potential explanation is that 500nM
SPINT2 was unable to saturate the proteases present in the individual experiments
and was not sufficient to prevent viral growth. In addition, the continuous
overexpression of matriptase and TMPRSS2 may have produced an artificially
high quantity of protein that exceeded the inhibitory capacities of SPINT2. This
problem could be solved either by using higher concentration of SPINT2 or by
optimizing its inhibitory properties. However, the data also demonstrates that
SPINT2 has the ability to inhibit proteases that expressed on the cell surface and
that inhibition is not limited to proteases that were added exogenously and preincubated with the inhibitor (Fig 4.5). SPINT2 did not express any cytotoxic effects
up to a concentration of 10 mM, significantly above the therapeutic dosage
required for inhibition. In comparison with other studies, the SPINT2 concentration
we used here were in the nanomolar range while other published inhibitors require
micromolar concentrations (383-385). However, we believe that future research
will allow to fully utilize the potential of SPINT2 as a broad-spectrum antiviral
therapy. Wu et al., recently described that the Kunitz domain I of SPINT2 is
responsible for the inhibition of matriptase (367). In future studies we will explore
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whether the inhibitory capabilities of SPINT2 can be condensed into small peptides
that may improve its efficacy. Its ability to inhibit a broad range of serine protease
that are involved in the activation of influenza A suggest that a SPINT2 based
antiviral therapy could be efficient against other pathogens too. TMPRSS2, for
example, not only plays a major role in the pathogenesis of H1N1 but is also
required for the activation of SARS-CoV and MERS-CoV and HMPV (388, 389).
Currently, treatment options for these viruses are very limited and therefore
SPINT2 could become a viable option if its potential as an antiviral therapeutic can
be fully exploited.
However, while SPINT2 has a therapeutic potential to treat ILIs caused by
viruses that require activation by trypsin-like serine proteases it may have its
limitation to provide a treatment option for infections caused by influenza HPAI
viruses, such as H5N1 (390) . These viruses are believed to be activated by furin
and pro-protein convertases that belong to the class of subtilisin-like proteases
(358) . Preliminary data from our lab demonstrated that SPINT2 did not inhibit furinmediated cleavage of HPAI cleavage site peptide mimics as well as peptides
carrying described furin cleavage sites (data not shown). In addition, furin acts
intracellularly and we have no evidence that SPINT2 is able to penetrate the cell
membrane and thus inhibiting proteases located in intracellular compartments.
Therefore, it seems unlikely that SPINT2 is able to inhibit furin in cell culture-based
studies or in vivo experiments.
In conclusion we believe SPINT2 has potential to be developed into a novel
antiviral therapy. In contrast to most similar drugs that are synthetic, SPINT2 is an
endogenously expressed protein product that confers resistance to a variety of
pathogenic viruses which can potentially be delivered directly into the respiratory
tract as an aerosol. Most importantly, SPINT2 demonstrated the ability to
significantly attenuate an ongoing viral infection in cell culture and further research
will be conducted to explore the time period during which SPINT2 demonstrates
the highest efficacy.
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A
TRYPSIN
MATRIPTASE
KLK5
HAT
KLK12
PLASMIN

VMAX (RFU/MIN)
135.25
9.24
5.80
2.99
0.00
37.86

B
IAV HA
H1N1 HA
H2N2 HA
H3N2 HA
H5N1
HPAI HA
H5N1
LPAI HA
H6N1 HA
H7N9 HA
H9N2 HA

IC50 values (nM)
Trypsin
70.57
155.40
207.90

Matriptase
25.00
NT
NT

HAT
24.08
34.74
15.33

KLK5
28.34
8.27
9.54

1135.00

194.10

NT

NT

NT

1166.00

145.80

5.32

23.56

6.38

3.66

160.10

30.52
20.97
99.16

NT
8.00
9.02

NT
NT
12.74

29.93
NT
11.79

14.04
NT
NT

NT
77.59
134.00

C
HMPV F

STDEV
17.55
0.39
0.12
0.41
0.00
2.07

Trypsin
0.04

IC50 values (nM)
Matriptase HAT
KLK5
0.0003
NT
0.95

KLK12 Plasmin
11.70 122.10
6.88
NT
NT
106.00

KLK12 Plasmin
NT
NT

Table 4.1: Cleavage of HMPV F and SPINT2 inhibition of peptide cleavage of various
proteases: (A) A fluorogenic peptide mimicking the cleavage site of HMPV F was incubated with
the indicated proteases and cleavage was monitored by the increase of fluorescence at 390 nm.
RFU = relative fluorescence units. StDev = Standard Deviation. Fluorogenic peptides mimicking
the cleavage sites of A/CA/04/09 H1N1, A/Japan/305/1957 H2N2 HA, A/Aichi/2/68 H3N2 HA,
A/Vietnam/1203/2004 H5N1 LPAI HA, A/Vietnam/1204/2004 H5N1 HPAI HA, A/Taiwan/2/2013
H6N1 HA, A/Shanghai/2/2013 H7N9 HA, A/Hong Kong/2108/2003 H9N2 HA and HMPV F were
incubated with the indicated proteases and different SPINT2 concentrations. Cleavage was
monitored by the increase of fluorescence at 390 nm and the resulting Vmax values were used to
calculate the IC50 values. (B) IC50 values of influenza A fluorogenic cleavage site peptide mimics.
Concentrations are in nanomolar. (C) IC50 values of the HMPV F cleavage site peptide mimic.
Concentrations are in picomolar. NT = Not tested.
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Figure 4.1: Cytotoxicity assay to evaluate the cytotoxic effect of SPINT2. 293T cells were

incubated with indicated SPINT2 concentrations for 24 hours. DMEM and 500 µM H2O2 served as
controls. After 24 hours cell viability was determined via a spectrophotometric assay.
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Figure 4.2: SPINT2 inhibits cleavage of HA protein expressed in 293T cells. Cells were
transfected with plasmids encoding for the indicated HA and allowed to express the protein for ~18
hours. The recombinant proteases were incubated for 15 minutes with the indicated SPINT2
concentrations and subsequently added to the cells for 10 minutes (trypsin) or 90 minutes
(matriptase and KLK5). Western blots were performed and the HA1 band was quantified using
ImageJ. (A) Quantification of the HA1 band comparing the signal intensity of the 0 nM SPINT2
samples against 10 nM and 500 nM SPINT2 of the respective HA/protease combination. Three
independent experiments were carried out and the western blots of each experiment were
analyzed. Quantifications were conducted as described in the methods section. (B – D) Western
blots showing the cleavage of (B) A/CA/04/09 H1N1 HA by matriptase and KLK5 at different
SPINT2 concentration, (C) A/Aichi/2/68 H3N2 HA by KLK5 at different SPINT2 concentration and
(D) A/Shanghai/2/2013 H7N9 HA by matriptase and KLK5 at different SPINT2 concentrations.
Statistical analysis was performed using a non-paired student’s t-test comparing the samples tested
with 10 nM SPINT2 against the respective sample incubated with 500 nM SPINT2. Error bars
indicate standard deviation. * indicates p = < 0.05.
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Figure 4.3: TMPRSS2, HAT, matriptase and KLK5 cleave HMPV F and SPINT2 is able to
prevent cleavage by exogenous proteases. HMPV F was either expressed alone or cotransfected with protease and allowed to express for ~ 18 hours. Cells were then metabolically
starved of cysteine and methionine followed by radioactive S35 labeling of protein for 4 hours in
the presence of TPCK-trypsin or specified protease. SPINT2 treated proteases were incubated at
room temperature for 10 minutes and placed onto cells for 4 hours. Radioactive gels were
𝐹𝐹

1
quantified using ImageQuant software with percent cleavage equal to ��𝐹𝐹 +𝐹𝐹
� 𝑥𝑥100�. (A) and (B)
0

1

Co-transfected proteases TMPRSS2, HAT and matriptase are able to cleave HMPV F (n=4) while
(C) and (D) exogenous proteases KLK5 and matriptase but not KLK12 are able to cleave HMPV F

(n=5). (E) and (F) SPINT2 prevented cleavage of HMPV F by trypsin, KLK5 and matriptase at nm
concentrations demonstrated by the loss of the F1 cleavage product (n=3). Statistical analysis was
performed using a one-way ANOVA followed by a student’s t-test with a bonferroni multiple
comparisons test correction. P<0.05 *, P<0.005 **, P<0.005 ***, P<0.001 ****. N values represent
independent replicates for each treatment group. Error bars represent SD.

70

Figure 4.4: SPINT2 inhibits HA-mediated cell-cell fusion. VERO cells were transfected with
plasmids encoding for (A) A/CA/04/09 H1N1 HA or (B) A/Shanghai/2/2013 H7N9 HA and allowed
to express the protein for ~18 hours. Recombinant matriptase and KLK5 were incubated with
different SPINT2 concentrations for 15 minutes and then added to the HA-expressing cells for 3
hours. After 3 hours the cells were briefly treated with cell fusion buffer at pH5, washed,
supplemented with growth medium and returned to the incubator for 1 hour to allow fusion. HA
protein was detected using HA-specific primary antibodies and a secondary fluorogenic Alexa488
antibody. Nuclei were stained using DAPI. Magnification 40x. (C) VERO cells expressed
A/Vietnam/1204/2004 H5N1 HA that was cleaved during its maturation process in the cell. SPINT2
was added at 0 nM or 500 nM at the time of transfection. Magnification 25x.
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Figure 4.5: SPINT2 reduces IAV growth in cell culture. MDCK cells were transfected with
plasmids encoding for human matriptase or human TMPRSS2 and allowed to express the proteins
for ~18 hours. Cells expressing human matriptase (B) or human TMPRSS2 (C) were then infected
with A/CA/04/09 H1N1 at a MOI of 0.1 and different SPINT2 concentration were added to each
well. Non-transfected cells to which trypsin was added served as a control (A). (D) MDCK cells
were infected with A/X31 H3N2 at a MOI of 0.1 and trypsin was added to assist viral propagation.
Different SPINT2 concentration was added as indicated. After 48 hours of infection the
supernatants were collected and used for an immuno-plaque assay to determine the viral loads.
Experiment was repeated three times and each dot represents the viral titer of a single experiment.
Statistical analysis was performed using a non-paired student’s t-test comparing the control (0 h)
against the respective sample. Error bars indicate standard deviation. * indicates p = < 0.05.
Extended horizontal line within the error bars represents mean value of the three independent
replicates.
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Figure 4.6: SPINT2 mitigates the spread of HMPV in cell culture. VERO cells were infected with
a MOI 1 of rgHMPV. SPINT2 and TPCK-trypsin were added at 500nM and 0.3µg/mL respectively
and spread was monitored up to 96hpi. Cells not treated with SPINT2 demonstrated significant
spread up through 96hpi whereas treated samples did not show any detectable virus up to 48hpi.
However, there was minimal detected virus at 72 and 96hpi. Error bars indicate standard deviation
of 4 independent samples completed in duplicate (all data points plotted within the graph).
Statistical analysis was performed using a student’s t-test. P <0.05 *, P <0.005 **, P <0.005 ***, P
<0.001 ****. ND indicates that the sample was below the limit of detection.

73

Figure 4.7: SPINT2 reduces viral growth when added 24 hours post infection. MDCK cells
were infected with A/CA/04/09 H1N1 at a MOI of 0.1 and trypsin was added. 500nM SPINT2 were
added at the time of infection or 24 hours post infection. Supernatants were collected 48 hours post
infection and used for an immuno-plaque assay to determine the viral titers. Statistical analysis was
performed using a non-paired student’s t-test comparing the control (0 h) against the respective
sample. Error bars indicate standard deviation. * indicates p = < 0.001. Extended horizontal line
within the error bars represents mean value of the three independent replicates.
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Chapter 5: Respiratory syncytial virus and human metapneumovirus
infections in 3-D airway tissues expose an interesting dichotomy in viral
replication, spread, and inhibition by neutralizing antibodies
* This work was completed in collaboration with Medimmune/Astrazeneca who
provided the RSV virus and RSV antibodies used during these studies. I performed
all experiments, data analysis, and figure creation. Dr. Carole Moncman helped
with imaging and image processing, post fixation processing of HAE tissues, and
data acquisition. This section was adapted from a manuscript (Kinder et al J Virol,
2020: JVI.01068-20)
Introduction
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)
are single-stranded, negative-sense RNA (nsRNA) enveloped viruses in the
Pneumoviridae family (18). As leading causes for respiratory infections in children,
95% of children by the age of two are infected with RSV (21) and nearly all are
seropositive for HMPV by the age of 5 (30, 354). Children, immunocompromised,
and elderly populations are at significant risk for contracting and developing severe
lower respiratory tract infection, with infants at the greatest risk (21-23, 26, 27, 30,
354, 391-397). While both RSV and HMPV cause severe morbidity and mortality,
no vaccines are available and only limited treatment options exist. For RSV, the
only FDA -approved therapy is palivizumab, a humanized monoclonal antibody
given prophylactically to high risk infants during the infectious season (28, 29). To
better understand how to target these viruses therapeutically, a deeper
understanding of viral infection in physiologically relevant model systems is
needed.
Pneumoviruses initiate infection by attaching to target cells via their surface
glycoproteins, the fusion protein (F) and /or the attachment protein (G), which
interact with host receptors and attachment factors. Subsequently, F undergoes a
large conformational change to mediate membrane fusion, after which the viral
nucleocapsids are released into the cytoplasm of the infected cell (99, 398). This
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membrane fusion process is critical, and inhibition of the fusion protein blocks entry
and infection. Interestingly, both HMPV and RSV mutants lacking surface
glycoproteins G and SH but containing F can mediate entry and infection, albeit
attenuated to some degree (121, 123, 399, 400), demonstrating that F has a critical
role for entry and is involved in attachment. Based on its critical role for infection,
targeting the fusion protein is one of the most common strategies for developing
therapeutics against HMPV and RSV (100-102, 401).
After entering the target cell, HMPV and RSV nucleocapsids are released
and used as templates for synthesis of viral mRNAs and genomic RNA (vRNA) by
the viral RNA dependent RNA polymerase. Research from our lab and others
suggests these processes occur in punctate cytosolic structures, termed inclusion
bodies (IBs), which are minimally composed of the nucleoprotein (N), the
phosphoprotein (P), and vRNA (251, 255). IB-like structures have also been
described for other nsRNA viruses, including ebola virus (261, 402), marburg virus
(262), rabies virus (256, 403), vesicular stomatitis virus (263), parainfluenza virus
3 (264) and parainfluenza virus 5 (266), suggesting a broadly conserved
mechanism for viral transcription and genome replication. Once newly
synthesized-nucleocapsids assemble in IBs, they traffic to assembly sites at the
plasma membrane. For HMPV, it has been suggested that the actin cytoskeleton
might play a crucial role in nucleocapsid transport and inclusion body coalescence
during infection (251), similar to what has been reported for ebola virus (404). In
addition, the actin cytoskeleton has been reported to have a role in movement of
ribonucleocapsids to sites of assembly in RSV and measles virus-infected cells,
further supporting the importance of the cytoskeleton for viral infection and spread
(320, 405, 406). After transport, the nucleocapsids coalesce with other viral
proteins at the plasma membrane, the proposed assembly site for pneumoviruses,
although recent research suggests a cell-to-cell dependent mechanism may play
an important role in pneumovirus spread (407). This mechanism allows for the
transfer of infectious particles via en bloc transmission by forming syncytia (395,
396, 408, 409), intercellular extensions (288, 298) or polyploid viruses (30, 84,
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410-412) to allow for transmission of multiple genomes from one cell to another,
compared with the traditional method of single particle release and reentry.
HMPV has been shown to be primarily cell-associated and induce the
formation of long, actin-based filamentous extensions, which are important for
direct cell-to-cell spread in vitro, even in the presence of neutralizing antibodies
(288). RSV has also been shown to form actin-based extensions involving Actin
Related Protein-2 (ARP2) , suggesting a potential role for these structures during
budding and spread in cell culture monolayers (298). RSV additionally induces cellto-cell fusion in immortalized cell monolayers, generating multinucleated cells
termed syncytia which are also a hallmark of other enveloped virus infections
(396). Similarly, HMPV has been shown to generate syncytia, although to a much
lesser extent compared to RSV (413, 414). While RSV replication is enhanced
through the formation of syncytia in vitro (301), the formation of these structures in
animal models and patients is not well understood. A few reports have described
the presence of syncytia in postmortem autopsies of patients infected with either
RSV or HMPV (395, 409). Currently, the roles of intercellular extensions and
syncytia have yet to be fully elucidated in more physiologically relevant model
systems in order to further understand how viruses enter and spread within
infected tissue.
Human airway epithelial (HAE) tissues have been used previously as model
systems to examine respiratory biology and pathogen interactions in cell culture
(136, 143, 144, 313, 315, 316, 321-325, 327, 415-419). This model system utilizes
primary human cells differentiated on a trans-well with an air-liquid interface to
generate polarized bronchial epithelial tissue composed of multilayered epithelial
cells including basal, apical ciliated, and goblet cells. This composition allows for
a more accurate recapitulation of the lung environment including cellular 3-D
structural organization, functional cilia, and mucus production.

This method

provides a more accurate model system to study respiratory viruses in vitro,
offering significant advantages compared to traditional 2-D cell monolayers (312,
313, 319, 415, 417-420). These tissue models have been used to study both RSV
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(143, 144, 314, 316, 319, 323-326, 420, 421) and HMPV (135, 136, 318, 333)
infections. For RSV, HAE models have demonstrated that apical ciliated cells are
the primary target cell, although occasional infection of non-ciliated cells was also
observed (323, 324, 326, 421). RSV-induced syncytia, a hallmark in 2-D cell
culture, have been observed in several HAE studies, but with varied results. No
syncytia were reported in several studies, even up to 36 days post infection (323,
324), whereas another study observed infrequent syncytia (326). For HMPV, very
few studies have been conducted using HAE tissues as a model system (135, 136,
318, 333). Consistent with findings from RSV, the primary target for HMPV is also
apical ciliated cells (136). However, there are limited studies examining viral and
host interactions for both HMPV and RSV in HAE tissues.
In this work, we performed a detailed analysis of RSV and HMPV infection
in 3-D HAE cultures, exploring aspects of the viral lifecycles that have not been
examined previously in HAE tissues. RSV demonstrated significantly higher rates
of infection, spread, and apical release than HMPV. Apical ciliated cells infected
with either RSV or HMPV generated large cytosolic IBs, consisting of at least N,
P, and vRNA, suggesting that these structures are critical replication complexes
formed during viral infection in vivo. No syncytia formation was observed for either
virus in our HAE studies. Interestingly, HMPV efficiently induced the formation of
filamentous extensions in HAE cultures, while RSV formed significantly fewer
extensions.
Lastly, we examined monoclonal antibody inhibition of entry and spread in
HAE tissues for RSV and HMPV. The only approved FDA treatment against RSV,
palivizumab, was able to inhibit RSV entry and spread. We also tested nirsevimab,
a novel monoclonal antibody against RSV that has demonstrated potent efficacy
against RSV in 2-D cell culture and animal models (422-424). We find that in HAE
tissues, nirsevimab is able to block entry and spread of RSV with greater potency
than palivizumab, supporting the findings in other model systems and supports its
potential as a novel antiviral therapeutic against RSV. The anti-HMPV antibody
54G10 effectively inhibited the entry of HMPV but only modestly, though
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significantly, reduced viral spread. Together, our results highlight the conserved
and varied aspects of entry, replication, and assembly between two closely related
pneumoviruses within HAE tissues and demonstrate an interesting dichotomy
between HMPV and RSV and their lifecycles.
Results
Both HMPV and RSV have been studied extensively in 2-D non-polarized
monolayers to analyze virus-host interactions. RSV has also been studied in 3-D
HAE tissues to assess viral infection and pathology (143, 144, 314, 316, 321, 324326, 421). In contrast, only a few reports examined HMPV in 3-D model systems
(135, 136, 318, 333). While many important aspects of infection have identified
been studies in 2-D cell studies, additional analysis in more physiologically relevant
model systems is needed to further our understanding of the viral lifecycle. To
address this, we utilized HAE tissues, a 3-D tissue model system which more
accurately recapitulates the lung environment, including cellular polarization,
mucus production, and functional cilia.
To compare the two pneumoviruses, we first assessed RSV and HMPV
infection, spread, and apical release side-by-side in HAE tissues. Tissues were
infected with recombinant green fluorescent protein (GFP) expressing RSV-A2
(rgRSV) or HMPV-A2 CAN97-83 (rgHMPV). At 24 hours post infection (hpi), GFP
expression was analyzed, and showed that both HMPV and RSV initiated infection
in this model system (Fig 5.1A). Initial infection was equivalent between both
viruses, but HMPV infection was less efficient compared to RSV, requiring a MOI
of 3 and 0.3 respectively to generate a comparable infection at 24 hpi (Fig 5.1B).
We then examined viral spread within tissues as well as release from the apical
surface up to 144 hpi. Using fluorescence threshold analysis (NIS elements) to
quantify GFP expression, we found that RSV efficiently spreads from 24 hpi
through 144 hpi, with the largest increase in infection seen from 24 to 48 hpi.
However, minimal changes in spread were observed past 72 hpi, suggesting
spread has plateaued (Fig 5.1A, quantified in 5.1C). In contrast, HMPV infected
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cells increased significantly, but modestly, from 24 hpi to 48 hpi, followed by a
decrease from 72 hpi to 144 hpi, with minimal infection remaining at later time
points (Fig 5.1A, quantified in 5.1C). Analysis of apical release of viral particles
showed a 3-log difference in the amount of released virus at 24 hpi between HMPV
and RSV, even though the number of infected cells were similar between the two
viruses (Fig 5.1B and 5.1D). In addition, there was no detectable release of HMPV
after 24 hpi. This result demonstrates a rapid spread and sustained release of high
titers of RSV particles from the apical surface whereas HMPV spread and particle
release was minimal at all time points with a decrease in spread after 48 hpi.
Previously, both RSV (323, 324, 326, 421) and HMPV (136) were reported
to primarily infect apical ciliated cells in HAE cultures. To verify this in our side-byside analysis, infected tissues were cryo-sectioned and stained for keratan sulfate
(KS), a marker for ciliated airway cells. RSV and HMPV both exclusively infected
ciliated cells, confirming this as the primary target cell type for both pneumoviruses
(Fig 5.1E). In a few instances, infected cells appeared below the apical surface.
However, staining with KS demonstrated that these cells were ciliated, though they
had not yet reached the apical surface. Based on these findings, the minimal
spread and release of HMPV compared to RSV cannot be attributed to a difference
in the type of cells infected, or the initial rates of infection. Therefore, we examined
other aspects of the viral lifecycle to better understand how both viruses interact
with host cells during infection.
HMPV and RSV induce the formation of replicative inclusion bodies
The formation of inclusion bodies (IBs) in 2-D cell monolayers has been
shown to be critical for viral genome replication and transcription for HMPV and
RSV (251, 255). However, to our knowledge, the presence of IBs has not been
examined in 3-D HAE tissues or in vivo. To verify these structures are found in
HAE infected tissues and to assess whether differences in the early stages of
infection were observed for RSV and HMPV, we examined the formation of IBs by
fluorescently staining RSV or HMPV N and P proteins, the minimal components
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required for IB-like structure formation (252, 253). Co-localization of both N and P
proteins was observed in cytoplasmic structures for RSV (Fig 5.2A and 5.2B) and
HMPV (Fig 5.3A and 5.3B) suggesting that IBs form in infected HAE tissues.
To confirm these structures were IBs, we conducted fluorescence in situ
hybridization (FISH) staining for vRNA, known to be localized to IBs during
infection of 2-D cells (251, 255). We observed strong co-localization of N and P for
both RSV (Fig 5.2C- 5.2F) and HMPV (Fig. 5.3C-5.3F) with their respective signal
of vRNA, confirming the formation of IBs in infected tissues for both viruses. These
findings are, to our knowledge, the first report of the formation of these structures
in 3-D HAE tissues for both RSV and HMPV, and thus strongly support the
hypothesis that these structures are critical for replication and spread of the viruses
in 3-D models and likely in vivo, thus providing a viable therapeutic target for
pneumoviruses.
N, P and vRNA had strong colocalization at inclusion bodies and at the
plasma membrane, suggesting the coalescence of these viral factors at sites of
assembly for both RSV and HMPV. In addition, P also demonstrated localization
at the plasma membrane independently of N and vRNA, often associated with cilialike structures at the apical surface for both RSV and HMPV infected cells.
However, the presence of P at these sites was much stronger for RSV compared
to HMPV. P has been previously reported to associate with IBs and the plasma
membrane to form extensions for HMPV (288) and in proposed assembly
complexes for RSV (425), which is supported by our findings. These suggest that
differences seen in spread dynamics of the viruses are not a result of differences
in the ability to cause initial infection or generate replicative structures.
HMPV and RSV form extensions but no syncytia in HAE tissues
There are numerous reports of actin cytoskeletal involvement in infectious
cycles for both HMPV (288, 335, 426) and RSV (298, 427-431). We have
previously shown that HMPV forms actin-based extensions, which were identified
as a mechanism for direct cell-to-cell spread in BEAS-2B bronchial epithelial cells
81

(288). HMPV P co-localized with actin, and transient expression of P alone
recapitulated some extension formation. Recent reports examining RSV
demonstrated that viral infection leads to the formation of actin-based extensions
in A549 cells (298). RSV-induced extensions were suggested to be filopodia and
could be induced by the expression of F alone. Additionally, disruption of actin
architecture in RSV infected cells decreased viral spread, suggesting that these
extensions are critical for infecting new cells.
To compare the formation of actin-based extensions between the two
pneumoviruses in different cell types, we infected Vero (monkey kidney), HEp-2
(human laryngeal carcinoma) and BEAS-2B (human bronchial epithelial, nondiseased) cells and analyzed extension formation. For all three cell types, both
RSV (Fig 5.4A) and HMPV (Fig 5.4B) induced the formation of filamentous
extensions at 24 hpi. Interestingly, a previous study did not observe extension
formation in RSV-infected Vero cells (298). These differences may be, due in part,
to other factors such as reagents or cell culture methodology.
We next examined extension formation of RSV and HMPV in 3-D HAE
tissues. When phenotypically examining cross-sections of HAE tissues, HMPVinfected cells demonstrated a high percentage of extensions compared with RSV,
where only a small number of infected cells with extensions were observed for
RSV (Fig 5.4C). RSV and HMPV-induced extensions had similar morphology, but
were infrequent in RSV-infected HAE tissues. The presence of extensions in HAE
tissues was further confirmed by microtome sectioning two full tissues at the peak
of infection with either HMPV (48 hpi) or RSV (72 hpi). Extensions were defined
and counted as thin protrusions extending from the cell body which were ≥ 0.5 of
the cell body diameter. For HMPV, 35.8% of infected cells contained extensions
(1541 total infected cells counted), while only 4.4% of RSV infected cells had
extensions (3859 total infected cells counted) (Fig 5.4D). Although both RSV and
HMPV have been shown to extensively modify the actin cytoskeleton in nonpolarized cell monolayers, RSV rarely forms extensions in HAE tissues, suggesting
these extensions are less important for infection and propagation in vivo.
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Conversely, HMPV generated intercellular extensions in both 2-D and 3-D model
systems, supporting the idea that HMPV is primarily cell-associated and may utilize
extensions for direct cell-to-cell spread (288).
A hallmark characteristic of RSV infection is the formation of multinucleated
cells, termed syncytia, which has been shown to be prominent in 2-D cell
monolayers. For HMPV, syncytia formation is less common compared with RSV,
but is observed in 2-D culture (241, 413). Studies on RSV-mediated syncytia
formation in HAE tissues have been inconclusive (321), while for HMPV, no reports
have reported formation in HAE models for HMPV. At the peak of infection for
both RSV (72 hpi) and HMPV (48 hpi), we examined syncytia formation in two fully
microtome sectioned HAE tissues. Interestingly, no syncytia were observed for
HMPV or RSV in either tissue examined nor was syncytia visible from the apical
side. However, the lack of syncytia did not hinder the infectivity or spread of RSV.
Since cell-to-cell fusion for both viruses is mediated by the fusion glycoprotein, we
examined the localization of F in cryo-sections using immunofluorescence staining
to determine if this finding was due to the localization of the F proteins. RSV F was
predominantly localized to the apical surface of infected cells but was also present
within extensions and throughout the infected cell, with a similar staining pattern
observed for HMPV F (Fig 5.4C). Since both viral fusion proteins were present at
locations beyond the apical surface, there are likely other variables that may
contribute to the lack of syncytia formation for HMPV and RSV. Further
investigation into the mechanisms that underlie fusion in tissues is required to
better understand the factors that contribute to this phenomenon and whether
syncytia formation impacts viral replication and spread in vivo.
Nirsevimab, palivizumab and 54G10 block viral entry and spread in HAE
tissues
Recently, a novel monoclonal anti-F antibody, nirsevimab, showed
significantly more potent neutralizing capacity in 2-D cultures and animal models
with an extended serum half-life compared with palivizumab (422, 423, 432).
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Conversely, no FDA approved anti-F antibodies are available against HMPV, but
a neutralizing monoclonal antibody, 54G10, has been described that has subnanomolar efficacy in vitro against all clades of HMPV and also has cross reactivity
to RSV, although efficacy against RSV is 6x less potent compared with
palivizumab (340). To better understand how HMPV and RSV infection might be
targeted in HAE tissues, we compared nirsevimab and palivizumab for RSV, and
54G10 for HMPV, for their ability to inhibit viral entry and spread in 3-D HAE
tissues.
We first conducted a microneutralization assay to assess the neutralizing
capacity of palivizumab and nirsevimab on RSV in HAE tissues. We pre-incubated
the virus in the presence or absence of neutralizing antibody for 1 hour and then
inoculated tissues at the apical surface. As expected, both nirsevimab and
palivizumab were able to completely neutralize RSV entry at a concentration of 0.5
µg/mL and 10 µg/mL respectively (Fig 5.5A and 5.5B). Congruent with previous
findings, nirsevimab demonstrated significantly higher neutralizing potency
compared with palivizumab (approximately 20-fold) (Fig 5.5C). Similarly, 54G10
demonstrated a complete block of infection at 10 µg/mL (Fig 5.6A and 5.6B,
quantified in 5.6C), indicating therapeutic potential for 54G10 against HMPV.
The effect of neutralizing antibodies on RSV and HMPV spread at the apical
surface of tissues after infection was examined. We inoculated tissues at the apical
surface with RSV or HMPV and then monitored fluorescence after infection. RSV
infection alone had a significant increase in spread from 24 hpi through 72 hpi (Fig
5.1A, 5.1B, 5.7A-5.7C). In the presence of palivizumab and nirsevimab, RSV
spread was almost completely inhibited compared with the 24 hpi time point,
demonstrating that RSV spread occurs mostly through apical release and reentry
which can be blocked by antibody present at the apical surface. Our results also
confirm previous observations for palivizumab and its ability to prevent spread in
HAE tissues (324). Nirsevimab again demonstrated a significantly higher potency
(approximately 10-fold) compared with palivizumab, showing similar inhibition of
spread at lower concentrations (Fig 5.7A-5.7C).
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We also examined 54G10 inhibition of HMPV spread from 24 hpi through
48 hpi. There was a modest, but statistically significant inhibition in HMPV spread
with increasing amounts of 54G10 (Fig. 5.8A-5.8C). Spread in the presence of 2.5
µg/mL and 25 µg/mL of neutralizing antibody was only reduced by 25%,
suggesting that a large fraction of HMPV spread likely still occurs via a direct cellto-cell transmission mechanism likely utilizing extensions as shown in 2-D cell
monolayers (288). Further investigation into the mechanisms for HMPV cell-to-cell
spread in 3-D tissues will help to elucidate how HMPV spread can be targeted
therapeutically. Altogether, our results indicate the mechanisms by which
neutralizing antibodies act to prevent RSV infections, although, a different strategy
may be needed to fully inhibit HMPV spread.
Discussion
In this study, we conducted a comparative analysis of HMPV and RSV
infection in HAE tissues. Altogether, our results demonstrate that two closely
related

human

respiratory

pathogens

may

utilize

significantly

different

mechanisms of spread in a 3-D model system. RSV can infect, replicate, and
release large amounts of virus apically, resulting in very efficient spread. In striking
contrast, HMPV is also able to infect ciliated cells in the HAE tissue, and productive
establishment of replication centers is seen, as judged by production of viral RNA,
but little apical release of virus was observed, leading to poor spread in this system.
Initial infection mediated by HMPV required higher MOIs to achieve similar
infection rates, suggesting that RSV infects HAE tissues more efficiently than
HMPV. RSV spread in HAE tissues increased significantly from 24 hpi up to 72
hpi, compared with HMPV which reached a peak of infection at 48 hpi and
significantly decreased thereafter. HMPV has been demonstrated to establish
persistent infection (75, 433-437). Thus, it is possible that the low replication rates
of HMPV in HAE tissues may drive the virus toward persistence rather than an
acute infection. In support of this, HMPV peaked at 48 hpi but a low, residual
infection was present up to 144 hpi. When examining infected tissues, both HMPV
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and RSV primarily infected apical ciliated cells, as previously demonstrated (136,
319, 321, 324). Therefore, the differences observed in entry and replication
between HMPV and RSV do not appear to be due to the cell types infected. A
recent publication utilized HMPV CAN97-82 (B strain) infection in human airway
epithelium obtained from nasal biopsies and showed limited apical release up to
five days post-infection (318). These studies and ours suggest strain differences
may affect how HAE tissues release and spread virus to some degree. The
presence of both the HMPV SH and G proteins, as well as the strain used, was
recently reported to impact spread in HAE tissues (135), with the deletion of HMPV
G especially deleterious. Interestingly, HMPV infection occurred at a higher level
in these studies and further investigation is needed to understand differences
involved in efficient HMPV entry in 3-D tissues (135, 136, 318, 333) .
Once cells have been infected, both HMPV and RSV form IBs. The
formation and characterization of these replication organelles in 2-D model
systems have been previously reported (251, 255), but IB formation has not been
previously examined in 3-D tissues. We showed that these IB structures form
within HAE-infected cells and contain markers for IBs, including P, N and viral
RNA. This is the first report of the formation of these structures in 3-D HAE tissues
for both RSV and HMPV, and suggests these structures are broadly important for
pneumovirus infection. As these structures appear in 2-D models for a number of
negative-sense, single-stranded RNA viruses (251, 256, 261-264, 266, 402, 403),
identifying and understanding critical host and viral components of these
organelles may provide a unique anti-viral approach against a wide range of
human viral pathogens.
Recent reports have shown both RSV and HMPV form actin-based
filamentous structures, important for viral spread within 2-D monolayers (288, 298).
Viral titer for RSV was significantly reduced when these structures were inhibited
(298). For HMPV, these filamentous structures were shown to be involved in cellto-cell spread of the virus, independent of neutralizing antibodies in BEAS-2B cells.
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Similar to RSV, when these cytoskeletal structures are inhibited, viral spread was
significantly reduced (288).
To assess the importance of cellular polarization on extension formation in
2-D monolayers, we examined extensions formation in 3-D HAE tissues.
Interestingly, extensions similar to those observed in 2-D cells were also detected
in approximately a third of HMPV-infected cells within HAE tissues, whereas RSVinfected cells had few extensions. Thus, we hypothesize that infection by RSV
relies primarily on abundant release of particles from the apical side of tissues and
re-infection of new target cells. However, the low apical release of virus and high
percentage of cells with extensions suggests that HMPV infection of new target
cells is likely dependent primarily on direct cell-to-cell contacts, similar to previous
findings in 2-D models. Furthermore, HMPV was also demonstrated to be primarily
associated with minimal release, and therefore extensions may be the primary
mechanism of spread (288). However, even with the formation of extensions,
spread of HMPV was minimal, suggesting that additional factors may be needed
for efficient cell-to-cell spread in HAE tissues.
RSV forms large, multinucleated cells termed syncytia, which are a hallmark
of infection in 2-D monolayers. In addition, while not as prominent, HMPV also
mediates cell-to-cell fusion during monolayer infection (413, 414). Some studies
have indicated that RSV can form minimal and infrequent syncytia in HAE tissues;
however, there are conflicting results (314, 321). Analysis of lung autopsy
specimens for both viruses suggested that syncytia formation can occur in vivo
(395, 409). We were unable to identify any syncytia in either the fully sectioned
tissues or apical images for RSV or HMPV. Studies in polarized cell monolayers
or in HAE tissues demonstrated that RSV F was primarily localized to the apical
surface (321, 438). Here, we also found that RSV and HMPV F were primarily
localized to the apical surface. In addition, we also observed the presence of
staining at the basolateral portion of infected cells. Other factors for cell-to-cell
fusion may be required in order to mediate the formation of syncytia in addition to
the cellular distribution of F. It is also unknown if syncytia formation is beneficial
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for viral replication. A RSV strain containing a hyperfusogenic fusion protein led to
larger syncytia in 2-D monolayers and higher pathogenesis in vivo, suggesting that
higher fusion is beneficial for viral replication and spread (301).
One caveat in HAE tissues that is different from in vivo studies is the lack
of immune cells, which play a major role during infection. Their absence may
contribute to our observations related to initial infection rate, apical release, spread
kinetics, and lack of cytopathic effects. The inflammatory response has been
suggested to be important for RSV infection (439), and may also play roles in
HMPV infection as well. The inflammatory response yields damage to the lung
epithelium layer, which may expose proteins and other factors present in tight
junctions, not normally accessible to the virus (440, 441), and this could aid in
HMPV spread. Further experiments are needed to understand how immune cells
and the inflammatory response could modulate HMPV infection of airways.
Lastly, therapeutic monoclonal antibodies against RSV and HMPV were
evaluated for their inhibition of viral infection and spread in this study. Preincubation of RSV with palivizumab or nirsevimab showed neutralization and
spread inhibition for RSV in HAE tissues. Nirsevimab demonstrated a significantly
higher neutralizing capacity compared to palivizumab (423). These results confirm
the potential for nirsevimab, which is currently in late stage clinical study, for
immunoprophylaxis against RSV. Studies in 2-D in vitro cultures and in vivo studies
has demonstrated increased efficacy and potency against RSV compared with the
only available therapeutic, palivizumab (422, 423, 432), which are further
supported by the results of this study.
We also examined the effect of 54G10, a potent neutralizing monoclonal
antibody against HMPV F (340) for inhibition HMPV infection and spread in HAE.
Pre-incubation of HMPV with 54G10 at a concentration of 5 µg/mL completely
inhibited viral entry. However, spread was only modestly, but significantly at 2.5
µg/mL and increasing the concentration of 54G10 to 25 µg/mL did not result in
further spread reduction. These results suggest that at least a portion of HMPV
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spread in HAE tissues may occur by a neutralizing antibody-independent cell-tocell mechanism. Thus, targeting the F protein of HMPV may not be the most
effective antiviral therapy. The RSV and HMPV antibodies have different potencies
in 2-D cell culture and bind the F protein at different sites (palivizumab: site II,
nirsevimab: site 0 and 54G10: site IV). It is unclear if the modest inhibition of spread
by 54G10 is related to a certain F binding mechanism of action. Future studies
evaluating a large panel of antibodies could help to determine if this phenomenon
is specific for HMPV or related to F protein binding.
While this study furthers our understanding of two important respiratory
pathogens in a more physiologically relevant model, there is further research
needed to characterize pneumovirus infection. Here, we utilize A2 subtypes of both
HMPV and RSV to model viral replication in HAE tissues. However, it is possible
there is strain-to-strain variation which can only be determined with additional
studies in this model system. We also exploited monoclonal antibodies to
understand entry and spread of RSV and HMPV in HAE tissues and examined the
efficacy these antibodies as potential antiviral therapeutics. However, additional
antibodies against both RSV and HMPV should be analyzed to determine which
viral protein sites are more important to entry and spread and use this information
to identify optimal sites for antiviral targets. HAE tissues offer a unique model
system to better understand viral infection in 3-D human tissue using an in vitro
culture method, with caveats. An important role of the respiratory tract is a
protective barrier for invading pathogens. In response, the lung signals the immune
system to fight infection. This results in the inhibition and clearance of infection,
but also generates tissue damage as a result of inflammation and infection. This
critical aspect is absent in the HAE system and therefore, this level of complexity
is inaccessible using this method.
Altogether, these results demonstrate a significant dichotomy between two
very closely related pneumoviruses and illustrate important aspects of their viral
lifecycles. RSV spreads primarily through release and re-entry of viral particles.
Current approaches to combat RSV entry and spread by targeting the F protein
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are a promising avenue for RSV antiviral therapeutics. However, HMPV spread is
poorly affected via this approach, suggesting other aspects of viral lifecycle may
be more effective. Both RSV and HMPV, in addition to other nsRNA viruses, form
punctate replication organelles in the cytoplasm of infected cells. It is possible
that targeting components involved in the formation and maintenance of these
viral organelles may prove to be a potent, broad spectrum antiviral for many
significant viral pathogens. As there are limited studies analyzing these
structures, more research is needed to better understand their formation,
function, and key role in viral replication.
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Figure 5.1: RSV and HMPV infection, spread and release in HAE tissues. (A) HAE tissues were
infected with MOI 0.3 of rgRSV or MOI 3.0 of rgHMPV, and initial infection and spread was
examined up to 144 hours post infection (HPI). (B) RSV and HMPV infection at 24hpi time point
(C) Spread analysis of HMPV and RSV were determined using fluorescence threshold analysis.
(D) Apical release of virus was determined by washing the apical surface of HAE tissues, titering
the viral wash in 2-D monolayers, and calculating fluorescence-forming units (FFU). (E) Infected
cells for HMPV (48hpi) and RSV (72hpi) were stained for actin cytoskeleton, as well as keratan
sulfate (KS) to stain for ciliated cells. Error bars represent SEM of 6 different tissues. Scale bar =
10µm.
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Figure 5.2: RSV inclusion body formation in HAE. (A) HAE tissues were infected with rgRSV
and stained for the nucleoprotein, N, and phosphoprotein, P, to assess the formation of inclusion
bodies in HAE tissues. (B) Co-localization of N and P was analyzed using co-localization
chromatography from NIS elements. (C) To confirm inclusion body formation in HAE tissues, FISH
analysis was conducted to label vRNA. (D) Both vRNA and RSV N colocalize to cytosolic punctate
structures in infected cells. (E) vRNA was also assessed in relation to RSV using fluorescence
microscopy. (F) Chromatogram analysis demonstrates that P and vRNA co-localize with one
another in infected cells. Scale bar = 10µm for combined images with DIC and 5µm for fluorescence
insets. Arrows indicate the cross-section measurement for the corresponding chromatograms.
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Figure 5.3: HMPV inclusion body formation in HAE. (A) HAE tissues were infected with rgHMPV
and stained for the nucleoprotein, N, and phosphoprotein, P, to determine the formation of inclusion
bodies in HAE tissues. (B) Co-localization of N and P was analyzed using co-localization
chromatography from NIS elements. (C) To confirm inclusion body formation in HAE tissues, FISH
analysis was conducted to label vRNA. (D) Both vRNA and HMPV N colocalize to cytosolic punctate
structures in infected cells. (E) vRNA was also assessed in relation to HMPV using fluorescence
microscopy. (F) Chromatogram analysis demonstrates that P and vRNA co-localize with one
another in infected cells. Scale bar = 10µm for combined images with DIC and 5µm for fluorescence
insets. Arrows indicate the cross-section measurement for the corresponding chromatograms.
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Figure 5.4: HMPV forms intercellular extensions significantly more than RSV. BEAS-2B, Vero
and HEp-2 cells infected with rgRSV (A) or rgHMPV (B) demonstrate the formation of long
filamentous extensions. (C) HAE tissues infected with either rgRSV or rgHMPV demonstrate the
formation of these filamentous extensions in a 3-D model system. (D) Extension formation is
significantly more common in rgHMPV infected tissues compared with those infected with rgRSV.
Statistical significance represented with p<0.05 *, P<0.005 **, P<0.0005 *** and P<0.0001 ****.
Scale bar = 25µm for 2-D cell culture and 10µm for HAE tissues, 5 µm for higher magnification
insets.
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Figure 5.5: Nirsevimab and palivizumab inhibition of RSV entry. (A) HAE tissues were infected
with rgRSV at MOI 1.0 preincubated with or without palivizumab (pali) or nirsevimab (nirsevi) for 1
hour at 37°C. After 48hours post infection, fluorescence was examined by inverted or confocal
microscopy to determine inhibition of infection as well as microtome cross sections (B) of infected
tissues to examine infection inhibition. (C) Threshold analysis of inverted fluorescence microscopy
images were quantified using ImageJ adaptive threshold analysis. Scale bar = 10µm. Error bars
represent SEM of 4-6 tissues for each treatment group.
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Figure 5.6: 54G10 inhibition of HMPV entry. (A) HAE tissues were infected with rgHMPV at MOI
3.0 preincubated with or without 54G10 for 1 hour at 25°C. After 48hours post infection,
fluorescence was examined by inverted or confocal microscopy to determine inhibition of infection
(B) as well as microtome cross sections of infected tissues to examine infection inhibition. (C)
Threshold analysis of inverted fluorescence microscopy images were quantified using ImageJ
adaptive threshold analysis. Scale bar = 10µm. Error bars represent SEM of 4-6 tissues for each
treatment group.
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Figure 5.7: Nirsevimab inhibits spread significantly more potently than palivizumab. (A) HAE
tissues were infected with rgRSV at MOI of 0.3. Tissues were treated apically with either
palivizumab or nirsevimab 6 hours post inoculation in 50µL of TEER buffer. Fluorescence
microscopy images were taken up to 72 hours post infection. (B) Tissues were fixed at 72hpi and
microtome-sectioned for each treatment group and examined for viral spread. (C) Fluorescence
threshold analysis of inverted fluorescence microscopy images demonstrate that both pali and
nirsevi are able to prevent the spread of rgRSV in HAE-infected tissues, with nirsevi able to inhibit
spread at lower concentrations compared with pali. Scale bar = 10um. Error bars represent SEM
of 6 tissues per treatment group. Statistical significance represented with p<0.05 *, P<0.005 **,
P<0.0005 *** and P<0.0001 ****.
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Figure 5.8: 54G10 significantly inhibits spread of HMPV. (A) HAE tissues were infected with
rgHMPV at MOI of 3.0. Tissues were treated apically with 54G10 6 hours post inoculation in 50µL
of TEER buffer. Fluorescence microscopy images were taken up to 72 hours post infection. (B)
Tissues were fixed at 48hpi and microtome-sectioned for each treatment group and examined for
viral spread. (C) Fluorescence threshold analysis of inverted fluorescence microscopy images
demonstrate that 54G10 modestly but significantly prevents the spread of rgHMPV in HAE infected
tissues. Scale bar = 10µm. Error bars represent SEM of 6 tissues per treatment group. Statistical
significance represented with p<0.05 *, P<0.005 **, P<0.0005 *** and P<0.0001 ****.
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Chapter 6: RSV and HMPV viral co-infections
* This chapter was completed with the help of Dr. Nicolas Cifuentes and Rachel
Thompson. Nicolas and Rachel generated the transfection inclusion body counts
(Figure 6.5) and Nicolas generated the recombinant mCherry virus for HMPV,
examined the co-infection potential over time, and conducted microscopy (Figure
6.1-6.4). I generated all figures as well as performed experiments in figure 6.6.
Nicolas contributed to the initial drafts of the written portion.
Introduction
The Pneumoviridae is a recently created viral family that harbors two
important pediatric respiratory pathogens, human metapneumovirus (HMPV) and
respiratory syncytial virus (RSV) (18). Pneumoviruses cause upper and lower
respiratory tract infections, symptomatically presenting as a mild cold-like disease
which can progress to severe pneumonia and bronchiolitis (21-23, 26, 27, 30, 354,
391-397). Despite the high prevalence of these viruses, no FDA-approved
vaccines are available against either RSV or HMPV. Only one prophylactic
therapeutic, palivizumab, is available for RSV (28, 29), and none are available
against HMPV. However, palivizumab is given only to high risk infants born during
the infectious season. An important, yet highly understudied feature of
pneumoviruses is the occurrence of viral co-infections, which have been
associated in some cases with a more severe outcome of the disease for these
two viruses (38, 40).
Pneumovirus particles are enveloped and contain a non-segmented,
negative-sense

single-stranded

RNA

genome

(nsNSV)

coated

by

the

nucleoprotein (N), giving rise to helical nucleocapsids (442, 443). The
nucleoprotein interacts with the viral phosphoprotein (P), which recruits both the
large RNA-dependent RNA-polymerase (L) and the M2-1 protein onto
nucleocapsids forming the replication complex. During initial infection, a
membrane fusion step mediated by the viral surface glycoproteins allows entry into
target cells, releasing the viral nucleocapsids into the cell cytoplasm. The viral
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RNA-dependent RNA polymerase then initiates transcription and replication of the
viral genome to generate messenger RNA (mRNAs) as well as the genomic RNA
(vRNA) (444). An important feature observed in pneumovirus infected cells is the
formation of perinuclear structures named inclusion bodies (IBs) (251, 445). The
available evidence indicates that IBs are the sites of pneumovirus genome
transcription and replication, producing both genomic material for viral particle
formation and mRNA for viral protein production (251, 254, 255, 445, 446).
Additional robust evidence linking IBs to genome transcription and replication has
been reported for other nsNSVs including rhabdoviruses (256, 263), filoviruses
(261, 262, 447) and paramyxoviruses (264, 266), further supporting an important
role for IBs in viral infections within the negative sense RNA viruses.
Here, we explored the dynamics of co-infections by RSV and HMPV in
immortalized cell lines. Infection experiments using both viruses showed the
population of HMPV-RSV co-infected cells was only a minor fraction of the total
infected cells and required significantly more HMPV compared to RSV. However,
the fraction of co-infected cells did show increases over time. Interestingly in coinfected cells, we found the presence of IBs with positive co-localizing signal for
both HMPV and RSV genomes, suggesting that replication and transcription of
both viruses can occur in the same specialized compartment. We recapitulated IB
formation by homologous and heterologous co-expression of pneumovirus N and
P proteins and found that HMPV P can complement RSV N to facilitate IB
formation. However, various permutations of N and P proteins yielded changes in
the minigenome replication efficiency for both viruses. Furthermore, using a
minigenome replication assay, we find that RSV N and P are able to partially
complement replication in addition to HMPV proteins and genome, but are less
efficient compared with homologous HMPV protein expression only. Conversely,
RSV again showed significant replication deficiency when HMPV N and P are
present, supporting a potential dominant negative phenotype where HMPV
interferes with RSV replication. To our knowledge, this is the first demonstration of
pneumovirus coinfections at a cellular level, providing new insights into the
consequences of viral coinfections in vivo.
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Results and Discussion
HMPV and RSV coinfections in immortalized cell lines
To quantitatively evaluate the frequency of HMPV-RSV co-infections by flow
cytometry, we created a recombinant HMPV carrying a mCherry cassette, located
between the N and P genes (Fig 6.1A). The recombinant virus, named rJPS0276mCherry (denoted rmcHMPV), was grown in the presence of TPCK-trypsin to
titers comparable to the previously reported rJPS02-76EGFP (192) (Fig 6.1B).
Human bronchial epithelial cells (BEAS2B) were infected with the rmcHMPV, with
a recombinant RSV carrying a GFP cassette (denoted rgRSV), or with
combinations of both at different multiplicities of infection (MOI), with infection by
both viruses carried out at the same time. The presence of coinfected cells was
initially evaluated by microscopy at 24, 48 and 72 hpi and subsequently analysed
by flow cytometry. Initially, we evaluated singly infected cells in three different cell
types: LLC-MK2, Vero, and BEAS-2B, to understand infection and spread kinetics
for each virus. rmcHMPV demonstrated a more robust infection and spread in LLCMK2 cells compared with both BEAS-2B or Vero cells, and the percent of infected
cells increased through 72hpi (Fig 6.2A). This result was not surprising since
HMPV has been described as a poor growing virus in vitro, and some cell lines
including BEAS2B are not as suitable for viral growth and Veros show lower
kinetics compared with LLC-MK2 (448). For RSV, LLC-MK2 and Vero cells
demonstrated similar percentage of infection and rates of spread, but BEAS-2B
cells again showed decreased permissiveness to infection and increased cell
death was observed at late times of infection when high MOIs were used (Fig
6.2B).

To examine for cells co-infected with HMPV and RSV, the levels of HMPV
were kept at a constant MOI of 1, and RSV was used at MOIs of 0.01, 0.1 or 1.
The highest levels of co-infected cells were observed when using infection ratios
of 1:1 of HMPV to RSV in BEAS-2B cells, but with much lower percentages of co106

infected cells observed when less RSV was used (Fig 6.3A). When examining
infection in Vero and LLC-MK2 cells, we observed a relatively low number of coinfected cells similar to that observed in BEAS-2B, although more abundant in
comparison. (Fig 6.3A). By 48 and 72 hpi, the number of co-infected cells
increased significantly, indicative of viral spread through infection a naïve cell or
entry of one virus into a cell previously infected by another virus (Fig 6.3B). In
addition, singly infected HMPV cells were almost undetectable at 72hpi, but the
total number of co-infected cells observed suggests that HMPV is still able to
spread, but eventually, almost all HMPV infected cells are present in a co-infection.
When analysing co-infections of singly vs co-infected cells infected at the same
time, RSV demonstrated a decrease in the number of infected cells at 24hpi. This
suggests that the presence of HMPV significantly alters initial entry and replication
of RSV, but is unaffected at later times post infection. Conversely, HMPV appears
to be unaffected and the infection percentage at 24hpi remains largely unchanged.
This phenomenon of viral interference has been reported for other viruses and
remains poorly understood (449-451), but offers one explanation for our
observations during co-infection. Similar reductions in viral loads were reported
clinically for co-infections of RSV and HMPV as well, further supporting our
observations in vitro (452-454)..
HMPV and RSV heterologous protein complementation
In order to better understand how these viruses are interacting, we first
examined co-infected cells in detail beginning with effects on replication. We
conducted fluorescence in situ hybridization (FISH), using probes that hybridize to
either the vRNA from HMPV or the vRNA from RSV. Different patterns of vRNA
signals were found in co-infected cells, the most striking being the colocalization
of signals in structures that resemble what has been described as IBs (Fig 6.4). Zstack analysis demonstrated that signals of vRNA from both viruses occupied the
same location within co-infected cells (Fig 6.4). One intriguing possibility for the
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observed co-localization is the heterologous complementation of viral proteins for
IB formation and/or RNA synthesis.
For pneumoviruses, IB formation can be minimally recapitulated by
homologous expression of P and N (254, 455), therefore, we decided to test if
heterologous protein expression between viruses would complement IB formation.
As a control, HMPV N and P, as well as RSV N and P, were verified to induce
formation of IBs when co-expressed in Vero cells. Interestingly, a significant
percentage of cells expressing HMPV P and RSV N still formed IBs, while cells
expressing HMPV N and RSV P formed no IB-like structures (Fig 6.5). In order to
test if heterologous proteins could be incorporated into already formed IBs, triple
transfections were performed. Upon HMPV N and P co-expression, the additional
expression of either RSV N or P had a strong deleterious effect on IB formation,
appearing to act in a dominate negative mechanism (Fig 6.5). Instead of large IBs
(>500nm), cells displayed speckles, consisting of small and abundant cytosolic
puncta for both signals but significantly smaller in size (<500nm) compared to
normal IBs. In contrast, RSV N and P still formed IBs in the presence of either
HMPV N or P, though to reduced levels (Fig 6.5). However, these experiments are
preliminary, and more investigation is needed to better understand the effects of
protein complementation for both viruses on IB formation.
To further examine the functional consequences of heterologous IB
formation, we employed HMPV and RSV mini-replicon assays. Here, the 3’ leader
region from the viral genomic RNA is placed in front of a luciferase reporter.
Successful binding and initiation by the viral replication complex results in the
production of luciferase transcript, resulting in luciferase protein production which
can be measured quantitatively. Heterologous expression of RSV N or P in place
of HMPV proteins in the mini-replicon assay resulted no replication, suggesting
these are not able to take the place of the cognate protein of HMPV. However,
expression of both RSV N and P did result in a 10% increase in luciferase activity,
which indicates that heterologous IBs were functional, but significantly less than
cognate protein expression (Fig 6.6A). Similarly, when examining HMPV N or P
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expression in the RSV mini-replicon assay, single complementation of N or P
resulted in no luciferase activity whereas both HMPV N and P expression resulted
in a 10% increase in luciferase activity (Fig 6.6B). Lastly, we conducted minireplicon assays using all HMPV proteins and co-expressed RSV N, P or all 4 of
the RSV proteins (including M2-1 and L) to determine if there were synergistic or
dominant negative effects on replication. Compared with the HMPV proteins alone,
addition of RSV P mildly decreased replication by 20%, whereas the addition of N
decreased it to nearly 50%. Co-expression of N/P from RSV or the addition of all
mini-genome components resulted in only 30% reduction in replication, suggesting
that RSV proteins do not completely inhibit HMPV replication, but these
components are less efficient in comparison. Conversely, the addition of any
HMPV components to the RSV mini-replicon resulted in significant reduction of
RSV replication to 20% compared with RSV components alone, suggesting HMPV
proteins are able to act in a dominant negative fashion instead of complementation,
where they inhibit the function of RSV proteins by competing for substrate and
prevent replication.
HMPV P (294 aa) and RSV P (241 aa) share only 37% amino acid identity.
However, their overall domain structure is highly similar and includes the presence
of N- and C-terminal intrinsically disordered regions (IDRs) and a central α-helical
tetramerization domain (456, 457). Most of the identical amino acids between
HMPV P and RSV P are in the tetramerization domain, but our results suggest that
these proteins are unlikely to form heteromeric protein complexes that complement
replication. Additionally, the deleterious effect of RSV N or P over HMPV IBs could
be explained by their higher affinity for critical cellular components, including actin
and/or actin related proteins which are important for virus lifecycle (251, 288, 406,
431, 458-460), but this remains to be further examined.
From 24 to 72hpi, singly infected HMPV cells are almost completely gone
and instead, only found in co-infected cells. However, the number of infected cells
that contain HMPV increased, suggesting that HMPV is able to spread, but also
results in more co-infected cells. One possibility is that RSV is able to infect nearly
109

100% of cells, and although the initial infection rates are altered when both viruses
are present, they are unaffected at later times post infection. This allows HMPV to
spread but permissiveness of RSV entry gives rise to an increase in both HMPV
positive and co-infected cells. Another explanation is a cooperative effect of these
viruses at the cell surface. RSV and HMPV proteins and nucleic acids move to the
plasma, aggregating at viral assembly sites. As both pneumoviruses bud, there
may be an interaction occurring, where HMPV and RSV particles travel closely
associated, leading to entry of both viruses into a single cell. Another purely
speculative idea is the presence of chimeric viruses. HMPV and RSV demonstrate
high similarity, with homologous proteins performing similar functions during the
viral lifecycle. We have also shown that there are some potential interactions of
replication components from one virus interacting with the genetic material of
another using the mini-replicon system. Therefore, as nucleic acids are being
packed into virions for spread, there could be a heterologous nucleic acid
population, containing genomes from both RSV and HMPV in newly formed
virions. This chimeric virus then delivers both genomes to a naïve cell, which
increases the number of HMPV and subsequently, co-infected cells. However,
there needs to be further investigation of assembly and spread to better
understand spread kinetics in co-infected populations and how this increase in coinfected cells is occurring and how it affects the replication efficiency of each virus.
In addition, there is no current evidence for the presence of chimeric viruses and
therefore, this mechanism needs to be examined further to identify if this is
possible.
The RSV genome is 2 kb larger than the HMPV genome, and contains two
non-structural proteins NS1 and NS2, absent in HMPV. Both proteins have antiinterferon activities, representing an additional advantage of RSV infections over
HMPV. However, while purely speculative, in the event that viral chimeras were
generated from co-infected cells, this offers a potential explanation of why coinfections between these two viruses are able to generate a worse clinical outcome
in patients, although this severity varies (39, 41, 44, 452-454, 461-472). It may also
offer one potential explanation for why co-infected cells are more prevalent at later
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times post infection and singly infected HMPV cells are absent. Our current data
suggests that HMPV and RSV have a potentially reduced synergy, but these are
examined in transfection and not infection experiments, where a host of other viral
proteins may interact to favour replication and spread for both viruses. However,
one study examined the amounts of RSV and HMPV viral loads in co-infected
patients and saw no change for HMPV but a small, significant decrease in RSV
titer (452), similar to our findings using the mini-replicon assay and suggested by
other studies as well (453, 454). In addition, there may be synergistic crossover
of HMPV and RSV proteins involved in other aspects of viral lifecycle, but further
studies examining key components needs to be conducted to better understand
interactions between pneumoviruses. Future work will define if these co-infections
are beneficial for viral infection and spread and the molecular mechanisms
underlying this phenomenon.
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Figure 6.1: Recombinant mCherry HMPV shows efficient growth. (A) Recombinant mCherryexpressing HMPV strain JPS07E2 (rmcHMPV) was created by placing the gene for the fluorophore
between the N and P gene segments. (B) rmcHMPV growth kinetics were similar to those observed
for the JPS07E2 strain expressing GFP. Growth was seen when exogenous trypsin was added at
3 and 0.3µg/mL but no growth when trypsin was not present (n=3).
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Figure 6.2: HMPV and RSV growth in infected cells. LLC-MK2, Vero, and BEAS-2B cells were
infected with (A) rmcHMPV and (B) rgRSV to observe infection and growth over time. LLC-MK2
cells demonstrated the highest infection and growth rate for both viruses (n=3).
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Figure 6.3: Analysis of HMPV and RSV co-infections. (A) rgRSV (MOI 0.01, 0.1 or 1) and
rmcHMPV (MOI 1) were added simultaneously to LLC-MK2, Vero, or BEAS-2B. At 24 hpi, the
percent of co-infected cells was determined using flow cytometry. (B) Co-infected cells were then
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analysed over time up to 72 hpi, showing that co-infected cells increase over time. (C)

Simultaneous infection of pneumoviruses affects RSV but not HMPV at 24hpi (n=3).

Figure 6.4: HMPV and RSV in co-infected cells can occupy the same IB. Vero cells infected
with rgRSV and wild type HMPV. Co-infected cells were examined using FISH against the RSV
and HMPV genomes which demonstrated co-localization within inclusion body like structures.
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Figure 6.5: Recombinant RSV or HMPV N and P expression alter inclusion body formation.
Permutations of RSV and HMPV N and P were co-expressed in Vero cells and inclusion bodies
were examined using fluorescence microscopy. Both RSV N and P contained an HA tag used for
staining. HA tagged HMPV P was used in conditions 1,4 and 9. Untagged HMPV P was used in
conditions 5,6, and 8. 100 cells were counted per transfection group and each was categorized
as containing large inclusion bodies (>500 nm), small inclusion bodies (<500 nm), or cytosolic
protein distribution.
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Figure 6.6: HMPV and RSV mini-replicon complementation, synergy, and dominant negative
effects. The HMPV (H) or RSV (R) mini-replicon plasmids along with genes for viral proteins in
the indicated permutations were transfected into BSR cells. Luciferase activity was measured 24
hours post transfection for each of the complementation and synergy/dominant negative groups
(n=3-5).
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Chapter 7: Discussion and Future Directions
The topics covered in this dissertation create a better understanding of key
molecular interactions for pneumovirus entry, spread, and inhibition. We identified
novel information about how HMPV strains can utilize low pH as a timing
mechanism for triggering and what residues within the protein contribute to this
phenomenon (Chapter 3). We further analyzed other known aspects of HMPV
lifecycle, identifying previously unknown proteases that process HMPV F and
using this new information to target multiple viruses therapeutically (Chapter 4).
Further exploring pneumovirus lifecycles, we employed a 3-D human airway tissue
model system to directly compare and contrast infection, spread, and phenotypes
associated with infection, identifying important information for potential therapeutic
development (Chapter 5). Lastly, we explored the phenomenon of viral coinfections, allowing us to better understand how these closely related
pneumoviruses co-occupy replication compartments in co-infected cells and
explore a potential synergy for these in vitro (Chapter 6). While our results
generate interesting and novel information about pneumovirus lifecycles, there
remain many more research questions that need to be explored.
Low pH mediate triggering of HMPV F: Analysis of new strains reveals
complex requirements for fusion
Understanding requirements for viral entry is an important aspect for preventing
entry as a therapeutic approach. Prior to research conducted during this thesis,
only a few fusion proteins from different HMPV strains had been shown to promote
low pH triggered fusion (189, 240-242). However, other HMPV F proteins had been
found to promote membrane fusion independent of pH while others are unable to
mediate fusion at all in cell-based assays. Analysis of specific residues that
contribute to low pH-mediated fusion had been examined using site directed
mutagenesis, recombinant viral strains, or viral strains with conserved amino acid
sequences reported for fusion phenotypes. Together, these results led to the
hypothesis that low pH fusion requires a glycine (G) at position 294, as well as
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lysine (K) at 296, tryptophan (W) at 396, asparagine (N) at 404, and histidine (H)
at 435, which are primarily associated with the A2 viral strain subtype and
therefore, a rare strain dependent phenomenon (189, 240-242). However, work
presented in this thesis has examined newly available strains of HMPV to better
understand low pH mediated fusion and the role for specific residues in this
process (chapter 3).
Fusion protein triggering is a complex phenomenon and its temporal and
spatial regulation is vital for viral spread. For many viruses, interactions between
the attachment protein and a cellular receptor trigger the fusion protein.
Alternatively, the fusion protein can directly interact with cellular factors to promote
fusion. For viruses that are neither triggered by receptor binding or signaling by the
cognate attachment protein, they must utilize some environmental signal, often
using low pH present in cellular endosomes (154). Low pH triggering is utilized by
the fusion proteins from many viruses, including members of Orthomyxoviridae,
Flaviviridae,

Togaviridae,

Rhabdoviridae,

Bunyaviridae,

Filoviridae,

and

Arenaviridae, although there are families containing members with mixed
requirements (154). These fusion proteins utilize specific residues, typically
involving a histidine salt bridge, to disrupt electrostatic interactions to promote the
conformational changes needed for fusion. In addition, there are direct, indirect, or
a combination of factors required to trigger fusion and entry. This process becomes
more complicated when factoring in the complex lipid membrane environment,
which is both a barrier for viruses to cross and subsequently a hijacked resource
to produce enveloped viral progeny.
For the closely related paramyxoviruses, it has been hypothesized that
many members enter at the plasma membrane due to pH-independent entry (94,
145, 157). When examining the pneumovirus family, results describe a more
complex entry pathway. RSV has been shown to mediate cell-to-cell fusion
independent of the other surface glycoproteins, G and SH (91, 399, 400). Reports
suggest RSV is also able to utilize multiple cellular factors for attachment and
entry, including CX3CR1, heparan sulfate, L-sign, DC-Sign, nucleolin, and TLR4
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(316, 473-478). These interactions subsequently allow RSV to enter via
micropinocytosis where it fuses with the endosomal compartment for genome
release (479). For HMPV, the fusion protein is able to mediate infection without G
or SH as well (121, 123), similar to RSV. However, HMPV lacking G or SH still
spreads in animal models whereas no detectible virus is recovered from animals
infected with RSV lacking G or SH, suggesting HMPV is more independent of other
surface glycoproteins, requiring only F for infection. While no receptor has been
reported, there have been two attachment factors that are critical for HMPV entry:
heparan sulfate and αvβ1 integrin (123, 243, 398). Subsequent entry of HMPV is
mediated by endocytosis in a dynamin- and clathrin-dependent manner in
bronchial epithelial cells (335). For the subtypes of HMPV that utilize low pH as a
trigger, this trafficking pathway provides a trigger for fusion. However, it remains
unexplored what factors are important for strains that do not use this mechanism.
Using chemicals, such as ammonium chloride, to prevent endosomal
acidification blocks entry of viruses such as influenza and VSV which require low
pH for triggering (480-482). When endosomal acidification was blocked prior to
addition of HMPV, TN94-49 (A1) about 50% inhibition in infection was observed,
whereas TN96-12 (A2) was still able to mediate efficient infection independent of
pH (335). The observation that TN94-49 requires low pH was recapitulated using
the isolated F protein, where low pH mediated cell-to-cell fusion was
demonstrated. However, we did not observe any fusion activity for TN96-12 F,
suggesting that other requirements are required independent of pH. TN96-12 was
also examined in the presence of the homotypic attachment protein, G, but failed
to promote fusion suggesting a further level of unexplored regulation (Fig 3.4).
Despite entry being mediated by F, independent of other viral surface
glycoproteins, strains of both HMPV and RSV have recently been identified that
contain a duplication site in the attachment protein, hypothesized to increase the
number of glycosylation sites present, potentially aiding in attachment to promote
viral fitness (138, 142). In addition, G is still retained in all clinical strains of HMPV,
suggesting an essential role that has not been fully understood in vivo.
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Both HMPV F S174H434 and HMPV F TN96-12 demonstrated significantly
higher overall and surface expression but showed significantly different fusion
phenotypes. The addition of a histidine at 434, in addition to the previously reported
435, appeared to enhance the fusogenic activity when exposed to low pH. H434
may therefore act to enhance de-stabilization, creating interactions that are more
sensitive to pH changes. Despite the significantly higher expression of TN96-12,
fusion was still unable to be mediated under any conditions, suggesting other
important factors required for fusion are still to be discovered.
Future experiments should explore the potential of a cellular receptor for
HMPV, potentially elucidating a common factor needed for strains not requiring low
pH for entry. Such a receptor would likely be present within the endosome, as
strains that are do not require low pH are also taken in by endocytosis, similar to
the multistep entry process required for Ebola (234, 236). There is currently limited
information on and resources available for clinical isolates of HMPV. Further
analysis of strain sequences and phenotypic characterization of HMPV F would
lead to a deeper understanding of which amino acids are important for fusion and
establish if low pH mediated fusion is a rare, strain dependent phenomenon or part
of a more complex regulatory interaction during infection for some strains.
Identifying and targeting proteases for antiviral treatment of HMPV
Viruses containing class I and II fusion glycoproteins require a cleavage
event of the fusion protein or accessory protein, respectively, during the infectious
process. This cleavage event allows priming of the fusion complex, creating a
metastable form to promote fusion upon appropriate signaling (483). One of the
most well studied respiratory viruses, influenza A, requires cleavage at a single
basic amino acid residue to prime its class I fusion protein, HA. Historically, trypsin
is used to promote cleavage in vitro (484, 485). Endogenous proteases required
for activation were not reported until recently when a variety of serine proteases
present in the lung that mediate cleavage of HA were identified (170, 173, 174,
176, 177, 376, 377, 380, 381, 383). Studies examining in vitro and animal model
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systems further demonstrated that influenza subtypes also have variable protease
specificity depending on the strain, but why this preference is present requires
more research (173, 176, 375, 377, 381). Highly pathogenic influenza strains have
a mutation in this cleavage site, converting it to a multi-basic stretch. This allows
recognition and cleavage by more abundant, non-tissue specific intracellular
proteases like furin (355). Identifying and understanding these proteases is
important for characterizing pathogenicity and tropism during infection and spread.
Similar to influenza, all HMPV strains contain a cleavage motif where a single basic
amino acid is cleaved to release the fusion peptide (189). There is only one
reported variation in the consensus sequence and these strains are considered
trypsin independent, but few strains harbor this modification (190, 193). Trypsin
independent strains did not grow to higher titers compared to strains requiring
trypsin or those with an inserted furin cleavage motif, suggesting that this mutation
does not enhance pathogenicity (190, 193).
Prior to our studies, it was known that trypsin and TMPRSS2 were able to
cleave HMPV F (189, 192). The hypothesis that other proteases could also
promote HMPV F cleavage led us to investigate other proteases identified for
influenza which may also be utilized by HMPV or other respiratory viruses that
have similar cleavage requirements. Other human respiratory viruses with class I
fusion proteins requiring cleavage at a basic amino acid include paramyxoviruses
such as parainfluenza virus 1-4 (486) and Sendai virus (486). In addition,
TMPRSS2 was shown to cleave one of the two cleavage sites present in
coronaviruses (CoV) such as 229-E (487),EMC (488), SARS-CoV (489, 490),
MERS-CoV (491) and the novel SARS-CoV-2 (492). SARS-CoV and MERS-CoV
have both been shown to be cleaved by TMPRSS2 and this protease plays an
important role in infection. One cleavage site of MERS-CoV has the basic furin
recognition motif (RXXR) for proteases recognizing multi-basic cleavage motifs,
suggesting some potential cleavage by more abundant, endogenous proteases
such as furin. However, HMPV shares a similar basic motif (RQSR) and is unable
to be cleaved by furin, suggesting a more restricted motif requirement for efficient
cleavage. The novel SARS-CoV-2 has a similar mutation compared with highly
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pathogenic influenza (493), where an addition of basic amino acids residues at
one of the cleavage sites (RRAR) which has a higher affinity for proteases that
recognize a multi-basic amino acid stretch for cleavage, ultimately leading to more
efficient processing. This mutation is a major contributing factor that lead to a
global pandemic that emerged in late 2019. Studies also support the use of
TMPRSS2 by SARS-CoV-2, but studies also suggest cleavage by furin and other
proteases that cleave at multi-basic amino acid motifs (494). However, there are
limited options available to target this specific aspect of the viral life cycle.
Therefore, a better understanding of how these respiratory viruses utilize host
proteases to activate their fusion proteins and initiate infection is important for
developing novel therapeutic targets against a broad range of viruses requiring this
class of proteases.
Targeting pathogen specific factors often leads to the development of drug
resistance. Using an approach that targets a broadly used host factor not only
prevents drug resistance from developing, but also could identify broad-spectrum
inhibitors of multiple pathogens using a single chemical and dosage. In our studies,
we used HAI-2 (362) (referred to as SPINT2) as a broad-spectrum serine protease
inhibitor that prevents spread of influenza and HMPV and therefore, inhibits the
cleavage of HA and F, respectfully (Chapter 4). Inhibiting serine proteases has
been explored previously including aprotinin (361, 495, 496) and camostat (385,
491, 495, 497). While aprotinin was able to inhibit entry and is an approved therapy
in Russia, the pharmacokinetics as a competitive inhibitor of several serine
proteases makes it an unfavorable treatment (496). Camostat has been approved
for use in Japan for the treatment of pancreatitis and postoperative reflux
esophagitis (386, 498). This protease inhibitor also demonstrates significant
potential for other morbidities, including some viral infections, but the limited
availability makes it difficult to rapidly achieve the use of camostat on a global
scale. Recently, the SARS-CoV-2 pandemic led to emergency drug repurposing
where camostat was a highly sought-after contender for treating SARS-CoV-2
patients (492). Camostat has been shown to inhibit SAR-CoV-2 infection in vitro
and there are several on-going clinical trials examining this protease inhibitor for
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effectiveness against SARS-CoV-2. However, a significant amount of research
needs to be conducted to better understand efficacy and safety. This
unprecedented time has allowed for the use of camostat world-wide which could
result in its use against influenza, CoV, and HMPV soon.
Identifying proteases involved in HMPV infection has revealed novel and
very important information about this ubiquitous pathogen. We show that targeting
cleavage is a significant mechanism for developing antivirals. However, other
proteases need to be identified and examined in more physiologically relevant
model systems to better understand how our findings translate to more complex
systems of infection. In addition, analyzing SPINT2 compared to camostat in
various model systems would help understand how advantageous this method
would be in comparison. The advantage of SPINT2 is that it is endogenously
expressed in humans, whereas camostat is a synthetic compound. This offers the
potential for less side effects and administration of higher, more efficacious doses
that may be needed to prevent infection. However, the generation of a protein
inhibitor on a large scale presents a significant challenge that must be overcome.
Identification of novel naturally occurring and synthetic protease inhibitors that
inhibit viral infection would provide for broad protection and prevention of viral
spread while simultaneously mitigating side effects to prevent and treat multiple
respiratory pathogens. Some of this research has already begun, but there is
significantly more needed to ensure an effective treatment (495, 496).
Complex 3-D human airway epithelial tissues as a model system of
infection.
Historically, RSV and HMPV infections have been studied using 2-D cell
monolayers, leading to a better understanding of infection. Because these viruses
are evolutionarily similar and share several key characteristics during the lifecycle,
we examined previous 2-D findings using a complex, more physiologically relevant
3-D human airway epithelial (HAE) model system. RSV has had multiple reports
using HAE tissues (143, 144, 314, 316, 319, 323-326, 420, 421), but only four
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HMPV studies have utilized HAE tissues (135, 136, 318, 333). However, none of
these reports have done extensive molecular characterization of these viruses
during the stages of infection. Using these models, other reports have suggested
that viruses grown in 2-D culture undergo adaptations, altering infection dynamics
in more complex models. For RSV, there is evidence suggesting growth of virus in
monolayers results in less infection when the virus is subsequently added to HAE
tissues (143, 144, 421), compared to virus initially grown on tissues which infects
with higher efficiency. These observations are true for many other viruses including
measles and PIV, where studying them out of context prevents important, tissue
specific information from being obtained (294, 297, 499-501). It is possible that
growth of RSV and HMPV in HAE tissues could alter the infectivity and spread
kinetics compared with strains grown in 2-D monolayers. Growing viruses in HAE
issues would generate strains with more physiologically relevant adaptations and
these studies would be important for understanding how this contributes to entry,
spread, and replication as well as how to target these more effectively. However,
growth of virus in these complex models is costly and therefore difficult to achieve
with current methods.
Other reports have demonstrated that cell polarity is an important factor for
determining where viral factors localize during infection. Polarized cell monolayers
infected with RSV showed F localized to the apical surface and this was
recapitulated using 3-D tissues. In comparison, 2-D cells demonstrate a general
localization to the plasma membrane (438). Having F localized at the apical
surface is consistent with proposed locations for viral assembly and budding sites
in vivo, which has been difficult to characterize using non-polarized models.
Similarly, RSV and HMPV have been demonstrated to form actin-based
extensions in 2-D cultures and chemically inhibiting actin dynamics in these
systems profoundly affects viral replication and spread (288, 298). However, when
we examined infection in our 3-D model, we found that these extensions were
significantly less prevalent in RSV infected cells compared to HMPV (Fig 5.4).
Therefore, it is possible that RSV-induced extensions in 2-D monolayers are a
result of cells lacking polarization, where the actin cytoskeleton is important for
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other functions not found in this system. Previous unpublished work in our lab
studying HMPV examined the effect of actin cytoskeletal inhibitors on HAE infected
tissues. We found that inhibition, similar to 2-D cells, significantly inhibited
replication and spread (El Najjar and Dutch, unpublished results), but further
analysis is needed to understand how it affects extension formation. Both HMPV
and RSV proteins are able interact with the actin cytoskeleton, supporting a critical
role for viral function (288, 427, 502). Actin and actin-related proteins are present
in isolated virus when analyzed by mass spectrometry, further supporting the role
of actin in viral assembly and spread (288, 503, 504). The role of extensions during
HMPV and RSV infection in HAE tissues needs to be analyzed to understand what
the purpose of these extensions is during assembly and spread.
We used this HAE system to analyze the therapeutic potential of
monoclonal antibodies (mAbs) for entry and spread inhibition. While both HMPV
and RSV were neutralized to prevent viral entry, there was a large difference
observed in the effect of neutralizing antibodies on spread kinetics (Fig 5.5 - 5.8).
RSV spread was completely inhibited when mAbs were added to the apical surface
after infection, but HMPV spread was only inhibited approximately 25%. These
findings were also shown for both viruses in 2-D monolayers where RSV entry and
spread were blocked but only entry was inhibited for HMPV and an approximately
50% reduction was seen for spread. These observations in both 2-D and 3-D
models highlight an interesting dichotomy between RSV and HMPV infections. Our
results support previous work that shows HMPV can spread directly from cell-tocell in monolayers, independent of neutralizing mAbs (288). Interestingly, HMPV
infection peaked at 48 hours, and spread was only observed within this 24-hour
window. HMPV is primarily cell associated and therefore, sloughing of apical cells
carrying infected HMPV may result in loss of infectious particles, potentially
explaining why limited spread was seen at later times post infection. In addition to
RSV and HMPV, there have been other respiratory viruses studied including
influenza, parainfluenza, measles virus, and adenoviruses and while our results
are preliminary, comparing and contrasting other well studied viruses also allows
for understanding how previously identified phenotypes in pneumoviruses may
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manifest in our model system (136, 143, 144, 313, 315, 316, 321-325, 327, 415419).
Even though using tissue systems allows for understanding infection in a
more physiologic context, there are some pitfalls. RSV spread inhibition was
observed for both palivizumab and nirsevimab in 2-D and 3-D models. However,
palivizumab is only effective when given prophylactically, but is not effective when
given during an already active infection. Therefore, this work suggests the
antibodies have strong potential as novel therapeutics, but the complexity of
systems present in other models is needed to fully explore the potential window
for therapeutic intervention. One major drawback of the HAE model is the lack of
an immune system, which is critical for understanding infection progression,
clearance, and treatment. Establishing more complex model systems that
incorporate both organ and immune system specific constituents would aid our
understanding of viral infections and the antiviral response. Further studying
pneumovirus infections in the presence of other important factors present within
lung tissue will be critical for understanding how the phenotypes reported here are
altered with increasing model system complexity.
Viral co-infections: Potential synergy for HMPV and RSV co-infected cells
Co-infections occur when opportunistic hosts are susceptible to one or more
pathogens which infect a specific organ system. Often, there combination of
fungal-bacterial-viral co-infections which result in one pathogen invading while
creating an environment that allows another pathogen to thrive in a synergetic
manner (505-507). There is a significant number of reports documenting the
simultaneous presence of one or more respiratory viruses that can result in
significant morbidity compared with single species infections. However, there is
also evidence of viral interference, infection with where one virus prevents the
entry of another. This phenomenon suggests co-infections often cannot occur and
therefore they have been infrequently studies so they remain poorly understood
(449-451). However, there is likely a benefit that arises from co-infection which
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promotes some fitness advantage for both viruses instead of competition, which
would only promote the growth and spread of one species.
More specifically, RSV and HMPV have been reported to co-infect
individuals, leading to increased disease severity as a result (38, 40), though coinfection at a cellular level has not been examined. These viruses also share many

similarities both genetically and in protein function during infection. We aimed to
better understand how RSV and HMPV were resulting in more severe pathology
by examining viral co-infected cells and the potential for synergy during infection.
We observed minimal amounts of co-infected cells initially, but these population
increased over time (Fig 6.3). We observed the phenomenon of viral interference
where initial infection with one virus affected the entry of another. Upon closer
examination, IB formation was observed, minimally composed of N, P and viral
RNA. Interestingly, RSV and HMPV vRNA and proteins co-localized to the same
inclusion bodies in co-infected cells, suggesting the potential for viral protein
complementation. The N and P proteins of each virus serve similar functions and
the overall structures compared with one another are quite similar, despite minimal
sequence conservation. However, testing various combinations of N and P
resulted in mixed results for IB formation (Fig 6.5). More interestingly, using a
minigenome replicon system, only 10% of replication efficiency was retained when
swapping out N and P from both viruses, but adding them in addition to all cognate
replication proteins suggests that HMPV is primarily unaffected whereas RSV still
has a significant reduction (Fig 6.7).
Our observations generate more questions about why RSV and HMPV
proteins and viral RNA in co-infected cells would occupy the same replication
organelle given that we currently observe minimal synergy for replication. We
primarily studied co-infections using protein expression in eukaryotic cells, which
takes away the complexity of other viral factors that may be important during
infection in addition to the replication complex. This could offer an explanation as
to why co-infected cells show IB co-habitation, but transfection experiments
resulted in minimal functionality. Both RSV and HMPV hijack cellular factors, many
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of which have not been identified, and these may promote a synergistic
environment within these cells. This suggests another potential scenario where
sequestration of these host factors into inclusion bodies draws HMPV and RSV
proteins together into these replication organelles and not be driven by viral
synergy which would explain the limited synergy observed in replication. However,
this still leaves the question of whether co-infections are a consequence of chance,
or if there is a benefit of two viruses co-infecting the same cell.
To examine this further, co-infected samples will need to be analyzed to
characterize replication and spread compared to singly infected cells. More
interestingly though, is the potential for the formation of viral chimeras, where
budding viruses contain multiple genomes from both viruses that can pass on and
co-infect other cells. Our time course data supports that at 72 hours, singly infected
HMPV appears to decrease and overall co-infected cells increase. However, more
analysis will need to be conducted to determine if this is due to chimera formation
or other potential mechanisms of spread. Additionally, critical host factors utilized
by both RSV and HMPV to form inclusion bodies is poorly understood due to the
high volatility and dynamic nature. Identifying key viral and host factors that are
critical for the formation and function of IBs would be critical to help elucidate the
interactions that govern the coalescence of both RSV and HMPV genomes in the
same IB and whether this is driven by a synergistic interaction or a co-dependence
on specific host factors that are critical for both viruses during infection.
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Appendix 1: Designing a clinical testing platform for the merging SARSCoV-2 (COVID-19) pandemic
* This chapter was completed with the help of David B. Cobb and Dr. Morgan
McCoy from the University of Kentucky microbiology clinic, who assisted with
validation and testing in the clinic. In addition, Dr. Kate Wolf from the University of
Kentucky, Department of Microbiology, Immunology, and Molecular Genetics
helped with design, testing, and troubleshooting. All data and graphs presented
here were generated by me.
Introduction
The emergence of viral epidemics and pandemics is difficult to
predict, leading to devastating and unforeseen outcomes (508). Historical
viral pandemics include smallpox (509), measles (510), yellow fever (511),
Zika (512), Ebola hemorrhagic fever (513), severe acute respiratory
syndrome/Middle Eastern respiratory syndrome (514, 515), human
immunodeficiency virus (516, 517), and influenza virus (518-521). However,
there have been significant advances in scientific research that have
allowed us to combat some potential outbreaks. Historically, both smallpox
and measles viruses were a significant health burden. This ultimately led to
the development of vaccines resulting in the complete eradication of
smallpox in 1979 (509). For measles, worldwide vaccination efforts led to a
significant decrease of infections and subsequent hospitalizations and
death. However, recent movements in the modern era challenging
vaccinations have generated a severe threat for the re-emergence of
measles (5, 510, 522).
Vaccines are not available for every pathogenic virus, so the
development and use of antivirals is critical (523-530). This is especially
true for those viruses that circulate in non-human reservoirs and re-emerge
in human populations periodically. However, effective antivirals can be
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challenging to maintain, as many viruses have high mutation rates and multiple
species transmission which makes these chances of resistance even higher (518,
521, 527). These factors can contribute to the generation of highly pathogenic
viruses resulting in outbreaks, epidemics, and in some cases leading to
pandemics. This is particularly dangerous for viruses that have high mutation rates,
which can result in vaccines or antiviral therapies losing the ability to combat the
pathogen effectively (530-533). For IAV, these evolutionary changes result in the
need for yearly vaccinations (534). Although the annual flu vaccine offers
protection, with the levels varying by year, it is difficult to predict which strain will
dominate and which epitopes are important for eliciting an immune response. In
addition, mutations that enhance the infection and spread can occur and result in
significant morbidity and mortality, such as those seen in the IAV pandemics (519,
535, 536). Altogether, pandemic viruses can generate extreme morbidity and
mortality and are difficult to prepare for given the vast number of variables that are
unable to be controlled.
Some viruses that have strong potential to cause outbreaks are poorly
understood and others are likely still to be discovered. Bat species in particular
harbor many viruses that have generated zoonotic transmission from an
intermediate host, eventually infecting humans (537, 538). These viruses include
Hendra (HeV) and Nipah (NiV) , which cause deadly respiratory disease and
encephalitis in horses and pigs respectively (7, 11, 13, 539-541). While HeV and
NiV are only responsible for a small amount of morbidity, the mortality rates of
those infected range from 50-100%. Due to the small amount of cases and rapid
epidemiologic analysis, further cases and outbreaks have been avoided and some
treatment and prevention options are available (14, 15). Outbreaks like these bring
up interesting questions as to what potential viruses are lying dormant in nature
that have high potential for outbreaks in humans that can ultimately lead to novel
a global pandemic.
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One viral family, Coronaviridae, has been involved in several global pandemics in
recent years. Coronaviruses (CoV) are enveloped, single stranded, positive sense
RNA viruses that infects both animals and humans (542). The conserved
components of CoV are the RNA-dependent-RNA polymerase (RdRp), membrane
protein (M), envelope protein (E), spike protein (S), and nucleocapsid protein (N).
Many strains also encode other accessory proteins that are less conserved,
serving roles specific to the needs of the specific strain. The first reports of
endemic CoV in humans dates back to the 1960s (543, 544), when HCoV-OC43
and HCoV-229E were first described, followed by HCoV-NL63 and HCoV-HKU1
which were described in the early 2000s (545, 546). All four of these CoV strains
cause mild to moderate cold-like symptoms in humans and typically follow a
seasonal distribution (542). However, in late 2002, a novel CoV called severe
acute respiratory syndrome (SARS-CoV) arose in China due zoonotic
transmission from bat to civet, and from civet to human, likely due to exposure
within food markets. SARS-CoV ultimately caused an epidemic affecting
approximately 8,000 individuals, demonstrating a mortality rate of up to 10%, with
individuals over 55 years of age significantly affected (547, 548). Since 2004, no
cases of SARS have been reported and therefore the threat for a global pandemic
was mitigated. A second novel coronavirus caused an epidemic which began in
2014 in the Middle East. Middle East respiratory syndrome (MERS-CoV) came
from a zoonotic transmission from camels to humans, likely originating from bat
species. This initially infected around 400 individuals and yielded a fatality rate of
up to 35% (549, 550). Subsequently, in 2015, a large secondary outbreak was
detected in South Korea, suggesting the potential for spread, but has not been
detected outside of the Middle East and Asia due to the requirement of camels as
the intermediate species. Unlike SARS, there have been annual cases reported in
the Middle East every year since the initial epidemic, establishing a cyclical
infectious cycle (550). While both SARS-CoV and MERS-CoV are regarded as
significant pathogens, both of these CoV epidemics were relatively small and short
lived, and therefore, lack of funding for continued research resulted in no approved
therapeutics or vaccines available.
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In late 2019, another novel CoV emerged in Wuhan, China, presenting with
respiratory distress symptoms (551-554). Genetic analysis suggested this viral
strain shared high homology with SARS-CoV, but contained important genetic
differences that lead to changes in spread and infection (554). Epidemiologic
surveillance found that some CoV strains present in both bats and pangolins
demonstrated high genetic similarity and may explain the point of origin (553, 555,
556). Since the first case was reported, COVID19, caused by the virus SARS-CoV2, has spread to almost every country and the virus has infected millions of people,
with cases increasing daily. Initially, the death rate was suspected to be close to
that reported for SARS-CoV (557, 558). Similarly, the death rate associated with
elderly individuals was significantly higher as well (553, 557, 558). Initial cases
were diagnosed using lab developed tests (LDT) that utilize reverse transcriptase
real-time polymerase chain reaction (RT-qPCR) against RNA isolated from patient
samples, and the U.S. put forth FDA guidelines to aid diagnostic potential (559).
However, there are currently no standard test kits available worldwide and
therefore, detection of the virus as well as nucleic acid extraction platforms are
being examined for emergency use. In addition, there are some commercially
available kits from several companies that are highly sensitive and automated.
However, these are either extremely long processes, have limited testing capacity,
or are unavailable in many places, all of which decrease the high throughput
testing needed for the current pandemic.
In this chapter, we develop a RT-qPCR based testing platform for the diagnosis
of SARS-CoV-2 for use in the University of Kentucky clinic. We used the Lyra, a
currently available RT-qPCR platform for SARS-CoV-2 in conjunction with a
magnetic bead based nucleic acid extraction kit to purify viral genetic material from
patient samples. We determined that our lab developed test is both sensitive and
precise and demonstrates a limit of detection of 400 copies/mL. In addition, when
used with patient samples, we are able to accurately detect the presence of virus
with similar sensitivity to currently approved diagnostic platforms.
133

Material and Methods
Thermocycler and PCR kit: The Lyra SARS-CoV-2 RT-qPCR assay kit (Quidel)
was used to complete the PCR testing on the QuantStudio 7 Flex (Thermofisher).
The kit contains a positive control that was used for the accuracy and precision
tests.
RNA isolation: RNA from either patient samples or standard control was isolated
using the Thermofisher MagMax viral and pathogen nucleic acid isolation kit
(A42352) according to the manufacturer’s protocol. Briefly, 380µL of patient
sample or standard with 20 µL of process control was placed into 550 µL of the
binding buffer and bead slurry then treated with 10 µL of proteinase K. The positive
control was 50 µL of Lyra kit positive control into 330 µL of saline buffer and 20 µL
of process control. Sample mixing was completed at 1050 rpm for all steps.
Samples were mixed for 2 min, incubated at 65°C for 5 min and mixed for 5 min
then allowed to sit on a magnetic stand for 10 min or until the beads collected and
the supernatant was aspirated. The beads were then washed with 1mL of wash
buffer followed by mixing for 2 min, incubated until beads settled and supernatant
was removed. This was completed two more times with 1mL and 0.5mL of 80%
ethanol. After the second wash, the beads were dried by mixing for 2 min. 50 µL
of elution buffer was placed in each sample, mixed for 5 min, incubated at 65°C
for 5 min and then mixed for 5 additional min. Beads were collected on the
magnetic stand for 3 min and the eluate was taken and moved into a new plate for
RT-qPCR.
Lyra RT-qPCR: The Lyra RT-qPCR was set up as designed by Quidel in the
emergency use authorization for the Thermofisher quant studio 7 pro. Briefly, 135
µL of rehydration buffer was added to each vial of dehydrated master mix (8
samples/vial). 5 µL of isolated RNA was placed into each well with rehydrated PCR
master mix and subsequently sealed and spun down. The PCR was performed
using the 96-well fast insert at 20 µL total volume with the following settings: 1)
55°C for 5 min 2) 60°C for 5 min 3) 65°C for 5 min 4) 92°C for 5 sec and 57°C for
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40 sec 5) repeat step 4 for 10 cycles without capture 6) 92°C for 5 sec and 57°C
for 40 sec 7) repeat step 6 for 30 cycles with capture. The threshold was set to
automatic detection based on cycle 3-15 of the PCR.
Limit of detection analysis: The limit of detection was established for the Quidel
Lyra SARS-CoV-2 assay using heat inactivated virus at a stock concentration of
1.7e7/mL in TE from BEI resources (NRC-52281 lot 70033641). Initial limit of
detection ranges was completed in triplicate diluting the initial stock to 1e5/mL
doing 1:2 dilutions from 100,000 copies/mL to 781 copies/mL. Subsequent LOD
testing was completed using serial dilutions from 1.7e7/mL to 1.7e5/mL in DEPC
water followed by diluting this stock into saline (0.9% NaCl) for 1600, 800, and 400
copies/mL of genome into a total volume of 8mL of saline. 380 µL of this dilution
was run 20 times through independent RNA isolation for RT-qPCR analysis.
Results and Discussion:
To generate a lab developed testing (LDT) platform for SARS-CoV-2, we
combined the Lyra SARSCoV-2 RT-qPCR kit with the MagMax nucleic acid
extraction platform. In order to achieve emergency use authorization (EUA)
approval for our kit, there are several test metrics that must be conducted to ensure
the platform is sensitive and accurate. First, we conducted an initial accuracy test
of replicates within the sample experimental procedure to ensure that there was
minimal variation. This accuracy test was composed of 10 positive and 10 negative
samples independently isolated and analyzed using RT-qPCR. All positive control
samples were detected at expected Ct values, with an average Ct value of 21.05
while no negative samples showed signal for the SARS-CoV-2 (Fig A-1A). In
addition, the internal isolation control standards were picked up at an average Ct
value of 17 for both the positive and negative samples, confirming the isolation
was successful and consistent.
Next, we conducted a precision assay that assessed the consistency between
runs completed over multiple days. To do this, 5 positive samples and 5 negative
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samples were prepared on 5 separate days, followed by RNA isolation and
analysis by PCR. The positive samples again showed an average Ct value of
21.42, 20.93, 20.95, 20.81, and 20.16, consistent with the initial accuracy
measurement (Fig A-1A and A-1B). There were no negative controls that
demonstrated any signal for SARS-CoV-2 nucleic acids. Additionally, the
internal controls showed high consistency with a Ct value of 17.68 ,17.32
,17.35, 17.39, and 17.11 (Fig A-1B). These results suggest that the current
testing platform is both accurate and precise while also demonstrating high
sensitivity for detection.
To ensure our findings were consistent with previous studies conducted
during the initial Lyra test development, we examined a panel of four verification
samples that contained nucleic acid material at known concentrations. These
samples were provided to us blinded for testing purposes from Quidel. We
isolated each member of this panel in duplicate and analyzed them by RTqPCR. The expected values for members 1 and 3 were 24 +/- 1 and members
2 and 4 were expected at 27+/- 1. During our nucleic acid isolation and RTqPCR, we detected member 1 at a ct value of 19.44, member 2 at 22.50,
member 3 at 20.95, and member 4 at 23.24, all of which were lower than the
expected values for detection, suggesting that the current testing and extraction
platform was operating with greater sensitivity than previously reported by the
current Lyra testing platform (Fig A-1C).
Lastly, in order to ensure that the test is sensitive and able to detect minimal
amounts of viral nucleic acids present in the samples, we conducted a limit of
detection (LOD) assay using gamma irradiated SARS-CoV-2 virus. Previously,
this method was utilized by Quidel to determine the LOD on a variety of
thermocycler platforms, including the Thermofisher Quantstudio 7 Pro, which
is closely related to the QuantStudio 7 Flex used in these studies. The LOD
established on these platforms demonstrated a detection limit at 800 copies/mL
and were able to detect 20/20 isolations with an average Ct value of 27.3 (Fig
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A-2A). Initially, we generated a stock of gamma irradiated virus at 100,000
copies/mL and conducted a 1:2 dilution down to 781 copies/mL in triplicate. We
were able to detect dilutions all the way down to 781 copies/mL which had an
average Ct value of 24.2 (Fig A-2A). Data from the 6,250 and 1,562 copies/mL
only yielded two data points per group due to loading error and internal control
failure.
Based on this initial LOD, we then proceeded to dilute gamma-irradiated virus
at 2x LOD (1600 copies/mL), 1x LOD (800 copies/mL) and 0.5x LOD (400
copies/mL) compared with the current established detection level. At 2x LOD, we
were able to pick up all 20 replicates at an average Ct value of 20.96. We were
also able to pick up all 20 replicates 1x LOD with an average Ct value of 22.37,
which is 5 Ct values lower than the current assays detection. At 0.5x the LOD, we
were able to detect 19/20 samples with an average Ct value of 23.02 which is still
4 Ct values lower than the current lyra assay LOD (Fig A-2B). One sample from
the 400 copies/mL group was lost during the extraction processes and therefore,
only 19/20 samples were detected. However, based on the other datapoints within
the set, the LOD may potentially be lower than 400 copies/mL.
In this chapter, we developed a testing platform for the detection of the novel
SARS-CoV-2 virus using a combination of a commercially available RT-qPCR kit
coupled with a magnetic bead-based nucleic extraction platform for emergency
use authorization. We were able to demonstrate that this test is able to deliver
consistent results with minimal variation between tests confirming both accuracy
and precision of detection. In addition, testing standards generated by Quidel
specifically for the Lyra platform were detected at lower Ct values when compared
to expected values, suggesting that this mechanism was more sensitive than the
currently approved Lyra platform. Further supporting this, we were able to establish
a LOD of 400 copies/mL compared with the current Lyra platform which has an
LOD of 800 copies/mL. Our current testing capacity was initially limited by the time
and capacity of currently available testing platforms. The LDT generated in this
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study is able to utilize another platform to increase the testing capacity while
ensuring that sensitivity, accuracy, and precision are conserved.
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Figure A-1: The LDT demonstrates high precision and accuracy for SARS CoV 2 detection.
The current LDT was able to detect the positive control both (A) accurately and (B) precisely, with
minimal variation between samples within a single run or over multiple days of testing. (C)
Validation samples (1-4) were provided in a blinded fashion for analysis and compared with
expected outcomes from previous studies demonstrating that the LDT is more sensitive than the
current testing platform.
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Figure A-2: The limit of detection of SARS CoV 2 is highly sensitive. (A) The initial limit of
detection was able to be determined using a 2-fold serial dilution starting from 100,000 copies/mL
down to 781 copies/mL. (B) 20 replicates of 1600, 800, and 400 copies/mL were independently
isolated and analyzed by RT-qPCR demonstrating a 95% confidence in the limit of detection at 400
copies/mL.
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Appendix 2: List of Abbreviations
HMPV

Human metapneumovirus

RSV

Respiratory syncytial virus

IAV

Influenza A virus

RNP

Ribonucleoprotein

N

Nucleoprotein

F

Fusion protein

P

Phosphoprotein

L

Large polymerase

M

Matrix protein

SH

Small hydrophobic protein

G

Attachment Protein

IB(s)

Inclusion Body/Bodies

FISH

Fluorescence in situ hybridization

HAE

Human airway epithelium

GFP

Green fluorescent protein

HRA

Heptad repeat A

HRB

Heptad repeat B

WT

Wild type
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